

**Temple University —
Of The Commonwealth System of
Higher Education and its Subsidiaries**

**Consolidated Financial Statements and Supplemental
Schedules as of and for the Years Ended June 30, 2025
and 2024, and Independent Auditor's Report June 30,
2025**




TABLE OF CONTENTS

	Page
FINANCIAL STATEMENTS SECTION:	
Summary of Consolidated Statements of Activities, Years Ended June 30, 2025 and 2024	i-ii
INDEPENDENT AUDITOR’S REPORT	1-3
CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES:	
Consolidated Balance Sheets as of June 30, 2025 and 2024	4
Consolidated Statements of Activities for the Years Ended June 30, 2025 and 2024	5-6
Consolidated Statements of Cash Flows for the Years Ended June 30, 2025 and 2024	7
Notes to Consolidated Financial Statements for the Years Ended June 30, 2025 and 2024	8-60
SUPPLEMENTAL SCHEDULES:	
Changes in Net Assets Without Donor Restrictions for the Years Ended June 30, 2025 and 2024	31-62
Subsidiary Organizations, June 30, 2025	63-64
FEDERAL AWARDS SECTION:	
INDEPENDENT AUDITOR’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF CONSOLIDATED FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS	65-66
INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE	67-70
Summary of Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2025	71-72
Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2025	73-95
Notes to Schedule of Expenditures of Federal Awards for the Year Ended June 30, 2025	96-98
Schedule of Findings and Questioned Costs of Federal Awards for Year Ended June 30, 2025	99-100
Schedule of Prior Year Findings of Federal Awards for Year Ended June 30, 2024	101
Corrective Action Plan	102
CITY OF PHILADELPHIA AWARDS SECTION:	
INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE FOR EACH MAJOR CITY OF PHILADELPHIA AWARDS; REPORT ON INTERNAL CONTROL OVER COMPLIANCE AND REPORT ON SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS; SCHEDULE OF CITY OF PHILADELPHIA PROGRAM EXPENDITURES AND PROGRAM REVENUE REQUIRED BY THE CITY OF PHILADELPHIA SUBRECIPIENT AUDIT GUIDE	104-106
Schedule of Expenditures of City of Philadelphia Awards for the Year Ended June 30, 2025	107-109
Notes to Schedule of Expenditures of City of Philadelphia Awards for the Year Ended June 30, 2025	110
Schedule of Findings and Questioned Costs of City of Philadelphia Awards For the Year Ended June 30, 2025	111
PENNSYLVANIA DEPARTMENT OF HEALTH SECTION:	
REPORT ON SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH REQUIRED BY THE PENNSYLVANIA DEPARTMENT OF HEALTH AUDIT GUIDANCE	113
Schedule of Revenue for the Commonwealth of Pennsylvania Department Health for the Year Ended June 30, 2025	114
Notes to Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health for the Year Ended June 30, 2025	114

Notes to Consolidated Financial Statements

	Page		Page
1. Description of Business and Operations	8	14. Pledged Assets	49
2. Summary of Significant Accounting Policies	9	15. Net Assets	50
3. Endowment, Investments, and Self-Insurance Trust Funds	19	16. Accounts Payable and Other Accrued Expenses	50
4. Accounts, Loans, and Contributions Receivable	21	17. Commonwealth of Pennsylvania Grants and Other Support	51
5. Pensions and Postretirement Benefits	23	18. Revenue	51
6. Deposits with Trustees	28	19. Expenses by Functional and Natural Classification	54
7. Property, Plant, and Equipment	28	20. Professional Liability Insurance	56
8. Asset Retirement Obligations	29	21. Patient Care Activities	57
9. Debt and Leases	30	22. Charity Care	58
10. Fair Value Measurements	38	23. Intangible Assets	58
11. Endowment Funds	44	24. Employee Retention Credit	59
12. Liquidity and Availability of Resources	48	25. Subsequent Events	59
13. Commitments and Contingencies	49	Supplemental Schedules	59

Page

Summary of Consolidated Statements of Activities, Years Ended June 30, 2025 and 2024

Consolidated Operating Revenues Without Donor Restrictions by Source	i
Consolidated Operating Expenses by Function and Natural Expense Type	ii

Independent Auditor's Report

[###](#)

Consolidated Financial Statements:



Consolidated Balance Sheets, June 30, 2025 and 2024	4
Consolidated Statement of Activities, Year Ended June 30, 2025	5
Consolidated Statement of Activities, Year Ended June 30, 2024	6
Consolidated Statements of Cash Flows, Years Ended June 30, 2025 and 2024	7
Notes to Consolidated Financial Statements	8

Supplemental Schedules:



Changes in Net Assets Without Donor Restrictions, Year Ended June 30, 2025	S-61
Changes in Net Assets Without Donor Restrictions, Year Ended June 30, 2024	S-62
Subsidiary Organizations, June 30, 2025	S-63

**Temple University —
Of The Commonwealth System of Higher Education and its Subsidiaries
Summary of Financial Statements
(dollars in thousands)**

Fiscal 2025 Operating Revenues Without Donor Restrictions by Source: \$4,668,527




Fiscal 2024 Operating Revenues Without Donor Restrictions by Source: \$4,115,240




Temple University —
 Of The Commonwealth System of Higher Education and its Subsidiaries
 Summary of Financial Statements
 (dollars in thousands)


Fiscal 2025 Operating Expenses by Function: \$4,543,245




Fiscal 2025 Operating Expenses by Natural Expense Type (Excluding Recoveries)



Fiscal 2024 Operating Expenses by Function: \$4,093,138



Fiscal 2024 Operating Expenses by Natural Expense Type (Excluding Recoveries)



This Page is Intentionally Blank

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Temple University – Of The Commonwealth System of Higher Education and subsidiaries ("Temple"), which comprise the consolidated balance sheets as of June 30, 2025 and 2024, and the related consolidated statements of activities, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Temple as of June 30, 2025, and 2024, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

The financial statements of Temple include various subsidiaries as outlined in Note 1 to the financial statements. The financial statements of Temple University – Of The Commonwealth System of Higher Education, includes subsidiaries of Temple University Health System Inc. ("TUHS"). The subsidiary of TUHS; TUHS Insurance Company, Ltd.; was audited by us; and the subsidiary of Temple; Temple Educational Support Services Ltd.; which was audited by other auditors were audited in accordance with generally accepted auditing standards but were not audited in accordance with *Government Auditing Standards* and, accordingly, are not covered by our reports in accordance with *Government Auditing Standards*.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Temple's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Temple's ability to continue as a going concern for a reasonable period of time.


We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Report on Supplemental Schedules

Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplemental schedules listed in the table of contents on pages S-1 through S-3 are presented for the purpose of additional analysis and are not a required part of the financial statements. These supplemental schedules are the responsibility of Temple's management and were derived from and relate directly to the underlying accounting and other records used to prepare the financial statements. Such schedules have been subjected to the auditing procedures applied in our audits of the financial statements and certain additional procedures, including comparing and reconciling such schedules directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, such schedules are fairly stated in all material respects in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated October 28, 2025 on our consideration of Temple's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Temple's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Temple's internal control over financial reporting and compliance.

A handwritten signature in black ink that reads "Deloitte & Touche LLP". The signature is written in a cursive, professional style.

October 28, 2025

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Balance Sheets
(in thousands)

	June 30, 2025	June 30, 2024
Assets		
Current assets:		
Cash and cash equivalents	\$ 404,694	\$ 408,268
Investments and self-insurance trust funds	1,581,663	1,537,549
Accounts, loans, and contributions receivable, net	759,277	730,670
Inventories and other assets	74,802	71,703
Deposits with trustees	24,296	23,981
Total current assets	2,844,732	2,772,171
Non-current assets:		
Accounts, loans, and contributions receivable, net	140,672	134,535
Endowment, investments, and self-insurance trust funds	1,365,056	1,215,205
Deposits with trustees	23,585	24,756
Other assets	120,357	123,673
Property, plant, and equipment, net	2,049,073	1,925,570
Operating lease right-of-use assets	97,594	87,446
Intangible assets, net	—	109
Funds held in trust by others	180,275	171,486
Total non-current assets	3,976,612	3,682,780
Total assets	\$ 6,821,344	\$ 6,454,951
Liabilities and Net Assets		
Current liabilities:		
Accounts payable and accrued expenses	\$ 647,334	\$ 617,830
Deferred revenue	75,729	90,644
Short-term debt	25,000	12,000
Current portion of long-term debt, net	47,472	46,341
Current portion of accrued pensions and postretirement benefits	268	16,984
Total current liabilities	795,803	783,799
Non-current liabilities:		
Accrued expenses and other liabilities	321,265	390,272
Deferred revenue	16,415	13,261
Long-term debt, net	821,018	887,867
Operating lease liabilities	81,866	76,388
Refundable federal student loans	28,481	30,578
Accrued pensions and postretirement benefits	1,278	6,468
Total non-current liabilities	1,270,323	1,404,834
Total liabilities	2,066,126	2,188,633
Net assets:		
Without donor restrictions	3,626,841	3,327,462
With donor restrictions	1,128,377	938,856
Total net assets	4,755,218	4,266,318
Total liabilities and net assets	\$ 6,821,344	\$ 6,454,951

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statement of Activities

For the Year Ended June 30, 2025

(in thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues:			
Tuition and fees, net of discounts of \$185,337	\$ 734,932	\$ —	\$ 734,932
Commonwealth of Pennsylvania appropriation (Note 17)	46,884	—	46,884
Grants and contracts (federal, state, local, and private)	319,254	—	319,254
Contributions for operations and endowments	28,087	37,936	66,023
Investment return, net of expenses	145,212	3,651	148,863
Sales of educational activities	15,033	—	15,033
Auxiliary enterprises	121,233	—	121,233
Patient care activities	3,188,952	—	3,188,952
Other sources	59,699	15	59,714
Net assets released from restrictions	9,241	(9,241)	—
Total revenues	4,668,527	32,361	4,700,888
Expenses:			
Educational and general:			
Academic and student services	839,236	—	839,236
Research and public service	296,440	—	296,440
Institutional support	180,166	—	180,166
Total educational and general	1,315,842	—	1,315,842
Auxiliary enterprises	141,333	—	141,333
Patient care activities	3,086,070	—	3,086,070
Total expenses	4,543,245	—	4,543,245
Excess of revenues over expenses	125,282	32,361	157,643
Other changes in net assets:			
Investment return, net of expenses	124,340	71,347	195,687
Commonwealth grants for property, plant, and equipment (PP&E)	—	93,612	93,612
Contributions for PP&E	1	16,459	16,460
Gain on extinguishment of debt	20,411	—	20,411
Loss on disposal of PP&E, net	(1,101)	—	(1,101)
Actuarial change in accrued pensions and postretirement benefits	35,602	—	35,602
Other components of net periodic postretirement benefit cost	12,209	—	12,209
Loss on asset retirement obligation	(1,052)	—	(1,052)
Currency translation adjustment and foreign exchange realized gain, net	1,421	—	1,421
Pension settlement charge	(41,992)	—	(41,992)
Net assets released from restrictions for PP&E	24,258	(24,258)	—
Total other changes in net assets	174,097	157,160	331,257
Change in net assets	299,379	189,521	488,900
Net assets, beginning of year	3,327,462	938,856	4,266,318
Net assets, end of year	\$ 3,626,841	\$ 1,128,377	\$ 4,755,218

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statement of Activities

For the Year Ended June 30, 2024

(in thousands)

	Without Donor Restrictions	With Donor Restrictions	Total
Revenues:			
Tuition and fees, net of discounts of \$157,533	\$ 723,316	\$ —	\$ 723,316
Commonwealth of Pennsylvania appropriation (Note 17)	65,919	—	65,919
Grants and contracts (federal, state, local, and private)	247,776	—	247,776
Contributions for operations and endowments	26,410	36,819	63,229
Investment return, net of expenses	103,007	4,062	107,069
Sales of educational activities	14,708	—	14,708
Auxiliary enterprises	108,527	—	108,527
Patient care activities	2,777,971	—	2,777,971
Other sources	37,702	(3)	37,699
Net assets released from restrictions	9,904	(9,904)	—
Total revenues	4,115,240	30,974	4,146,214
Expenses:			
Educational and general:			
Academic and student services	793,701	—	793,701
Research and public service	284,717	—	284,717
Institutional support	178,850	—	178,850
Total educational and general	1,257,268	—	1,257,268
Auxiliary enterprises	133,550	—	133,550
Patient care activities	2,702,320	—	2,702,320
Total expenses	4,093,138	—	4,093,138
Excess of revenues over expenses	22,102	30,974	53,076
Other changes in net assets:			
Investment return, net of expenses	99,333	54,082	153,415
Commonwealth grants for property, plant, and equipment (PP&E)	2,300	63,859	66,159
Contributions for PP&E	1	1,057	1,058
Loss on disposal of PP&E, net	(4,026)	—	(4,026)
Actuarial change in accrued pensions and postretirement benefits	(5,330)	—	(5,330)
Other components of net periodic postretirement benefit cost	13,373	—	13,373
Loss on asset retirement obligation	(8,141)	—	(8,141)
Currency translation adjustment and foreign exchange realized gain, net	316	—	316
Net assets released from restrictions for PP&E	4,617	(4,617)	—
Total other changes in net assets	102,443	114,381	216,824
Change in net assets	124,545	145,355	269,900
Net assets, beginning of year	3,202,917	793,501	3,996,418
Net assets, end of year	\$ 3,327,462	\$ 938,856	\$ 4,266,318

See accompanying notes to the consolidated financial statements.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Consolidated Statements of Cash Flows
(in thousands)

	Year Ended June 30,	
	2025	2024
Cash flows from operating activities:		
Change in net assets	\$ 488,900	\$ 269,900
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Currency translation adjustment and foreign exchange realized gain, net	(1,421)	(316)
Provision for bad debts	5,717	4,375
Depreciation	176,979	171,485
Amortization and accretion	(6,854)	(5,752)
Impairment of intangibles	—	352
Realized and unrealized gain on investments, net	(250,657)	(178,496)
Actuarial change in accrued pensions and postretirement benefits	(35,602)	5,330
Gain on extinguishment of debt	20,411	—
Loss on asset retirement obligation	1,052	8,161
Loss on disposal of property, plant, and equipment (PP&E) and assets held for sale, net	1,101	4,026
Gain on lease modification	—	(20)
Noncash contributions received	(4,611)	(6,718)
Proceeds from sale of noncash contributions	4,611	6,718
Contributions, grants, and investment income restricted for PP&E and long-term investment	(135,634)	(94,836)
Equity method investment loss	3,663	17,005
Changes in operating assets and liabilities:		
Accounts and contributions receivable	(50,224)	(187,065)
Inventories and other assets	(8,202)	15,872
Accounts payable and accrued expenses	(36,273)	101,677
Deferred revenue	(12,184)	(17,654)
Accrued pensions and postretirement benefits	(6,460)	(6,704)
Net change in operating lease right of use assets / liabilities	(3,952)	(167)
Net cash provided by operating activities	<u>150,360</u>	<u>107,173</u>
Cash flows from investing activities:		
Purchases of investments, deposits with trustees, and self-insurance trust funds	(1,568,694)	(851,512)
Sales and maturities of investments, deposits with trustees, and self-insurance trust funds	1,671,975	691,997
Net change in short-term investments	(45,289)	116,265
Purchases of PP&E	(300,471)	(207,814)
Loans to students	(3,276)	(2,891)
Proceeds from collections on student loans	5,758	7,014
Cash advances to equity method investment	—	(21,200)
Proceeds from loans to equity method investment	26,303	4,697
Net cash used in investing activities	<u>(213,694)</u>	<u>(263,444)</u>
Cash flows from financing activities:		
Proceeds from contributions, grants, and investment income restricted for PP&E and long-term investment	135,634	94,836
Refundable federal student loans	(2,097)	(129)
Change in split interest agreements	173	372
Proceeds from long-term debt, net of bond issuance cost of \$1,035	263,707	—
Repayment of long-term debt	(345,866)	(43,230)
Proceeds from short-term borrowings (line of credit)	65,000	65,000
Repayment of short-term borrowings (line of credit)	(52,000)	(53,000)
Net cash provided by financing activities	<u>64,551</u>	<u>63,849</u>
Effect of exchange rate changes on cash and cash equivalents	1,643	(115)
Net change in cash, cash equivalents, and restricted cash	2,860	(92,537)
Cash, cash equivalents, and restricted cash, beginning of the year	432,934	525,471
Cash, cash equivalents, and restricted cash, end of the year	<u>\$ 435,794</u>	<u>\$ 432,934</u>
Cash and cash equivalents	\$ 404,694	\$ 408,268
Restricted cash included in investments	31,100	24,666
Total cash, cash equivalents, and restricted cash	<u>\$ 435,794</u>	<u>\$ 432,934</u>
Supplemental disclosure of cash flow information:		
Cash paid for interest	\$ 38,803	\$ 45,496
PP&E acquired through new and modified finance leases	930	6,512
Amounts accrued related to PP&E	26,752	26,034

See accompanying notes to audited consolidated financial statements and Note 9 for additional supplemental cash flow disclosures related to leases.

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Notes to Consolidated Financial Statements

June 30, 2025 and 2024

(dollars in thousands)

1. Description of Business and Operations

Founded in 1884, Temple University — Of The Commonwealth System of Higher Education (the “University”) is a comprehensive state-related research university with its headquarters and largest campus located in Philadelphia, Pennsylvania. The University provides education and training services to approximately 32,800 students at the undergraduate, graduate, and postdoctoral/professional levels, and performs research, training, and other services under grants, contracts, and similar agreements with sponsoring organizations, including federal, state, and local sponsors. The University offers more than 650 academic programs in 17 schools and colleges, including programs in art; business; education; engineering; law; liberal arts; media and communications; music and dance; science and technology; social work; sport, tourism, and hospitality management; theater, film, and media arts; and various health professions, including dentistry; medicine; pharmacy; podiatric medicine; and public health. The University has eight campuses; including six campuses across Pennsylvania and international campuses in Italy (Rome) and Japan (locations in Tokyo and Kyoto), and offers study abroad programs in various locations. The University is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code.

As a state-related institution, the University receives annual operating and capital non-preferred appropriations from the Commonwealth of Pennsylvania (the “Commonwealth”). Non-preferred appropriations require a two-thirds vote of each chamber of the Commonwealth's General Assembly for passage. The General Assembly is not obligated to appropriate funds to the University, and there is no guarantee that funding from the Commonwealth will continue consistent with historical levels or at levels requested by the University. In 2025 and 2024, the annual operating appropriation from the Commonwealth was \$158,206 (both years) and the capital appropriation was \$51,000 (both years). In addition to the annual appropriations, the Commonwealth also provides funding for sponsored programs, as well as patient care activities provided by the University’s health system (see Notes 17 and 18).

The University is the sole member of its subsidiary Temple University Health System, Inc. (“TUHS”). The University and TUHS are collectively referred to herein as “Temple”. See the accompanying supplemental schedule for a complete listing of Temple’s subsidiary organizations. A summary of Temple’s active and recently active subsidiaries and clinical faculty practice plan is as follows:

Temple’s Active Subsidiaries as of June 30, 2025	
Temple University Health System, Inc. (“TUHS”)	A Pennsylvania nonprofit corporation dedicated to providing access to quality patient care and supporting excellence in medical education and research, of which the University is the sole member. TUHS was incorporated in August 1995 and serves principally to coordinate the activities and plans of its health care subsidiaries in Philadelphia and the surrounding area. TUHS’ subsidiaries and affiliates include a network of hospitals and outpatient centers, a comprehensive physician network of primary care and specialty practices, ambulatory services, various research entities, a foundation to support the health-care related activities of TUHS, and a captive insurance company established to reinsure the professional liability claims of certain subsidiaries of TUHS. See the accompanying supplemental schedules for a complete listing of TUHS’ subsidiaries.
Temple Educational Support Services, Ltd. (“TESS”)	A limited liability company organized and incorporated under the laws of Japan. TESS was established in December 1995 to operate the University’s Japan campus and is a wholly-owned subsidiary of the University.
Temple University School of Podiatric Medicine, Inc. (“TUSPM”)	A Pennsylvania nonprofit corporation that holds the real estate associated with the University's School of Podiatric Medicine. With the exception of holding certain real estate, TUSPM has not had any activity since the Pennsylvania College of Podiatric Medicine became affiliated with Temple University in July 1998.

2. Summary of Significant Accounting Policies

Basis of Presentation and Consolidation — The consolidated financial statements have been prepared on the accrual basis of accounting, in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and with the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 958, *Not-for-Profit Entities*. The accompanying consolidated financial statements include the accounts of Temple and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Temple is required to classify its net assets into two categories based on the existence or absence of donor-imposed restrictions: net assets without donor-imposed restrictions and net assets with donor-imposed restrictions. Descriptions of the two net asset categories are as follows:

Net Assets without Donor Restrictions — Net assets not subject to donor-imposed restrictions. These net assets may be designated for specific purposes by action of the board of trustees or may otherwise be limited by contractual agreements with outside parties. Temple reports donor-restricted support whose restrictions are met in the same reporting period as support within *Net assets without donor restrictions*. All expenses from operations are reported as a reduction of *Net assets without donor restrictions*, since the use of restricted contributions in accordance with donors’ stipulations results in the release of the restriction.

Net Assets with Donor Restrictions — Net assets subject to donor-imposed restrictions, which are donor stipulations that specify a use for a contributed asset that is more specific than broad limits resulting from the following: a) the nature of the not-for-profit entity, b) the environment in which it operates and c) the purposes specified in its articles of incorporation or bylaws or comparable documents. Net assets subject to donor-imposed restrictions include contributions for which donor-imposed restrictions have not been met (primarily future capital projects), donor restricted endowment funds, charitable remainder unitrusts, pooled income funds, gift annuities, and pledges receivable. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, donor-restricted net assets are reclassified to *Net assets without donor restrictions* and reported in the consolidated statements of activities as *Net assets released from restrictions*.

Cash, Cash Equivalents, and Restricted Cash — Temple considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Temple maintains cash balances in financial institutions, which exceed federal depository insurance limits. Management believes that credit risks related to these deposits are minimal. Cash equivalents that are not traded on an active exchange are carried at cost, which approximates fair value.

Endowment and Investments — Endowment and investments (collectively referred to as “investments”) are comprised of the assets of Temple’s endowment, certain donor restricted funds, funds designated by the board of trustees to be invested as endowments, certain funds set aside to retire long-term debt, other plant-related funds, and other funds without donor restrictions held for operating purposes. These investments vary as to their level of liquidity, with differing requirements for notice prior to redemption or withdrawal. Investments established for donor and board-designated endowments, investments pledged as collateral, and certain investments set aside to retire long-term debt are classified as non-current assets. All other investments are classified as current assets (see Notes 3, 10, 11, and 14).

Temple reports investments including debt and equity securities at fair value. Temple also invests in various limited partnerships, hedge funds, and other investment funds whose fair value is measured at net asset value per share as determined by the respective fund managers and financial information provided by the

investment entities. This financial information includes assumptions and methods that are reviewed by Temple. Because these investments are not readily marketable, the estimated fair values are subject to uncertainty and, therefore, may differ from the value that would have been used had a ready market existed, and such differences could be material.

Temple has adopted, for endowments and funds designated by the board of trustees to be invested as endowments, a spending rule based on a percentage of the fair value of such investments, computed as a moving average over the prior twelve quarters. For these investments, the spending rule amount is reported as *Investment return* in revenues with the excess or shortfall of total return over the spending rule amount reported as *Investment return* in *Other changes in net assets* in the consolidated statements of activities. For all other investments, interest and dividend income is reported as *Investment return* in revenues and realized and unrealized gains or losses are reported as *Investment return* in *Other changes in net assets* in the consolidated statements of activities (see Notes 3 and 11).

Investment return, net of external and direct internal investment expenses, is reported as increases to net assets without donor restrictions or assets with donor restrictions based upon the existence or absence of donor-imposed restrictions.

Investments, in general, are exposed to various risks such as interest rate, credit, and overall market volatility. As such, it is reasonably possible that changes in the value of investments will occur in the near term and that such changes could materially affect the amounts reported in the consolidated financial statements.

Derivatives — The University enters into derivative financial instruments, principally futures contracts, to manage equity price risk. Futures contracts are recorded as contractual commitments on a trade-date basis and are carried at fair value based on closing exchange quotations. The fair value of derivative financial instruments at the reporting date generally reflects the amount the University would receive or pay to terminate the contract at the reporting date. Changes in fair value are recorded as *Investment return* in *Other changes in net assets*. The University does not designate any derivative instruments as hedging instruments (see Note 3).

Self-Insurance Trust Funds — Temple self-insures or maintains deductibles under its various insurance policies for property, casualty, automobile, general liability, medical malpractice, workers' compensation, certain health and welfare, and other claims. Self-insurance trust funds include assets that are designated for payments of workers' compensation risk retained by Temple. Provisions are made for estimated losses (claims made and claims incurred but not reported) generally based on actuarial methods, which include discounting of certain loss provisions (see Note 3).

Accounts, Loans, and Contributions Receivable — Accounts, loans, and contributions receivable are reported at their net realizable value. The allowance for doubtful accounts is based upon management's judgment including such factors as historical collection history, type of receivable, and periodic assessment of individual accounts. Temple writes-off receivables when they are determined to be uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts. Temple does not accrue interest on these amounts (see Note 4).

Inventories and Other Assets — Inventories are stated at the lower of cost or net realizable value, with cost being determined on the first-in, first-out, or average cost method. Inventories at June 30, 2025 and 2024, totaled \$40,355 and \$40,048, respectively, and are included in *Inventories and other assets* in the consolidated balance sheets. *Inventories and other assets* also include prepaid expenses, and advances. *Other assets, non-*

current include pension and postretirement plans that are in an over-funded position, which totaled \$76,512 and \$84,446 at June 30, 2025 and 2024, respectively (see Note 5).

Deposits with Trustees — Deposits with trustees include assets held in escrow by designated bond trustees for debt service payments and construction or enhancement of property, plant, and equipment (see Note 6).

Property, Plant, and Equipment — Property, plant, and equipment are recorded at cost less accumulated depreciation. Property, plant, and equipment gifted to Temple are recorded at the fair value at the date of acquisition. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from three to forty years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the leasehold improvements or the lease term. Land is not depreciated. Depreciation for equipment commences once it is placed in service and depreciation for buildings and leasehold improvements commences once they are ready for their intended use (see Note 7).

Estimated useful lives of property, plant, and equipment are as follows:

	Useful Life
Land improvements	8 - 20 years
Buildings	20 - 40 years
Building improvements	15 - 40 years
Furniture, fixtures, and equipment	3 - 20 years
Library books	10 years

Cost of maintenance and repairs is charged to expense as incurred. Upon retirement or other disposition, the cost of the asset and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the consolidated statements of activities.

Long-Lived Assets — Temple reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes indicate that the carrying value of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to their expected undiscounted future cash flows. If such assets are considered to be impaired, the impairment is measured by the amount the carrying value exceeds the fair value of the assets. No impairment of long-lived assets occurred in 2025 or 2024.

Intangibles — Intangible assets are accounted for in accordance with the accounting guidance in FASB ASC Topic 350 *Intangibles—Goodwill and Other*. Goodwill and indefinite-lived intangible assets are not amortized, but are evaluated for impairment annually, or when indicators of a potential impairment are present. Temple’s annual impairment assessment date is June 30. The annual assessment for impairment of goodwill and indefinite-lived intangible assets is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans. During 2025 and 2024, there were no intangible assets with indefinite lives.

The cost of intangible assets with determinable useful lives is amortized to reflect the pattern of economic benefits consumed on a straight-line basis over the estimated periods benefited. Intangibles with contractual terms are generally amortized over their respective legal or contractual lives. When certain events or changes in operating conditions occur, an impairment assessment is performed and the lives of intangible assets with determinable lives may be adjusted and impairment charges recorded. In 2025 and 2024, based on the results of Temple’s assessment, impairments of intangible assets with determinable useful lives totaled \$0 and \$(352), respectively. At June 30, 2025, all goodwill and other intangible assets were either fully amortized or impaired (see Note 23).

Leases — Temple determines if an arrangement is a lease at inception. A contract is or contains a lease if the contract conveys the right to control and obtain substantially all of the economic benefits from an identified asset, and provides Temple with the right to direct the use of the identified asset for a period of time in exchange for consideration. Operating leases are included in *Operating lease right-of-use assets*, *Operating lease liabilities (non-current)*, and *Accounts payable and accrued expenses (current)*. Operating lease right-of-use (“ROU”) assets represent Temple’s right to use an underlying asset for the lease term. Operating lease liabilities represent Temple’s obligation to make lease payments arising from the lease. Operating lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. If a lease agreement does not provide an implicit rate, based on the information available at the commencement date, Temple uses its incremental borrowing rate in determining the present value of lease payments. The rate implicit on Temple’s leases were not readily available and, as such, Temple used the incremental borrowing rate when measuring all leases. Temple determines its incremental borrowing rate based on the approximate rate at which Temple would borrow, on a collateralized basis over a similar term. The determination of the incremental borrowing rate includes numerous assumptions such as credit standing, lease term, amount of borrowing, and location of leased assets. Certain real estate leases include options to extend or terminate agreements. Options to extend or terminate the lease are considered in determining the lease term only when it is reasonably certain that the option will be exercised (see Note 9). Lease expense for lease payments is recognized on a straight-line basis over the lease term. Temple elected the practical expedient that allows lessees to choose not to separate lease and non-lease components and is applying this expedient to all real estate leases and all embedded equipment leases related to consumable purchase agreements. Certain lease agreements for real estate include payments based on actual common area maintenance and other expenses, such as insurance and taxes. These variable lease payments are recognized within operating expenses, but are not included in the calculation of right-of-use asset or liability balances. Additionally, Temple elected to not recognize lease assets and lease liabilities for all leases with a term of 12 months or less; such lease payments are recognized as expense on a straight-line basis over the lease term. Temple’s operating leases are primarily for facility space, automobiles, and office equipment. Temple’s finance leases are included in *Property, plant, and equipment, net*, and *Long-term debt* in the consolidated balance sheet (See Note 9).

Funds Held in Trust by Others — Temple is the irrevocable beneficiary of the income from certain perpetual trusts administered by third parties. Temple’s beneficial interest is reported at the fair value of the underlying trust assets. Because the trusts are perpetual and the original corpus cannot be used, these funds are reported as donor-restricted net assets. As Temple does not have the ability to redeem funds held in trust by others, these assets are categorized as Level 3 assets (see Note 10).

Asset Retirement Obligations — Temple recognizes the fair value of an asset retirement obligation in the period in which it is incurred if a reasonable estimate of fair value can be made. When the liability is initially recorded, Temple capitalizes the cost of the asset retirement obligation by increasing the carrying amount of the related long-lived asset. Changes in the obligation due to revised estimates of the amount or timing of cash flows required to settle the future liability are recognized by increasing or decreasing the carrying amount of the asset retirement obligation liability. Changes due solely to the passage of time (accretion of the discounted liability) are recognized as an increase in the carrying amount of the liability and as an operating expense in the statement of activities. The capitalized cost associated with the retirement obligation is depreciated over the useful life of the related asset. Upon settlement of the obligation, any difference between the cost to settle the asset retirement obligation and the liability recorded is recognized as a gain or loss in the consolidated statement of activities (see Note 8).

Defined Benefit Pension and Other Postretirement Plans — Temple recognizes the over-funded or under-funded status of its defined benefit pension and other postretirement plans as an asset or liability in its balance

sheets and recognizes changes in the funded status of the plans that arise during the period, but are not recognized as components of net periodic benefit cost, as *Actuarial change in accrued pensions and postretirement benefits* in the consolidated statements of activities (see Note 5).

Fair Value Measurements — Temple categorizes its assets and liabilities measured at fair value into a three-level hierarchy, based on the priority of the inputs to the respective valuation techniques, with assets that are measured using the net asset value per share practical expedient being excluded from the fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). An asset's or liability's classification within the fair value hierarchy is based on the lowest level of significant input to its valuation. Temple's assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels (see Note 10).

The carrying values of short-term assets and liabilities, including cash equivalents (not traded on an active exchange), accounts receivable, and accounts payable, approximate their fair values. Investments, self-insurance trust funds, and deposits with trustees are carried at their estimated fair value (see Notes 3 and 10). The fair value of long-term debt is estimated based upon discounted cash flows at current market rates for instruments with similar remaining terms, which Temple considers Level 2 inputs (see Notes 9 and 10). Contribution receivables are recorded at the present value of expected future cash flows (see Note 4). Considerable judgment is necessary to interpret market data and develop estimated fair values. Accordingly, the estimates presented are not necessarily indicative of the amounts at which these instruments could be purchased, sold, or settled.

A reasonable estimate of the fair value of loans receivable from students under government loan programs and refundable federal student loans could not be made because the loans are not readily salable. These loans are recorded at cost, less an allowance for doubtful accounts (see Note 4).

Revenue Recognition — Temple's revenues primarily consist of tuition and fees, auxiliary enterprises, Commonwealth appropriations, grants and contracts, contributions, and patient care activities. Revenue recognition accounting policies for Temple's primary revenue sources are as follows (see Note 18 for additional revenue disclosures):

Tuition and Fees — Tuition and fees are recognized ratably on a daily straight-line basis over the academic period as the University satisfies its performance obligation (e.g., as instruction is provided to students). The University's transaction price is determined based on established fixed tuition rates based on student residency (in-state or out-of-state) and the school or college in which they enroll, net of financial assistance provided directly by the University. Such financial assistance is recorded as a tuition discount and represents the difference between the stated charge for tuition and fees and the amount that is billed to the student and/or third parties making payments on behalf of the student. Financial assistance provided to students was \$185,337 in 2025 and \$157,533 in 2024.

Auxiliary Enterprises — Auxiliary services exist to furnish goods or services to students, faculty, staff, or incidentally to the general public, and charges a fee directly related to, although not necessarily equal to, the cost of the goods or services. The distinguishing characteristic of auxiliary services is that they are managed as essentially self-supporting activities. Revenues from auxiliary enterprises include revenues from contracts with customers to provide student housing and dining facilities, ticket sales for athletic and community events, other athletic department revenues, parking services, and other miscellaneous activities.

The University's transaction price for housing and meal plans is determined based on established fixed rates based on the dorms students chose to live in (e.g., residence halls and room type) and the meal plan type they elect. Payments for housing services are due approximately two weeks subsequent to the start of the academic term (consistent with tuition). Performance obligations for housing and dining services are delivered over the academic terms. Consequently, revenue from housing and dining services is recognized ratably as services are rendered. For ticket sales, revenue is recognized after the event occurs and for other auxiliary services (e.g., event parking, programs, merchandise, concessions) revenue is recognized at a point in time.

Commonwealth of Pennsylvania Appropriation — The University receives annual operating and capital appropriations from the Commonwealth. Operating appropriations are provided to support the general operations of the University, which, along with additional support provided by the University, allows for a reduction in tuition rates for Pennsylvania resident students. Funds are required to be spent in accordance with applicable laws and revenue is recognized ratably over the fiscal year as the funds are expended. Capital appropriations are provided to fund certain approved capital projects in support of the University's mission. Revenue from Commonwealth capital funding is recognized on an expense reimbursement basis and is classified as "with donor restrictions" until the capital project is completed and placed in service, at such time the net assets are released from restrictions.

Strategic Support Assessment — On an annual basis, the University charges TUHS a strategic support assessment ("SSA") in support of the Lewis Katz School of Medicine ("LKSOM") for its mission of research and education, and the associated benefit to TUHS and the patients it serves. The amount of the SSA and payment terms are determined annually as part of the annual budget process. The revenue, recorded by the University, and the equal expense, recorded by TUHS, are eliminated in consolidation. The SSA is comprised primarily of the share of appropriation used to support matching funds under the Commonwealth of PA Medical Assistance Program (see Note 17).

Grants, Contracts, and Contributions — Temple receives sponsored program funding from various governmental, corporate, and private sources. The funding may represent a reciprocal transaction in exchange for an equivalent benefit in return, or it may be a nonreciprocal transaction in which the resources provided are for the benefit of Temple, the funding organization's mission, or the public at large.

Revenues from exchange transactions are recognized as performance obligations are satisfied, which in some cases are as related costs are incurred. Revenues from non-exchange transactions (contributions) may be subject to conditions, in the form of both a barrier to entitlement and a refund of amounts paid (or a release from obligation to make future payments). Revenues from conditional non-exchange transactions are recognized when the barrier is satisfied. In addition, Temple has elected the simultaneous release option for conditional contributions that are also subject to purpose restrictions. Under this option, net assets without donor restrictions will include the donor-restricted contributions for which the purpose restrictions are met in the same reporting period as the revenue is recognized. Funds received in advance (for an exchange transaction prior to the performance obligation being satisfied; or for a contribution non-exchange transaction, prior to the condition being achieved) are recorded as *Deferred revenue* on the consolidated balance sheets.

In 2025 and 2024, sponsored programs revenue earned from federal, state, local, and private sources totaled \$319,254 and \$247,776, respectively. The 2025 balance includes employee retention tax credits credits (see Note 24). Indirect costs recovered on federally sponsored programs are generally based on predetermined reimbursement rates, which are stated as a percentage and distributed based on the modified total direct costs incurred. The University negotiates its federal indirect rate with its cognizant federal agency. Indirect

costs recovered on all other grants and contracts are based on rates negotiated with the respective sponsors. Funds received from federal sources are subject to audit in accordance with compliance standards.

Patient Care Activities — Patient care activities provided by Temple are invoiced daily, from which revenue is recognized at a point in time as patient services are provided. *Patient care activities* include revenues from TUHS as well as clinical activities provided by the University.

Patient care activities revenue is recognized at the amount that reflects the consideration to which Temple expects to be entitled in exchange for providing patient care. These amounts are due from Medicare and Medicaid, managed care health plans, commercial payors, patients, and others. Reimbursement is primarily based on the payment terms of contractual arrangements, such as predetermined rates per visit or procedure, per diem rates, or discounted fee-for-service rates. Generally, Temple bills the patients and third-party payers several days after the services are performed and/or the patient is discharged. In addition, Temple receives medical assistance payments for the reimbursement of services for charity and uncompensated care services. The federal funding of such costs is subject to an upper payment limit and retrospective settlement.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Temple recognizes revenues for performance obligations satisfied over a period of time based on actual charges incurred in relation to total expected (or actual) charges. Temple believes that this method provides a reasonable representation of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in TUHS receiving inpatient acute care services. TUHS measures performance obligations from admission to the point where there are no further services required for the patient, which is generally the time of discharge. Temple recognizes revenues for performance obligations satisfied at a point in time, which generally relates to patients receiving outpatient services, when: (a) services are provided and (b) Temple does not believe the patient requires additional services. The patient care activities provided by the University are for outpatient type services. The University recognizes revenues for performance obligations satisfied at a point in time, which generally relates to patients receiving outpatient services, when services are provided.

Temple estimates the transaction price for patients based on gross charges for services provided, reduced by explicit price concessions which include contractual adjustments provided to third-party payers and discounts provided to uninsured patients in accordance with Temple's policy. Temple determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies and historical collection experience. Revenues are also adjusted for implicit price concessions. Implicit price concessions are determined based on historical collection experience. The implicit price concessions included in estimating the transaction price represent the difference between amounts remaining to be paid and the amounts Temple generally expects to collect based on its historical experience. Subsequent changes to the estimate of transaction price are generally recorded as adjustments to patient service revenue in the period of change and are accrued on an estimated basis in the period the related services are rendered. Adjustments may also occur in future periods as final settlements are determined.

Because Temple's patient service obligations generally relate to contracts with duration of less than one year, Temple has elected to apply the optional exemption and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

Generally, patients who are covered by third-party payors are responsible for related co-payments, coinsurance and deductibles, which vary in amount. Temple also provides services to uninsured patients and offers uninsured patients a discount from standard charges. Temple estimates the transaction price for patients with co-pays, co-insurance and deductibles and for those who are uninsured based on historical collection experience and current market conditions. Under Temple's uninsured discount programs, the discount offered to certain uninsured patients is recognized as a contractual discount, which reduces net operating revenues at the time the self-pay accounts are recorded. The uninsured patient accounts, net of contractual discounts recorded, are further reduced to their net realizable value at the time they are recorded through implicit price concessions based on historical collection trends for self-pay accounts and other factors that affect the estimation process. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to *Patient care activities* revenue in the period of the change.

Consistent with Temple's mission, care is provided to patients regardless of their ability to pay. Temple provides care without charge, or at a standard rate discounted for uninsured patients that is not related to published charges, to patients who meet certain criteria under Temple's charity care policy. Some patients qualify for charity care based on federal poverty guidelines or their financial condition being such that requiring payment would impose a hardship on the patient. Because Temple does not pursue collection of amounts determined to qualify as charity care, they are not reported as *Patient care activities* revenue. Temple has determined that it has provided sufficient explicit price concessions for these accounts (see Notes 18, 21, and 22).

In assessing collectability, Temple uses a combination of contract specific adjustments (such as high dollar and long length-of-stay accounts) as well as a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. This portfolio approach is being used as Temple has a large volume of similar contracts with similar classes of customers. Temple reasonably expects that the effect of applying a portfolio approach would not differ materially from considering each contract separately. Management's judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level.

Amounts received under Medicare and Medicaid programs are subject to review and final determination by program intermediaries or their agents and the contracts Temple has with commercial payers typically provide for retroactive audit and review of claims. Revenue includes an estimate of variable consideration for retroactive revenue adjustments due to settlements of audits, reviews and investigations. Retroactive adjustments are accrued on an estimated basis in the period the related services are rendered or when known by Temple and adjusted in future periods as final settlements or changes in estimates are determined. Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates could change by a material amount in the near term.

Temple engages in various contracts with insurance companies where Temple is at risk for the total cost of care to an attributed patient population as well as contracts that provide for pay-for-performance incentives. The value of these agreements is estimated and included in net patient service revenue.

Advertising — Temple charges the costs of advertising to expense as incurred. Advertising expense was \$22,752 and \$21,768 in 2025 and 2024, respectively.

Other Changes in Net Assets — Temple considers all realized and unrealized gains and losses on investments, net of the endowment payout under Temple's spending formula, as *Other changes in net assets*.

Other changes in net assets also includes interest and dividends on endowments and funds designated by the board of trustees to be invested as endowments; activity related to property, plant, and equipment (including grants and contributions, gains (losses) on disposals, and net assets released from restrictions); gains (losses) on extinguishment of debt; actuarial changes in accrued pensions and postretirement benefits; other components of net periodic benefit cost (see Note 5); gains (losses) on asset retirement obligations (see Note 8); gains on insurance recoveries; and foreign currency adjustments.

Income Taxes — With the exception of TUHIC (Temple’s captive insurance company domiciled in Bermuda), TESS (operator of the University’s Japan campus), and certain inactive subsidiaries (see supplemental schedule), substantially all of the individual members of Temple are not-for-profit corporations as described in Section 501(c)(3) of the Internal Revenue Code and are exempt from federal income taxes on related income pursuant to Section 501(a) of the Internal Revenue Code. Temple files U.S. federal, state, and local information returns and no returns are currently under examination. The statute of limitations on Temple’s U.S. federal information returns remains open for three years following the year they are filed.

U.S. GAAP requires that a tax position be recognized or derecognized based on a “more likely than not” threshold. This applies to positions taken or expected to be taken in a tax return. Temple does not believe its consolidated financial statements include any uncertain tax positions that would require disclosure.

Functional Expense Allocation — Temple’s operation and maintenance of plant expenses (“O&M”) and depreciation expense (excluding depreciation related to auxiliary and library books) are allocated to the functional expense classifications based upon the proportionate share of expenses (excluding O&M and depreciation) reported in each functional classification in the statement of activities. Depreciation related to auxiliary fixed assets (e.g., dormitories, parking garages, and athletics) is fully allocated to *Auxiliary enterprises expense* and depreciation related to library books is fully allocated to academic support expense included in *Academic and student services* in the statement of activities (see Note 19).

Contributions from Related Parties — During the years ended June 30, 2025 and 2024, there were contributions from members of the Board of Trustees that did not have a material impact on the consolidated financial statements.

Use of Estimates — The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Temple’s critical estimates and assumptions include explicit and implicit price concessions on patient service revenue and patient accounts receivable; revenue recognition; adequacy of allowance for accounts, loans, and contribution receivable; the valuation of assets and liabilities recorded at fair value; valuation of claim based liabilities and conditional asset retirement obligations; useful lives for depreciation and amortization; impairment of intangible assets; incremental borrowing rate used in determining the present value of lease payments; estimated settlements with third-party payors; state Medicaid audit settlements; and accounting for pension and other postretirement benefits. Actual results could differ materially from these estimates.

Recently Issued Accounting Pronouncements — Recently issued accounting pronouncements that are applicable to Temple’s consolidated financial statements are as follows:

Standard	Description	Adoption
Standards that were adopted during fiscal years 2025 and 2024:		
<p>Financial Instruments - Credit Losses</p> <p>ASU 2016-13 and subsequent amendments (Topic 326)</p>	<p>In June 2016, the FASB issued ASU 2016-13, <i>Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (“ASU 2016-13”). The ASU adds to U.S. GAAP an impairment model (known as the current expected credit loss, or “CECL” model) that is based on expected losses rather than incurred losses. Under the new guidance, an entity recognizes as an allowance its estimate of expected credit losses, which is intended to result in the more timely recognition of losses. Under the CECL model, entities will estimate credit losses over the entire contractual term of the instrument from the date of initial recognition of the financial instrument. The adoption of this standard update did not have a material impact on the consolidated financial statements. There was no impact on beginning balance net assets upon adoption of this ASU.</p>	<p>July 1, 2023</p> <p>Modified-retrospective application</p>
Standards issued, but not yet adopted:		
<p>Financial Instruments - Credit Losses</p> <p>ASU 2025-05 Financial Instruments — Credit Losses: Measurement of Credit Losses for Accounts Receivable and Contract Assets. (Topic 326)</p>	<p>In July 2025, the FASB issued ASU 2025-05, <i>Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets</i>. The new guidance provides targeted relief to simplify the application of the CECL model for certain receivables.</p> <p>The standard introduces two key changes: a practical expedient and an accounting policy election: i) Practical Expedient: provision allows all entities to assume that current economic conditions as of the balance sheet date will not change over the remaining life of the asset when estimating expected credit losses. This eliminates the need for entities to develop complex, forward-looking macroeconomic forecasts for these short-term receivables, such as student tuition and fees; and ii) Accounting Policy Election: permits an accounting policy election to consider cash collections that occur after the balance sheet date but before the financial statements are issued. This allows the University to factor in actual cash received on receivables, which can reduce the allowance for credit losses and provide a more accurate picture of collectibility.</p> <p>ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025, with early adoption permitted. Temple is currently evaluating the impact of this new standard on its consolidated financial statements. The adoption will be applied prospectively, with no restatement of prior periods required.</p>	<p>July 1, 2026</p> <p>Prospective application</p>

Remainder of this Page is Intentionally Blank

3. Endowment, Investments, and Self-Insurance Trust Funds

The carrying values of investments, including the endowment (see Note 11), at June 30, 2025 and 2024 are as follows:

	<u>June 30, 2025</u>	<u>June 30, 2024</u>
Investments (including endowment):		
Money market funds	\$ 69,595	\$ 47,015
Corporate bonds, notes, and other debt securities	421,174	403,129
U.S. government and agency securities	489,311	494,648
Municipal bonds	1,528	3,160
Fixed income funds	78,804	125,220
Equity funds and securities	1,295,642	1,142,714
Futures contracts	3,431	555
Commodity funds	18,076	18,040
Private equity funds	110,869	90,065
Real estate funds	94,148	91,437
Multi-strategy hedge funds	309,562	281,739
Opportunistic funds	36,751	37,686
Other	4,409	4,266
Total investments	<u>\$ 2,933,300</u>	<u>\$ 2,739,674</u>

The University utilizes an outsourced chief investment officer for its investment management responsibilities related to the University's endowment, pension plans, and postretirement plan assets.

The carrying values of self-insurance trust funds at June 30, 2025 and 2024 are as follows:

	<u>June 30, 2025</u>	<u>June 30, 2024</u>
Self-insurance trust funds:		
Money market funds	\$ 1,674	\$ 1,818
Corporate bonds and notes	876	142
U.S. government securities	10,869	11,120
Total self-insurance trust funds	<u>\$ 13,419</u>	<u>\$ 13,080</u>

Investment return reported in the statements of activities for the years ended June 30, 2025 and 2024 is as follows:

	<u>Year Ended June 30,</u>	
	<u>2025</u>	<u>2024</u>
Investment income:		
Interest and dividends	\$ 93,893	\$ 81,988
Realized gains, net	44,927	41,517
Change in unrealized gains, net	205,730	136,979
Total investment income (loss)	<u>\$ 344,550</u>	<u>\$ 260,484</u>

Derivatives:

Futures Contracts — A futures contract is a contractual agreement to make or take delivery of a standardized quantity of a type of commodity or financial instrument at a specified future date in accordance with the terms specified by a regulated futures exchange. The University uses equity index futures contracts to manage equity price risk. Losses in value may arise from changes in the value of the underlying instrument or if there is an illiquid secondary market for the futures contracts.

Upon entering into a futures contract, the University is required to deposit either cash or securities in an amount equal to a certain percentage of the nominal value of the contract (“initial margin”). Pursuant to the futures contract, the University agrees to receive from, or pay to, the broker an amount of cash equal to the daily fluctuation in the value of the futures contracts. Such receipts or payments are known as “variation margin” which are settled daily. Any variation margin unsettled at period-end is recorded as an unrealized gain (loss) in *Investment return in Other changes in net assets* in the statements of activities. The University recognizes a realized gain or loss when the contract is closed. Futures contracts expose the University to off-balance sheet market and liquidity risk. The University is exposed to market risk to the extent that adverse changes occur in the fair values of the underlying securities or indices. This market risk is in excess of the amount recognized in the statement of assets and liabilities. Liquidity risk represents the possibility that the University might not be able to rapidly adjust the size of its futures position in times of high volatility and financial stress at a reasonable price.

The University has credit risk associated with counterparty nonperformance. However, credit risk associated with exchange-traded contracts are typically perceived to be less because exchanges typically provide clearing house arrangements in which the collective credit of the managers of the exchange is pledged to support the financial integrity of the exchange. Margins, which may be subject to loss in the event of a default, are generally required in exchange trading and further mitigate credit risk. All of the futures contracts held by the University at June 30, 2025 and 2024 were exchange traded contracts.

At June 30, 2025 and 2024, the University had the following open futures subject to equity price risk, for which U.S. Treasury notes were pledged as collateral (see Note 14):

June 30, 2025	Number of Contracts	Notional Amount	Variation Margin Unrealized Gain
Equity price futures contracts, not designated as hedging instruments, included in:			
Endowment	1,022	\$ 162,152	\$ 3,431
Postretirement benefits plan assets	517	66,864	1,485
Pension plans assets	52	7,562	183
June 30, 2024	Number of Contracts	Notional Amount	Variation Margin Unrealized Gain
Equity price futures contracts, not designated as hedging instruments, included in:			
Endowment	582	\$ 82,663	\$ 555
Postretirement benefits plan assets	161	20,131	112
Pension plans assets	50	6,057	39

4. Accounts, Loans, and Contributions Receivable

Accounts receivable, net of allowances are as follows:

	June 30, 2025	June 30, 2024
Students	\$ 53,605	\$ 48,717
Patients	324,548	314,734
Health care programs	165,351	142,788
Grants and contracts [£]	109,463	82,152
Commonwealth (operating and capital appropriations) [^]	25,489	47,294
Recoveries from insurance providers	67,382	72,322
Other	79,303	88,092
Accounts receivable, gross	825,141	796,099
Less: Allowance for doubtful patient accounts	(541)	(720)
Less: Allowance for doubtful students, grants, contracts, and other accounts	(24,883)	(23,918)
Total accounts receivable, net	\$ 799,717	\$ 771,461

[£] Grants and contracts in 2025 includes employee retention credits (see Note 24).

[^] Decrease in Commonwealth receivables at June 30, 2025 is due to capital support from the Commonwealth for infrastructure projects that are billed quarterly. Amounts at June 30, 2024, include higher amount of capital costs incurred related to an infrastructure project for the University's School of Public Health, which was placed into service in fall 2025.

Loans to students are disbursed based on financial need and consist of loans granted by the University under federal government loan programs and loans granted from institutional resources. Upon the earlier of graduation or no longer having full-time student status, the students have a grace period, which varies by loan type, until repayment of loans is required.

The availability of funds for loans under federal government revolving loan programs is dependent on reimbursements to the pool from repayments on outstanding loans. At June 30, 2025 and 2024, funds advanced by the federal government totaled \$28,481 and \$30,578, respectively. Interest and fees collected are included in the revolving loan funds available for students. Federal loan funds are ultimately refundable to the government and are classified as liabilities in the consolidated balance sheets. Outstanding loans canceled under the program result in a reduction of the funds available for loan and a decrease in the liability to the government.

Loans to students are shown net of allowances as follows:

	June 30, 2025	June 30, 2024
Federal government loan programs:		
Perkins loan program*	\$ 6,155	\$ 8,511
Health professional and disadvantaged student loans	23,239	23,345
Nursing student loans	443	423
Federal government loan programs	29,837	32,279
Institutional loan programs	620	661
Student loans receivable, gross	30,457	32,940
Less: Allowance for doubtful federal government loan programs	(6,487)	(6,623)
Less: Allowance for doubtful institutional loan programs	(299)	(292)
Total student loans receivable, net	\$ 23,671	\$ 26,025

* On September 30, 2017, the Federal Perkins Loan program was not renewed in Congress, thus effectively ending the loan program. Previously loaned funds will continue to be collected, however, no new loans are being originated.

Student loans are considered past due when payment has not been received in over 30 days. Allowances for doubtful accounts are established based on prior collection experience and current economic factors which, in management's judgment, could influence the ability of loan recipients to repay the amounts per the loan terms. Further, the University does not evaluate the credit quality of the student loans receivable after the initial approval and calculation of the loans. Institutional loan balances are written off when they are deemed to be permanently uncollectible.

The aging of student loans receivable is as follows:

	June 30, 2025	June 30, 2024
30 days or less past due	\$ 22,645	\$ 24,317
31 through 89 days past due	550	777
90 days and greater past due	476	931
Total student loans receivable, net	<u>\$ 23,671</u>	<u>\$ 26,025</u>

Contributions receivable are unconditional promises to give, restricted by donors for scholarships, capital acquisitions, and other operating purposes. They are expected to be realized in the following periods:

	June 30, 2025	June 30, 2024
In one year or less	\$ 13,894	\$ 16,252
One to five years	29,556	25,399
Greater than five years	59,770	40,473
Contributions receivable, gross	103,220	82,124
Less: Allowance for doubtful contributions	(7,272)	(4,938)
Less: Present value discount	(19,387)	(9,467)
Total contributions receivable, net	76,561	67,719
Less: Current portion of contribution receivable, net	(9,053)	(12,829)
Non-current portion of contribution receivable, net	<u>\$ 67,508</u>	<u>\$ 54,890</u>

Changes to net contributions receivable during the years ended June 30, 2025 and 2024 are as follows:

	Year Ended June 30,	
	2025	2024
Balance, beginning of the year	\$ 67,719	\$ 59,913
New pledges	36,941	24,755
Collection of pledges	(15,371)	(14,224)
Pledges written off	(474)	(1,777)
Change in allowance	(2,334)	(401)
Change in discount to present value	(9,920)	(547)
Balance, end of the year	<u>\$ 76,561</u>	<u>\$ 67,719</u>

The discount rates used to calculate the present value discount are tied to U.S. Government treasury notes in effect at the time of contribution. Discount rates for durations between 1 and 30 years were between 4.33% and 5.09% for contributions made during the year ended June 30, 2025, and between 4.33% and 5.09% for contributions made during the year ended June 30, 2024.

Temple also receives bequest intentions and certain other conditional promises to give. These intentions and conditional promises to give are not included in the consolidated financial statements.

5. Pensions and Postretirement Benefits

Temple sponsors various postretirement programs, which include defined benefit pension plans, retiree health benefits pre-funding plans, referred to below as “postretirement benefits”, and defined contribution plans. Participation in these plans is based on prescribed eligibility requirements and certain TUHS employees also participate in the University’s defined benefit plan.

Temple makes contributions to its defined benefit pension plans that comply with the funding provisions of the Internal Revenue Code. Employees participating in the pension plans are eligible to begin receiving benefit payments upon retirement, provided age and service requirements have been met. In 2001, two of the University’s defined benefit pension plans were frozen, with no future accruals. The third pension plan sponsored by the University remains active for two collectively bargained groups of employees. In 2008, the remaining TUHS sponsored defined benefit plans were closed to new participants; only certain grandfathered employees are eligible to participate in the TUHS sponsored defined benefit pension plans.

Effective June 30, 2022, the TUHS sponsored pension plans were merged into a single defined benefit plan; and the single pension plan was subsequently terminated effective June 30, 2023. The pension plan termination was approved by the Pension Benefit Guaranty Corporation (“PBGC”). During 2025, TUHS executed a lump sum window for the terminated plan, resulting in total lump sum payments of \$14,070 to plan participants. TUHS purchased annuities totaling \$81,729 from an insurance company and transferred \$1,769 to the PBGC missing participant program. This settlement activity resulted in a settlement charge of \$41,992, recognized in *Other changes in net assets* in the 2025 statement of activities. As of June 30, 2025 all remaining plan assets and liabilities from the TUHS sponsored plans have been transferred to the insurance company.

Effective June 30, 2025, the University consolidated its three defined benefit pension plans into a single defined benefit pension plan. This consolidation did not affect the benefits provided to plan participants.

The postretirement benefits plans are postretirement trusts established for the purpose of providing medical and prescription drug coverage to eligible retirees. Eligible active employees could elect to pre-pay a portion of their future medical costs. Contributions for a period of ten years were required in order to be eligible to retire and receive benefits on or after the age of 62. This plan had a series of sunset dates beginning in 1999 through June 30, 2003. No employees hired or rehired on or after the earlier of their respective sunset date or June 30, 2003 are eligible to participate in the postretirement benefits plan.

Defined contribution retirement plans are offered to all full-time faculty and staff, with the exception of the two collectively bargained groups that participate in the defined benefit pension plan. Deposits to the defined contribution plans are provided through contributions made by Temple and its employees into participant managed accounts. Temple’s contributions to participants’ accounts are based on a defined percentage of the participants’ elected contributions, base wages, and length of service. Temple’s contributions to the defined contribution plans in 2025 and 2024 were \$97,292 and \$88,522, respectively.

Certain union employees are covered by multi-employer pension plans to which Temple contributes. A contributor to a multi-employer plan is liable, upon termination of the plan or its withdrawal from the plan, for its share of the plan’s unfunded vested liabilities. Until either event occurs, Temple’s share, if any, of the unfunded vested liabilities cannot be determined. At present, Temple has no plans to withdraw from the multi-employer pension plans. Pension expense for these plans was \$13,034 and \$12,430 in 2025 and 2024, respectively.

The activity of the defined benefit pension and postretirement benefit plans for the years ended June 30, 2025 and 2024 is as follows:

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Change in benefit obligation:				
Benefit obligation, beginning of year	\$ 169,193	\$ 174,936	\$ 307,813	\$ 294,137
Service cost	2,393	3,282	9,088	8,878
Interest cost	6,852	8,738	17,530	15,807
Plan participant contributions	267	173	1,081	1,113
Actuarial (gain) loss	1,479	(3,114)	20,249	6,042
Benefits paid	(24,466)	(11,465)	(19,424)	(18,164)
Plan expenses	(2,159)	(3,357)	—	—
Annuities purchased and PBGC transfers	(83,498)	—	—	—
Settlement	(4,239)	—	—	—
Benefit obligation, end of year	<u>\$ 65,822</u>	<u>\$ 169,193</u>	<u>\$ 336,337</u>	<u>\$ 307,813</u>
Change in plan assets:				
Fair value of plan assets, beginning of year	\$ 153,211	\$ 163,371	\$ 384,789	\$ 366,912
Actual return on plan assets	9,101	4,488	39,042	31,028
Employer contributions	15,359	—	3,820	3,900
Plan participant contributions	267	173	1,081	1,113
Benefits paid	(24,466)	(11,465)	(19,424)	(18,164)
Plan expenses	(2,159)	(3,357)	—	—
Annuities purchased and PBGC transfers	(83,498)	—	—	—
Fair value of plan assets, end of year	<u>\$ 67,816</u>	<u>\$ 153,211</u>	<u>\$ 409,308</u>	<u>\$ 384,789</u>
Funded status:				
Funded status, end of year	<u>\$ 1,994</u>	<u>\$ (15,982)</u>	<u>\$ 72,971</u>	<u>\$ 76,976</u>

The accumulated benefit obligation for the pension plans at June 30, 2025 and 2024 was \$64,574 and \$167,937, respectively.

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
The funded status recognized in the balance sheets:				
Assets, non-current	\$ 1,994	\$ 5,593	\$ 74,518	\$ 78,853
Liabilities, current	—	(16,664)	(269)	(320)
Liabilities, non-current	—	(4,911)	(1,278)	(1,557)
Net amount recognized, funded status	<u>\$ 1,994</u>	<u>\$ (15,982)</u>	<u>\$ 72,971</u>	<u>\$ 76,976</u>

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Accumulated amounts recognized in net assets without donor restrictions:				
Unrecognized net loss (gain)	\$ 13,703	\$ 61,402	\$ (70,264)	\$ (82,361)
Net amount recognized	<u>\$ 13,703</u>	<u>\$ 61,402</u>	<u>\$ (70,264)</u>	<u>\$ (82,361)</u>

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Changes in plan assets and benefit obligations recognized in other changes in net assets:				
Actuarial (gain) loss	\$ (4,450)	\$ 830	\$ 8,582	\$ (311)
Amortization of net actuarial (loss) gain	(1,113)	(1,492)	3,515	6,303
Recognition of settlement loss	(41,992)	—	—	—
Total recognized in other changes in net assets	<u>\$ (47,555)</u>	<u>\$ (662)</u>	<u>\$ 12,097</u>	<u>\$ 5,992</u>

The amortization of any prior service cost and unrecognized net loss is determined using a straight-line amortization of the cost over the average remaining service period of employees expected to receive benefits under the pension plans or the expected average future service to retirement under the postretirement benefit plan.

Temple uses the full yield curve (or spot rate) approach to estimate the service and interest costs related to Temple's pensions and postretirement benefits plans. Such approach estimates service and interest costs by applying specific spot rates along the yield curve to determine the benefit obligation of relevant projected cash outflows (as opposed to applying an average rate). The full yield curve approach (compared to an average rate approach) provides a more precise measurement of service and interest costs by aligning the timing of the plans' liability cash flows to the corresponding spot rate on the yield curve.

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Components of net periodic cost:				
Operating expenses:				
Service cost	\$ 2,393	\$ 3,282	\$ 9,088	\$ 8,878
Other changes in net assets:				
Interest cost	6,852	8,738	17,530	15,807
Expected return on plan assets	(7,267)	(8,433)	(27,372)	(24,673)
Amortization of net actuarial loss (gain)	1,113	1,492	(3,516)	(6,304)
Settlement	41,992	—	—	—
Net periodic cost (including settlement expense)	<u>\$ 45,082</u>	<u>\$ 5,079</u>	<u>\$ (4,270)</u>	<u>\$ (6,292)</u>

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Weighted-average assumptions used to determine the benefit obligations at end of year:				
Discount rate(s)	5.54%	5.41%-5.47%	5.50%	5.44%
Expected long-term rate of return on plan assets	6.80%	4.70%-6.30%	8.00%	7.30%
Rate of compensation increase	2.50%	2.50%	N/A	N/A
Assumed health care cost trend rates (pre-65 / post-65):				
Health care cost trend rate assumed for next year	N/A	N/A	7.79% / 8.39%	7.60% / 8.02%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	N/A	N/A	4.45% / 4.45%	4.45% / 4.45%
Year that ultimate rate is reached	N/A	N/A	2034 / 2034	2033 / 2033

	Pensions		Postretirement Benefits	
	2025	2024	2025	2024
Weighted-average assumptions used to determine net periodic cost at beginning of year:				
Discount rate(s) for benefit obligations	5.33%-5.47%	5.12%-5.16%	5.44%	5.14%
Discount rate(s) for service cost	5.62%	5.25%	5.63%	5.26%
Discount rate(s) for interest cost	5.29%-5.34%	5.15%-5.17%	5.27%	5.08%
Expected long-term rate of return on plan assets	4.70%-6.30%	4.50%-5.40%	7.30%	6.90%
Rate of compensation increase	2.5%	2.5%	N/A	N/A
Assumed health care cost trend rates (pre-65 / post-65):				
Health care cost trend rate assumed for current year	N/A	N/A	8.30% / 8.95%	8.35% / 8.42%
Rate to which the cost trend rate is assumed to decline (the ultimate trend rate)	N/A	N/A	4.45% / 4.45%	4.45% / 4.45%
Year that ultimate rate is reached	N/A	N/A	2034 / 2034	2033 / 2033

Plan Assets and Expected Return — The long-term investment strategy for assets held in the pension and postretirement benefits plans is to meet present and future benefit obligations to all participants and beneficiaries; cover reasonable expenses incurred to provide such benefits; and provide a total return that maximizes the ratio of assets to liabilities by maximizing investment return at the appropriate level of risk. The expected return on plan assets equals a weighted-average of the individual expected returns for each asset category in the plans’ portfolio. The target and actual asset allocation as of June 30, 2025 and 2024 is as follows (see Note 10 for plan asset fair value disclosures):

Asset class:	Pensions			Postretirement Benefits		
	Target*	2025	2024	Target*	2025	2024
Equity funds and securities	25%	21%	9%	67%	65%	53%
Fixed income and cash	75%	79%	91%	33%	35%	47%

* Target asset allocations presented above are as of June 30, 2025 and include the impact of the portable alpha overlay strategies. The target asset allocations, excluding portable alpha, are as follows: Pensions 15% equity / 85% fixed income; Postretirement benefits 62% equity / 38% fixed income. The 2024 actual asset allocations include plan assets previously sponsored by TUHS. In 2025, TUHS executed a lump sum window for its terminated pension plans and transferred all remaining plan assets and liabilities to a third-party insurance company (see above).

Expected Cash Flows — The following table shows expected cash flows of the pension and postretirement benefits plans:

	Pensions		Postretirement Benefits	
Expected contributions for next fiscal year:				
Employer	\$	—	\$	268
Employee		N/A		1,200
Estimated future benefit payments reflecting expected future service for fiscal years ending June 30:				
2026	\$	4,292	\$	20,078
2027		4,381		21,080
2028		4,517		22,118
2029		4,643		23,032
2030		4,772		23,561
2030 through 2034		24,630		122,836

Other Plans — The actuarial present value of accumulated plan benefits related to a non-active group annuity pension plan has neither been determined nor included above because a guarantee of payment to the plan’s beneficiaries has been made by The Equitable Life Assurance Society of America. This plan had total net assets available for benefits of \$601 and \$708 at June 30, 2025 and 2024, respectively.

6. Deposits with Trustees

Temple has on deposit with trustees amounts established for debt repayment. These deposits are primarily invested in U.S. Government securities and money market funds (see Note 9 for a description of debt issuances and Note 10 for fair value disclosures).

The fair values of deposits with trustees by debt issuance at June 30, 2025 and 2024 are as follows:

	June 30, 2025	June 30, 2024
Debt Repayment Funds:		
PAID, Second Series of 2016 (University)*	\$ 3	\$ 3
PAID, First Series of 2015 (University)*	9	18
PHEFA, First Series of 2010B (University)*	1,101	1,158
THHEFAP, First Series of 2022 (TUHS)	3,741	3,727
THHEFAP, First Series of 2017 (TUHS)	43,027	43,831
Total deposits with trustees	<u>\$ 47,881</u>	<u>\$ 48,737</u>

* Amount includes a federal subsidy payment received subsequent to the debt service payment and interest earned on deposits.

7. Property, Plant, and Equipment

Property, plant, and equipment at June 30, 2025 and 2024 is summarized as follows:

	June 30, 2025	June 30, 2024
Land and land improvements	\$ 147,898	\$ 143,713
Buildings and building improvements	2,859,440	2,735,096
Furniture, fixtures, equipment, and library books	1,448,723	1,418,343
Construction in progress	248,628	163,098
Property, plant, and equipment, gross	<u>4,704,689</u>	<u>4,460,250</u>
Less: Accumulated depreciation	(2,655,616)	(2,534,680)
Total property, plant, and equipment, net	<u>\$ 2,049,073</u>	<u>\$ 1,925,570</u>

Depreciation expense was \$176,979 and \$171,485 in 2025 and 2024, respectively.

In February 2025, the University acquired Terra Hall through a formal bankruptcy process. The property, formerly owned by the University of the Arts, is located at Broad and Walnut Streets in Center City, Philadelphia. The 274,000 square-foot building was acquired for approximately \$18,000, plus customary closing costs. Terra Hall will serve as the new home for Temple University Center City beginning in the 2027-2028 academic year. Additionally, the building will host specific programs for the Tyler School of Art and Architecture and the Boyer College of Music and Dance. The University plans to terminate its current center city campus lease effective June 2027 (see Note 9).

Construction in progress includes the renovation of Paley, which was placed into service in August 2025.

8. Asset Retirement Obligations

Temple has recognized liabilities for conditional asset retirement obligations, primarily related to asbestos remediation in certain University facilities, which are included in *Accrued expenses and other liabilities* in Temple's consolidated balance sheets. Changes to the asset retirement obligation liability during the years ended June 30, 2025 and 2024 are as follows:

	2025	2024
Balance, beginning of the year	\$ 19,984	\$ 19,828
Liabilities incurred	1,052	—
Accretion expense	1,104	721
Revision of estimated cash flows	45	7,891
Liabilities settled	(562)	(507)
Foreign currency translation	40	(35)
Balance, end of the year	<u>\$ 21,663</u>	<u>\$ 27,898</u>

During 2025 and 2024, the University determined that the anticipated costs to abate asbestos in certain facilities has changed and that the current estimated costs are more than the prior estimated amounts. In 2025, the University recorded new liabilities of \$1,052 related to the acquisition of a building that contains future asbestos remediation obligations. In 2024, the increase in estimated cash flows of \$7,891 consists of \$(270) in derecognition for razed buildings and \$8,161 in remeasurements.

The fair value at June 30, 2025 and 2024 of \$21,663 and \$27,898, respectively, was calculated using the expected cash flow (expected present value) valuation method with the following Level 3 inputs: years to abatement ranging from 1 to 13 years and 1 to 14 years, respectively, an inflation factor of 2.00% to 4.50% (both years), a credit-adjusted risk free rate of 4.63% to 7.00% (both years), and a contractor market risk premium of 5.00% to 5.70% (both years).

Remainder of this Page is Intentionally Blank

9. Debt and Leases

Long-term debt consists of the following at June 30, 2025 and 2024:

	Maturity	Interest Rate [†]	Effective Rate 2025	June 30,	
				2025	2024
Long-term debt:					
University bond issuances:					
Revenue Bonds, First Series of 2025, including unamortized premium of \$24,332	April 1, 2045	5.00%	1.77%	\$ 263,972	\$ —
Revenue Bonds, First Series of 2020, issued at par	April 1, 2042	0.85%-3.18%	2.40%	\$ 121,275	\$ 157,065
PAID Revenue Bonds, First Series of 2016, including unamortized premium of \$2,552 and \$0, respectively	April 1, 2029	5.00%	3.78%	—	69,727
PAID Revenue Bonds, Second Series of 2016, including unamortized premium of \$7,899 and \$0, respectively	April 1, 2036	5.00%	3.70%	—	86,009
PAID Revenue Bonds, First Series of 2015, including unamortized premium of \$8,237 and \$0, respectively	April 1, 2045	5.00%	3.76%	—	111,702
PHEFA Revenue Bonds, First Series B of 2010, issued at par	April 1, 2040	5.37%-6.29%	4.07%	101,490	106,365
Total University bond issuances				486,737	530,868
TUHS bond issuances:					
THHEFAP Hospital Revenue Bonds, Series 2022, including unamortized premium of \$21,161 and \$22,608, respectively	July 1, 2041	4.00%-5.00%	3.30%	184,159	185,605
THHEFAP Hospital Revenue Bonds, Series 2017, including unamortized premium of \$13,609 and \$15,832, respectively	July 1, 2034	5.00%	3.70%	189,184	205,331
Total TUHS bond issuances				373,343	390,936
Other long-term debt:					
PENNVEST (Pennsylvania Infrastructure Investment Authority)	May 1, 2039	1.00%-1.29%	1.00%	4,838	5,153
Loans payable (TESS)	Various	0.30%	0.30%	415	979
Equipment financing arrangements (TUHS)	December 31, 2024	2.86%		1,415	2,320
Finance leases				9,398	11,904
Deferred financing costs				(7,656)	(7,952)
Total long-term debt, net of deferred financing costs				868,490	934,208
Less: Current maturities of long-term debt				(47,472)	(46,341)
Non-current maturities of long-term debt, net of deferred financing costs				<u>\$ 821,018</u>	<u>\$ 887,867</u>

[†] Stated interest rate remaining through maturity. All bonds have an interest rate mode of fixed.

University Bond Issuances:

Revenue Bonds, First Series of 2025 — In January 2025, The University issued \$239,630 of Federally Tax-Exempt Revenue Bonds, First Series of 2025 (“First Series of 2025 Bonds”) with a stated interest rate of 5%. The proceeds from the sale of the 2025 Bonds were used to (i) refund through defeasance and redemption of the Philadelphia Authority for Industrial Development’s (a) Temple University Revenue Bonds, First Series of 2015, (b) Temple University Revenue Bonds, First Series of 2016, and (c) Temple University Revenue Bonds, Second Series of 2016, previously issued on behalf of the University; (ii) refund, through a tender offer, a portion of the University’s Federally Taxable Revenue Bonds, First Series of 2020; and (iii) pay the issuance costs of the 2025 Bonds and the tender offer expenses. The First Series of 2025 Bonds require annual principal payments of varying amounts beginning April 1, 2026 and ending on April 1, 2045, with a first option call date of April 1, 2035. The First Series of 2025 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2025 Bonds during the year ended June 30, 2025 was \$3,501.

Revenue Bonds, First Series of 2020 — On June 25, 2020, the University issued \$176,690 of Temple University Federally Taxable Revenue Bonds, First Series of 2020 (“First Series of 2020 Bonds”) with stated interest rates ranging from 0.80% to 3.18%. The proceeds from the sale of the First Series of 2020 Bonds, together with other available funds, were used for the following items: (i) advance refund, on a taxable basis, a portion of the Pennsylvania Higher Educational Facilities Authority (“PHEFA”) Temple University First Series of 2012 previously issued on behalf of the University and (ii) paying costs of issuing the First Series of 2020 Bonds. The First Series of 2020 Bonds require annual principal payments of varying amounts beginning April 1, 2021 and ending on April 1, 2042. The First Series of 2020 Bonds are subject to redemption prior to their stated maturities at the option of the University, in whole or in part, on any date at the make-whole redemption price. The make-whole redemption price is the greater of (i) 100% of the principal amount of the bonds to be redeemed and (ii) the sum of the present values of the remaining scheduled payments of principal and interest to the maturity date of the bonds to be redeemed. During 2025, the University used proceeds from the First Series of 2025 Bonds to tender and redeem a portion of the First Series of 2020 bonds, totaling \$28,565. The First Series of 2020 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series of 2020 Bonds during the years ended June 30, 2025 and 2024 was \$3,495 and \$4,112, respectively.

PAID Revenue Bonds, First Series of 2016 — In fiscal 2016, the University, via the Philadelphia Authority for Industrial Development (“PAID”) issued \$134,080 of PAID Temple University Revenue Bonds, First Series of 2016 (“First Series of 2016 Bonds”) with a stated interest rate of 5.00%. The proceeds from the sale of the First Series of 2016 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University, (ii) refunding a portion of the PHEFA Temple University Revenue Bonds, First Series of 2006, and (iii) paying costs of issuing the First Series of 2016 Bonds. The First Series of 2016 Bonds were secured by a pledge of the University's gross revenues, excluding those from TUHS. The bonds were scheduled to mature in varying annual principal payments from April 1, 2016, to April 1, 2029, with a first option call date of April 1, 2025. During 2025, the proceeds from the First Series of 2025 bonds were used to defease and redeem the outstanding principal balance of the First Series of 2016 Bonds. As of June 30, 2025, there is no outstanding balance for the First Series of 2016 Bonds. Interest expense on the First Series of 2016 Bonds during the years ended June 30, 2025 and 2024 was \$1,686 and \$2,868, respectively.

PAID Revenue Bonds, Second Series of 2016 — In fiscal 2016, the University, via PAID issued \$78,110 of PAID Temple University Revenue Bonds, Second Series of 2016 (“Second Series of 2016 Bonds”) with a stated interest rate of 5.00%. The proceeds from the sale of the Second Series of 2016 Bonds, together with other available funds, were used for the following items: (i) refunding the outstanding portion of PHEFA’s

Temple University Revenue Bonds, First Series of 2006, and (ii) paying costs of issuing the Second Series of 2016 Bonds. The Second Series of 2016 Bonds were secured by a pledge of the University's gross revenues, excluding those from TUHS. The bonds were scheduled to mature in varying annual principal payments from April 1, 2030, to April 1, 2036, with a first option call date of April 1, 2025. During 2025, the proceeds from the First Series of 2025 bonds were used to defease and redeem the outstanding principal balance of the Second Series of 2016 Bonds. As of June 30, 2025, there is no outstanding balance for the Second Series of 2016 Bonds. Interest expense on the Second Series of 2016 Bonds during the years ended June 30, 2025 and 2024 was \$2,125 and \$3,210, respectively.

PAID Revenue Bonds, First Series of 2015 — In fiscal 2016, the University, via PAID issued \$130,440 of PAID Temple University Revenue Bonds, First Series of 2015 (“First Series of 2015 Bonds”) with stated interest rates ranging from 2.00% to 5.00%. The proceeds from the sale of the First Series of 2015 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University, (ii) refunding a portion of PHEFA’s Temple University Revenue Bonds, First Series of 2006, and (iii) paying costs of issuing the First Series of 2015 Bonds. The First Series of 2015 Bonds were secured by a pledge of the University's gross revenues, excluding those from TUHS. The bonds were scheduled to mature in varying annual principal payments from April 1, 2016, to April 1, 2045, with a first option call date of April 1, 2025. During 2025, the proceeds from the First Series of 2025 bonds were used to defease and redeem the outstanding principal balance of the First Series of 2015 Bonds. As of June 30, 2025, there is no outstanding balance for the First Series of 2015 Bonds. Interest expense on the First Series of 2015 Bonds during the years ended June 30, 2025 and 2024 was \$3,030 and \$4,627, respectively.

PHEFA Revenue Bonds, First Series B of 2010 — In fiscal 2010, the University, via PHEFA issued \$143,590 of PHEFA Temple University Revenue Bonds, Federally Taxable Build America Bonds, First Series B of 2010 (“First Series B of 2010 Bonds”) with stated interest rates ranging from 4.21% to 6.29%. The proceeds from the sale of the First Series B of 2010 Bonds, together with other available funds, were used for the following items: (i) capital projects of the University and (ii) paying costs of issuing the First Series B of 2010 Bonds. The First Series B of 2010 Bonds require annual principal payments of varying amounts beginning April 1, 2016 and ending on April 1, 2040, with an optional redemption at any time upon payment of the redemption price. The First Series A of 2010 Bonds are secured by a pledge of gross revenues of the University, excluding all revenues of TUHS. Interest expense on the First Series B of 2010 Bonds during the years ended June 30, 2025 and 2024 was \$4,362 and \$4,571, respectively.

TUHS Bond Issuances:

THHEFAP Hospital Revenue Bonds, Series 2022 — In fiscal 2022, TUHS, via the Hospitals and Higher Education Facilities Authority of Philadelphia (“THHEFAP”) issued \$165,890 of THHEFAP Hospital Revenue Bonds, Series 2020. The proceeds of the Bonds were used to defease the Authority’s outstanding Revenue Bond Series A of 2012, which is recorded as a non-operating loss in other income.

THHEFAP Hospital Revenue Bonds, Series 2017 — In fiscal 2018, TUHS, via THHEFAP issued \$235,240 of THHEFAP Hospital Revenue Bonds, Series 2017. The proceeds of the Bonds were used to defease the Authority’s outstanding Revenue Bond Series A and B of 2007 and Revenue Bond Series B of 2012.

The TUHS bond issuances are generally collateralized by the assets and gross revenues of the TUHS Obligated Group. The TUHS Obligated Group includes TUHS, Temple University Hospital, Inc., Temple Physicians, Inc., Temple Health System Transport Team, Inc., American Oncologic Hospital, Institute for Cancer Research, Fox Chase Cancer Center Medical Group, Inc., and Fox Chase Network, Inc.

Interest expense on TUHS long-term debt during the years ended June 30, 2025 and 2024 was \$16,963 and \$18,059, respectively.

Temple has complied with all financial debt covenants during the years ended June 30, 2025 and 2024.

Other Long-term Debt:

PENNVEST Debt Obligation — In June 2017, the University and the Pennsylvania Infrastructure Investment Authority (“PENNVEST”) entered into an agreement for PENNVEST to provide financing totaling \$6,748 for the construction of certain storm water improvements, including a green roof assembly and green roof landscaping on the University’s library. Construction commenced in fiscal 2018 and the library project was completed and placed into service in the first quarter of fiscal year 2021. During the years ended June 30, 2020 and 2019, the University borrowed \$1,644 and \$5,104, respectively, against the obligation. The stated interest rate is 1.00% for years 1 through 5 and 1.29% for years 6 through maturity (May 1, 2039). Interest expense during the years ended June 30, 2025 and 2024 was \$65 and \$54, respectively.

Loans Payable (TESS) — In September 2019, TESS obtained two unsecured bank loans totaling \$2,792. The bank loans were in equal amounts of \$1,396 from Mizuho Bank, Ltd. (the “Mizuho Loan”) and Sumitomo Mitsui Banking Corporation (the “SMBC Loan”). Proceeds from the bank loans were used to fund TESS’ campus relocation in Tokyo, Japan. The Mizuho Loan matures in June 2029 and the SMBC Loan matured in September 2024; and both Loans accrue interest at 0.3 %. Interest expense on the two bank loans during the years ended June 30, 2025 and 2024 was \$4 and \$3, respectively.

Lines of Credit — TUHS has a \$100,000 line of credit (the “TUHS JPM Line of Credit”) with JPMorgan Chase Bank, N.A. (“JPM”) that expires in November 2025. Amounts borrowed accrue interest at the secured overnight financing rate (“SOFR”) plus 95 basis points. During 2025 and 2024, TUHS borrowed \$65,000 (both years) against the TUHS JPM line of Credit and had outstanding borrowings of \$25,000 at June 30, 2025 and \$12,000 at June 30, 2024. Interest expense on the TUHS JPM Line of Credit (related to drawn and undrawn capacity) during the years ended June 30, 2025 and 2024 was \$1,465 and \$2,013, respectively.

During 2025 and 2024, the University had a \$50,000 revolving line of credit with an accordion feature permitting certain increases to the revolving commitment up to an additional maximum principal amount of \$50,000 (the “JPM Line of Credit”) and a \$7,500 unsecured line of credit (the “JPM Unsecured Line of Credit”) from JPMorgan Chase Bank, N.A. (“JPM”). In April 2025, the JPM Line of Credit and JPM Unsecured Line of Credit were renewed (amounts unchanged) with a maturity date of April 24, 2026. Through April 24, 2025 (and unchanged through April 24, 2026), amounts borrowed against the JPM Line of Credit accrued interest at the secured overnight financing rate (“SOFR”) plus 60 basis points; with an unused fee of 15 basis points. Amounts pledged against the JPM Unsecured Line of Credit accrue interest at 60 basis points, with no unused fee. The JPM Line of Credit is secured by a subordinated gross revenue pledge of the University and is cross-defaulted to the University's covenants in the various bond documents. The JPM Line of Credit can be used to fund seasonal working capital requirements, fund capital expenditure bridge financing, and fund general corporate purposes. During the years ended June 30, 2025 and 2024, no amount under the JPM Line of Credit or JPM Unsecured Line of Credit was outstanding, drawn, or pledged as collateral. Interest expense on the JPM Line of Credit (related to undrawn capacity) during the years ended June 30, 2025 and 2024 was \$114 and \$52, respectively.

Interest — Total interest expense incurred, net of capitalized interest, was \$35,360 and \$37,561 for the years ended June 30, 2025 and 2024, respectively. Temple capitalizes interest cost on qualifying assets. There was no capitalized interest at June 30, 2025 or 2024.

Fair Value and Maturity — As of June 30, 2025 and 2024, the fair value of Temple’s bond issuances (excluding net unamortized premium of \$52,160 and \$49,904, respectively, deferred financing costs of \$7,656 and \$7,952, respectively, and accrued interest of \$13,545 and \$14,316, respectively) with a principal value of \$807,920 and \$871,900, respectively, was approximately \$856,450 and \$866,344, respectively. The fair value was determined based upon discounted cash flows at current market rates for instruments with similar remaining terms. Temple considers these valuation inputs to be Level 2 inputs in the fair value hierarchy (see Note 10). The market prices utilized reflect the rate that Temple would have to pay to a credit-worthy third-party to assume its obligation and do not reflect an additional liability to Temple.

Long-term debt matures in varying amounts through 2045. The aggregate amounts of principal payments are as follows:

2026	\$	41,430
2027		43,603
2028		43,772
2029		46,540
2030		45,851
Thereafter		593,392
Total principal payments		814,588
Deferred financing costs		(7,656)
Unamortized premium and discount, net		52,160
Finance leases		9,398
Total long-term debt, net of deferred financing costs	\$	868,490

Leases:

Temple reports its leases in accordance with FASB ASC 842 – *Leases*, which defines a lease as a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (the underlying asset) for a period of time in exchange for consideration. Both finance leases and operating leases create a right-of-use asset and a liability measured at the present value of the lease payments, with the corresponding right-of-use asset being adjusted for any prepaid (accrued) rent, lease incentives, and initial direct costs.

Temple leases certain facilities and equipment with initial terms in excess of one year. Leases with an initial term of 12-months or less are not recorded on the consolidated balance sheet; Temple recognizes lease expense for these leases on a straight-line basis over the lease term. The useful life of assets and leasehold improvements are limited by the expected lease term, unless there is a transfer of title or purchase/renewal option that is reasonably certain of exercise. There are no material restrictions or covenants imposed by Temple’s leases. See Note 2 for a summary of Temple’s lease accounting policy.

The right-of-use assets and lease liabilities under Temple’s finance and operating leases as of June 30, 2025 and 2024 are as follows:

Leases	June 30, 2025		June 30, 2024	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Assets:				
Right-of-use assets	\$ 21,224	\$ 154,649	\$ 22,308	\$ 134,701
Accumulated amortization on finance leases and periodic reduction of ROU assets on operating leases	(11,794)	(57,055)	(10,394)	(47,255)
Right-of-use assets, net	<u>\$ 9,430</u>	<u>\$ 97,594</u>	<u>\$ 11,914</u>	<u>\$ 87,446</u>
Balance sheet classification (non-current)	PP&E	Operating lease right-of-use assets	PP&E	Operating lease right-of-use assets
Liabilities:				
Current portion of lease liability, balance	\$ 3,292	\$ 13,843	\$ 3,262	\$ 13,125
Non-current portion of lease liability, balance	6,106	81,866	8,642	76,388
Lease liabilities	<u>\$ 9,398</u>	<u>\$ 95,709</u>	<u>\$ 11,904</u>	<u>\$ 89,513</u>
Current portion of lease liabilities, classification	Long-term debt, current	AP and accrued expenses	Long-term debt, current	AP and accrued expenses
Non-current portion of lease liabilities, classification	Long-term debt, non-current	Operating lease liabilities	Long-term debt, non-current	Operating lease liabilities

A summary of the components of lease expense for the year ended June 30, 2025 and 2024 is as follows:

	Natural Expense Type	2025		2024	
Operating lease cost:					
Fixed rent expense	Operating expenses	\$	15,218	\$	15,246
Finance lease cost:					
Amortization of ROU assets	Depreciation		3,239		3,499
Interest expense (on lease liability)	Interest		441		489
Short-term lease cost	Operating expenses		10,849		9,930
Variable lease cost	Operating expenses		5,389		4,126
Total lease cost		\$	<u>35,136</u>	\$	<u>33,290</u>

A maturity analysis of the future lease payments under finance and operating leases (with initial terms excess of one year) at June 30, 2025 is as follows:

Maturity of Lease Liabilities	Finance Leases		Operating Leases	
2026	\$	3,618	\$	15,528
2027		2,882		14,864
2028		2,271		11,177
2029		1,076		8,085
2030		202		7,132
Thereafter		1		49,859
Obligation, gross		<u>10,050</u>		<u>106,645</u>
Liability accretion		(652)		(10,936)
Total obligation, net of liability accretion	\$	<u>9,398</u>	\$	<u>95,709</u>

Supplemental lease information as of June 30, 2025 and 2024 is as follows:

Lease-Term and Discount Rates	June 30, 2025		June 30, 2024	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Weighted average remaining lease-term (years)	3.44	12.80	4.23	14.36
Weighted average discount rates	4.21 %	1.97 %	4.20 %	1.83 %

Supplemental Cash Flow Information	June 30, 2025		June 30, 2024	
	Finance Leases	Operating Leases	Finance Leases	Operating Leases
Cash paid for amounts included in the measurement of lease liabilities:				
Operating cash flows [§]	\$ 441	\$ 19,185	\$ 489	\$ 14,951
Financing cash flows from finance leases [†]	3,437	N/A	3,625	N/A
Right-of-use assets obtained in exchange for new and modified finance and operating lease liabilities [¢]	930	20,014	6,512	15,983

§ Payments arising from operating leases and the interest portion of finance leases are presented within operating activities in the consolidated statements of cash flows.

† Principal payments of lease liabilities arising from finance leases are included in Repayment of long-term debt and principal payments on finance leases in the financing section of the consolidated statements of cash flows.

¢ 2025 balance includes new and modified operating leases for facilities in Japan. 2024 balance includes new and modified operating leases for facilities in Japan and Rome (see below).

As most of Temple's leases do not provide an implicit rate, the incremental borrowing rate, which is based on information available at the lease commencement date, is used to determine the present value of future lease payments. Temple's incremental borrowing rate applicable to the lease, is determined by estimating what it would cost Temple to borrow a collateralized amount equal to the total lease payments over the lease term based on the contractual terms of the lease and the location of the leased asset. The incremental borrowing

rate on July 1, 2020 is used for operating leases that commenced prior to July 1, 2020 (the effective date of ASC 842).

Temple Japan — The University’s Japan Campus leases facilities space with a lease term of 20 years (terminating on July 31, 2039). After the first ten years from commencement, the University may terminate the agreement, provided a three years notice is given to the lessor. At this time, the University has no intent to terminate the lease prior to July 31, 2039. At June 30, 2025 and 2024, the present value of lease payments related to this operating lease totaled \$24,937 and \$33,197, respectively.

In January 2025, the University's Japan campus opened a satellite campus in Kyoto. The Kyoto facilities lease commenced on January 1, 2025, and extends through December 31, 2044. The University may terminate the lease with 12 months' notice. Termination within the initial 10-year term incurs a monetary penalty of 6,000 Japanese yen (approximately \$40) multiplied by the number of unused months remaining in the initial 10-year term. Currently, there is no intention to terminate the lease before December 31, 2044. At June 30, 2025, the present value of lease payments related to this operating lease totaled \$6,406.

On June 1, 2024, the University’s Japan Campus entered into an operating lease for additional facilities in Tokyo with a lease term of 20 years (terminating on May 31, 2044). After the initial ten years from commencement, the University may terminate the agreement, provided a 13 month notice and a payment of 13 months rent within six months of the notice being provided to the lessor. At this time, the University has no intent to terminate the lease prior to May 31, 2044. At June 30, 2025 and 2024, the present value of lease payments related to this operating lease totaled \$7,065 and \$6,623, respectively.

Temple Rome — Effective June 30, 2024, the University’s Rome Campus terminated the remaining term on its operating lease for its primary facilities space.

In September 2023, The University’s Rome Campus entered into an operating lease for primary facilities space with a lease term of 12 years (terminating on August 31, 2035). The University may terminate the lease, at any time, provided a 12-month notice is given to the lessor. At this time, the University has no intent to terminate the lease prior to August 31, 2035. At June 30, 2025 and 2024, the present value of lease payments related to this operating lease totaled \$9,583 and \$10,346, respectively.

Temple University Center City — The University leases facilities space in Center-City Philadelphia, for its Temple University Center City (“TUCC”) Campus. During 2022, the TUCC lease was renewed through 2027 and includes two separate three-year extension options, at the discretion of the University, that extend the lease through June 30, 2033. The University does not intend to exercise these extension options and plans to terminate the lease on June 30, 2027 (see Note 7). At June 30, 2025 and 2024, the present value of lease payments related to this operating lease totaled \$5,985 and \$9,570, respectively.

Related Party Lease Transactions — The University enters into various lease arrangements with TUHS, primarily for the use of facilities. During 2025 and 2024, lease payments to TUHS totaled \$73 and \$57, respectively, and lease payments collected from TUHS totaled \$1,104 and \$1,086, respectively.

TUHS has certain consumable agreements in which a vendor provides certain equipment at no additional cost in exchange for a commitment to purchase a minimum quantity of consumable products. These agreements are considered embedded finance leases. At June 30, 2025 and 2024, ROU assets related to these agreements totaled \$0 and \$220, respectively, (included in *Property, plant, and equipment, net*), and lease liabilities totaled \$0 and \$231, respectively, (included in *Accounts payable and accrued expenses, current*). During the years ended June 30, 2025 and 2024, amortization of the leased assets totaled \$220 and \$1,309, respectively, interest on the lease liabilities totaled \$1 and \$20, respectively, operating cash flows totaled \$1 and \$20,

respectively, and financing cash flows totaled \$231 and \$1,354, respectively. At June 30, 2025, there are no future lease payments remaining under these agreements.

10. Fair Value Measurements

Temple applies the provisions of FASB ASC 820, *Fair Value Measurement*, for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the consolidated financial statements. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

A financial asset or liability classification is determined based on the lowest level input that is significant to the fair value measurement. The fair value hierarchy consists of the following three levels:

Level 1 — Quoted prices (unadjusted) in active markets for identical assets or liabilities that Temple can access at the measurement date. Active markets are those in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 assets primarily consist of money market funds, U.S. treasury securities, equity securities, exchange traded futures contracts, and equity and fixed income mutual funds.

Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 2 assets primarily consist of corporate bonds and notes, U.S. government agency securities, municipal bonds, and certain equity and fixed income funds.

Level 3 — Unobservable inputs based on management's own assumptions used to measure assets and liabilities at fair value or assets that management does not have the ability to redeem. Level 3 inputs include values determined using pricing models, discounted cash flow methodologies, or similar techniques reflecting Temple's own assumptions. Level 3 assets consist of perpetual trusts administered by third parties for which Temple does not have the ability to manage or redeem.

Investments for which fair value is measured using the net asset value per share practical expedient are not included within the fair value hierarchy.

Remainder of this Page is Intentionally Blank

The following tables provide the financial assets and liabilities carried at fair value measured on a recurring basis as of June 30, 2025 and 2024:

June 30, 2025	Level 1	Level 2	Level 3	Total
Investments (including endowment):				
Money market funds	\$ 68,614	\$ 981	\$ —	\$ 69,595
Corporate bonds, notes, and other debt securities	1,751	419,423	—	421,174
U.S. government and agency securities	404,044	85,267	—	489,311
Municipal bonds	—	1,528	—	1,528
Fixed income funds	25,343	—	—	25,343
Equity funds and securities	915,833	—	—	915,833
Futures contracts [§]	3,431	—	—	3,431
Real estate funds	—	324	—	324
Other	—	97	—	97
Total investments in fair value hierarchy	<u>\$ 1,419,016</u>	<u>\$ 507,620</u>	<u>\$ —</u>	1,926,636
Investments measured at NAV				1,002,352
Investments carried at equity				4,312
Total investments				<u>\$ 2,933,300</u>
Self-insurance trust funds:				
Money market funds	\$ 1,674	\$ —	\$ —	\$ 1,674
Corporate bonds and notes	876	—	—	876
U.S. government securities	10,869	—	—	10,869
Total self-insurance trust funds	<u>\$ 13,419</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 13,419</u>
Deposits with trustees:				
Money market funds	\$ 24,443	\$ —	\$ —	\$ 24,443
U.S. government securities	15,646	3,344	—	18,990
Corporate bonds and notes	—	4,448	—	4,448
Total deposits with trustees	<u>\$ 40,089</u>	<u>\$ 7,792</u>	<u>\$ —</u>	<u>\$ 47,881</u>
Funds held in trust by others:				
Funds held in trust by others	\$ —	\$ —	\$ 86,482	\$ 86,482
Beneficial interest in assets held by Episcopal Foundation	—	—	32,489	32,489
Beneficial interest in the Fox Chase Cancer Center Foundation	—	—	61,304	61,304
Total funds held in trust by others	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 180,275</u>	<u>\$ 180,275</u>

[§] Futures contracts are valued at the net unrealized appreciation (depreciation) on the instrument (see Note 3).

June 30, 2025	Level 1	Level 2	Level 3	Total
Pension plans:				
Money market funds	\$ 2,965	\$ —	\$ —	\$ 2,965
Corporate bonds and notes	—	22,499	—	22,499
U.S. government and agency securities	22,663	721	—	23,384
Municipal bonds	—	525	—	525
Collateralized mortgage obligations	—	1,348	—	1,348
Equity funds	364	—	—	364
Total pension plans in fair value hierarchy	<u>\$ 25,992</u>	<u>\$ 25,093</u>	<u>\$ —</u>	51,085
Pension plans measured at NAV				<u>16,731</u>
Total pension plans				<u>\$ 67,816</u>
Postretirement plans:				
Money market funds	\$ 17,070	\$ —	\$ —	\$ 17,070
U.S. government securities	93,982	—	—	93,982
Total postretirement plans in fair value hierarchy	<u>\$ 111,052</u>	<u>\$ —</u>	<u>\$ —</u>	111,052
Postretirement plans measured at NAV				298,256
Total postretirement plans				<u>\$ 409,308</u>

Remainder of this Page is Intentionally Blank

June 30, 2024	Level 1	Level 2	Level 3	Total
Investments (including endowment):				
Money market funds	\$ 46,053	\$ 962	\$ —	\$ 47,015
Corporate bonds, notes, and other debt securities	—	403,129	—	403,129
U.S. government and agency securities	392,527	102,121	—	494,648
Municipal bonds	—	3,160	—	3,160
Fixed income funds	79,747	—	—	79,747
Equity funds and securities	802,782	—	—	802,782
Futures contracts [§]	555	—	—	555
Real estate funds	—	324	—	324
Other	—	92	—	92
Total investments in fair value hierarchy	<u>\$ 1,321,664</u>	<u>\$ 509,788</u>	<u>\$ —</u>	<u>1,831,452</u>
Investments measured at NAV				904,048
Investments carried at equity				4,174
Total investments				<u>\$ 2,739,674</u>
Self-insurance trust funds:				
Money market funds	\$ 1,818	\$ —	\$ —	\$ 1,818
Corporate bonds and notes	142	—	—	142
U.S. government securities	11,120	—	—	11,120
Total self-insurance trust funds	<u>\$ 13,080</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 13,080</u>
Deposits with trustees:				
Money market funds	\$ 28,883	\$ —	\$ —	\$ 28,883
U.S. government securities	10,900	8,954	—	19,854
Total deposits with trustees	<u>\$ 39,783</u>	<u>\$ 8,954</u>	<u>\$ —</u>	<u>\$ 48,737</u>
Funds held in trust by others:				
Funds held in trust by others	\$ —	\$ —	\$ 81,801	\$ 81,801
Beneficial interest in assets held by Episcopal Foundation	—	—	31,500	31,500
Beneficial interest in the Fox Chase Cancer Center Foundation	—	—	58,185	58,185
Total funds held in trust by others	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 171,486</u>	<u>\$ 171,486</u>

§ Futures contracts are valued at the net unrealized appreciation (depreciation) on the instrument (see Note 3).

June 30, 2024	Level 1	Level 2	Level 3	Total
Pension plans:				
Money market funds	\$ 7,480	\$ —	\$ —	\$ 7,480
Corporate bonds and notes	—	89,333	—	89,333
U.S. government and agency securities	29,253	1,018	—	30,271
Municipal bonds	—	2,224	—	2,224
Collateralized mortgage obligations	—	7,135	—	7,135
Equity funds	185	—	—	185
Total pension plans in fair value hierarchy	<u>\$ 36,918</u>	<u>\$ 99,710</u>	<u>\$ —</u>	136,628
Pension plans measured at NAV				16,583
Total pension plans				<u>\$ 153,211</u>
Postretirement plans:				
Money market funds	\$ 13,250	\$ —	\$ —	\$ 13,250
U.S. government securities	116,367	—	—	116,367
Total postretirement plans in fair value hierarchy	<u>\$ 129,617</u>	<u>\$ —</u>	<u>\$ —</u>	129,617
Postretirement plans measured at NAV				255,172
Total postretirement plans				<u>\$ 384,789</u>

Temple assesses the valuation hierarchy for each asset or liability measured on an annual basis. From time to time, assets or liabilities will be transferred within the fair value hierarchy as a result of changes in, among other things, inputs used, liquidity, or valuation methodologies.

There were no transfers into or out of Level 3, nor were there any purchases or sales of Level 3 assets.

Information for investments whose fair value is estimated using its net asset value (“NAV”) practical expedient (or its equivalent) at June 30, 2025 and 2024 is as follows:

June 30, 2025	Fair Values			Redemption	
	Investments / Endowment	Pensions	Post- retirement	Frequency	Notice Period
Commodity funds	\$ 18,076	\$ —	\$ 7,486	Daily	2 days
Multi-strategy hedge funds	309,562	7,067	81,731	Quarterly- Annual	45-90 days
Private equity	110,869	—	42,430	Illiquid	N/A
Real estate funds	93,824	—	11,111	Quarterly	45-90 days [^]
Fixed income funds	53,461	2,994	34,003	Monthly- Semi-annually	15-90 days
Equity funds	379,809	6,670	104,293	Daily- Quarterly	1-90 days
Opportunistic funds	36,751	—	17,202	Quarterly- Illiquid	60 days - N/ A
Total value	<u>\$ 1,002,352</u>	<u>\$ 16,731</u>	<u>\$ 298,256</u>		

June 30, 2024	Fair Values			Redemption	
	Investments / Endowment	Pensions	Post- retirement	Frequency	Notice Period
Commodity funds	\$ 18,040	\$ —	\$ —	Daily	2 days
Multi-strategy hedge funds	281,739	6,869	75,671	Quarterly- Annual	45-90 days
Private equity	90,065	—	35,951	Illiquid	N/A
Real estate funds	91,113	—	11,141	Quarterly	45-90 days [^]
Fixed income funds	45,473	2,728	51,680	Monthly- Semi-annually	15-90 days
Equity funds	339,932	6,986	62,776	Daily- Quarterly	1-90 days
Opportunistic funds	37,686	—	17,953	Quarterly- Illiquid	60 days - N/ A
Total value	<u>\$ 904,048</u>	<u>\$ 16,583</u>	<u>\$ 255,172</u>		

[^] Subject to fund liquidity.

Unfunded commitments at June 30, 2025 and 2024 are as follows:

	June 30, 2025			June 30, 2024		
	Endowment	Post- retirement	Total	Endowment	Post- retirement	Total
Private equity	\$ 122,347	\$ 37,668	\$ 160,015	\$ 102,859	\$ 33,266	\$ 136,125
Fixed income funds	5,162	—	5,162	3,256	—	3,256
Opportunistic funds	7,318	2,570	9,888	8,072	3,981	12,053
Unfunded commitments	<u>134,827</u>	<u>40,238</u>	<u>175,065</u>	<u>114,187</u>	<u>37,247</u>	<u>151,434</u>

Commodity funds include investments in both long and short commodity derivatives in a unitized fund structure.

Multi-strategy hedge funds include hedge fund-of-funds that invest in the commingled funds of hedge fund managers. Funds are allowed to take both long and short positions, use leverage and derivatives, and invest in many markets. Hedge funds may make equity, credit/fixed income, rate, and currency investments. Strategies employed may include long/short, event-driven, arbitrage, and macro.

Private equity investments include private partnerships, funds and/or other special purpose vehicles that invest in a range of strategies including, venture capital, growth equity, leveraged buyouts, credit-oriented opportunities, mezzanine and distressed debt, and special situations. Investments fund “start-up” companies or the buyout of existing companies or divisions within a company. Investments include domestic or international and encompass private and public securities. These funds can never be redeemed and these investments typically require capital lock-ups of 10 years or more.

Real estate funds include investments in public or private partnerships, funds and/or special purpose vehicles that make private real estate investments located within or outside the United States. Major sectors within this space include apartments, office properties, regional properties, industrial properties, and hotels, but may include land, medical facilities, self-storage and other real property investments. Investments may include

equity, debt, or both and may encompass “core”, “value-added”, or “opportunistic” opportunities. Investments are typically structured as partnerships.

Fixed income funds include investments made in commingled funds or fund-of-funds that invest in sovereign and government debt securities, corporate debt securities, U.S. Treasury Inflation-Protected securities. These funds generally seek long-term capital appreciation and provide a hedge against inflation.

Equity funds include investments made in commingled funds or fund-of-funds that invest in U.S., international, and global equity securities through a variety of active strategies. The funds generally seek long-term capital appreciation.

Opportunistic funds include investments with attractive risk/return characteristics based on a particular market environment. These investments include strategies such as private credit, distressed debt, and direct lending.

11. Endowment Funds

Temple’s endowment consists of a portfolio of actively managed individual funds established for a variety of purposes, including providing a funding source for (i) operations; (ii) scholarships and awards; (iii) academic leadership funds; and (iv) the master facility plan. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the Board of Trustees to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

Board-Designated Endowment Funds — Board-designated endowment funds are quasi-endowment funds created by the Board of Trustees by designating a portion of Temple’s net assets without donor restrictions to be invested to provide income for an intended purpose. Board-designated endowment fund assets are recognized in net assets without donor restrictions.

Interpretation of Relevant Law — ASC 958, *Not-for-Profit Entities*, provides guidance on the net asset classification of donor-restricted endowment funds for not-for-profit organizations subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act (“UPMIFA”) and improves disclosure about an organization’s endowment funds regardless of whether the organization is subject to UPMIFA. The Commonwealth has not adopted UPMIFA, but rather has enacted Pennsylvania Act 141. The Board of Trustees has interpreted Commonwealth of Pennsylvania Act 141 as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, Temple classifies amounts in its donor-restricted endowment funds as net assets with donor restrictions because those net assets are time restricted until the Board of Trustees appropriates such amounts for expenditure. Most of those net assets also are subject to purpose restrictions that must be met before reclassifying those net assets to net assets without donor restrictions. The Board of Trustees of Temple has interpreted the relevant law as not requiring the maintenance of purchasing power of the original gift amount contributed to an endowment fund, unless a donor stipulates the contrary. As a result of this interpretation, when reviewing its donor-restricted endowment funds, Temple considers a fund to be underwater if the fair value of the fund is less than the sum of (a) the original value of initial and subsequent gift amounts donated to the fund and (b) any accumulations to the fund that are required to be maintained in perpetuity in accordance with the direction of the applicable donor gift instrument. Temple has interpreted the relevant law to permit spending from underwater funds in accordance with the prudent measures required under the law. Additionally, in accordance with the relevant law, Temple considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds: (i) the duration and preservation of the fund; (ii) the purposes of the organization

and the donor-restricted endowment fund; (iii) general economic conditions; (iv) the possible effect of inflation and deflation; (v) the expected total return from income and the appreciation of investments; (vi) other resources of the organization; and (vii) the investment policies of Temple.

Underwater Endowment — From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below their original value or the level that the donor requires Temple to retain as a fund of perpetual duration. When donor-restricted endowment deficiencies exist, they are classified as a reduction of donor-restricted net assets. These deficiencies resulted from unfavorable market fluctuations that occurred subsequent to the investment of contributions (often shortly after the investment of newly established endowments) and continued appropriation for certain programs that was deemed prudent by the Board of Trustees.

Underwater endowments at June 30, 2025 and 2024 are as follows:

	<u>June 30, 2025</u>	<u>June 30, 2024</u>
Underwater endowments:		
Number of underwater donor-restricted endowments	6	7
Original gift value	\$ 1,677	\$ 1,677
Fair value	1,545	1,399
Endowment deficiencies	<u>\$ (132)</u>	<u>\$ (278)</u>

Endowment Investment Policy — Temple has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment while seeking to maintain the purchasing power of the endowment assets. Under this approach, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce results that exceed the total of the amount drawn annually for operations plus the rate of inflation and investment management fees. Temple expects its endowment funds, over time, to provide an average real rate of return, net of investment management fees, of approximately 5.00% annually. Actual returns in any given year may vary from this amount. To satisfy its long-term rate-of-return objectives, Temple relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). Temple targets a diversified asset allocation that places a greater emphasis on equity-based investments to achieve its long-term return objectives within prudent risk constraints.

Endowment Spending Policy — Annually, the Board of Trustees approves a spending rule distribution percentage that is consistent with the long-term preservation of the real value of the assets, but in no event shall the percentage be less than 2.00% nor more than 7.00% per year. In 2025 and 2024, the spending rule limited the spending of endowment resources to 4.25% (both years) for the University, and 4.00% (both years) for TUHS, of the average fair value of endowment funds for the prior twelve fiscal quarters. To the extent that current yield is inadequate to meet the spending rule, a portion of cumulative realized net gains is available for current use. These endowment funds include scholarship funds, awards funds, academic leadership funds, and master facility funds. The draw to operations under the spending policy for the years ended June 30, 2025 and 2024 totaled \$40,194 and \$38,608, respectively.

Temple's endowment balances, including board-designated endowment funds, by net asset classification at June 30, 2025 and 2024 are as follows:

June 30, 2025	Without Donor Restrictions	With Donor Restrictions	Total
Board-designated endowment funds	\$ 375,766	\$ —	\$ 375,766
Donor-restricted endowment funds:*			
Original donor-restricted gift amount and amounts required to be maintained in perpetuity by donor	—	482,448	482,448
Accumulated investment gains	—	204,377	204,377
Term endowment funds	—	17,075	17,075
Total endowment funds	<u>\$ 375,766</u>	<u>\$ 703,900</u>	<u>\$ 1,079,666</u>

June 30, 2024	Without Donor Restrictions	With Donor Restrictions	Total
Board-designated endowment funds	\$ 337,450	\$ —	\$ 337,450
Donor-restricted endowment funds:*			
Original donor-restricted gift amount and amounts required to be maintained in perpetuity by donor	—	461,957	461,957
Accumulated investment gains	—	145,893	145,893
Term endowment funds	—	15,629	15,629
Total endowment funds	<u>\$ 337,450</u>	<u>\$ 623,479</u>	<u>\$ 960,929</u>

* Excludes donor restricted funds held in trust by others of \$86,482 at June 30, 2025 and \$81,801 at June 30, 2024 (see Notes 10 and 15).

Remainder of this Page is Intentionally Blank

The changes in Temple's endowment assets (excluding changes in funds held in trust by others, see Notes 10 and 15) for the years ended June 30, 2025 and 2024 are as follows:

June 30, 2025	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of the year	\$ 337,450	\$ 623,479	\$ 960,929
Investment return:			
Net investment income	9	7,863	7,872
Net realized gain	12,154	20,151	32,305
Net unrealized gain	36,863	61,120	97,983
Total investment return	49,026	89,134	138,160
Contributions and transfers:			
Donor contributions	7	18,232	18,239
Board-designated endowment	2,050	—	2,050
Other	48	434	482
Total contributions and transfers	2,105	18,666	20,771
Appropriation of endowment assets for expenditure (spending rule)	(12,815)	(27,379)	(40,194)
Endowment net assets, end of the year	<u>\$ 375,766</u>	<u>\$ 703,900</u>	<u>\$ 1,079,666</u>

June 30, 2024	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of the year	\$ 311,619	\$ 559,126	\$ 870,745
Investment return:			
Net investment income	6	7,379	7,385
Net realized gain	20,665	33,373	54,038
Net unrealized gain	16,597	26,802	43,399
Total investment return	37,268	67,554	104,822
Contributions and transfers:			
Donor contributions	804	22,393	23,197
Board-designated endowment	100	—	100
Other	46	627	673
Total contributions and transfers	950	23,020	23,970
Appropriation of endowment assets for expenditure (spending rule)	(12,387)	(26,221)	(38,608)
Endowment net assets, end of the year	<u>\$ 337,450</u>	<u>\$ 623,479</u>	<u>\$ 960,929</u>

Remainder of this Page is Intentionally Blank

12. Liquidity and Availability of Resources

Temple's financial assets and liquidity resources available within one year of the consolidated balance sheet date for general expenses (e.g., operating expenses and scheduled payments on debt) are as follows:

	<u>June 30, 2025</u>	<u>June 30, 2024</u>
Financial assets:		
Cash and cash equivalents	\$ 404,694	\$ 408,268
Investments (excluding purpose designated funds)	1,568,450	1,524,149
Accounts, loans, and contributions receivable, net (excluding donor restricted receivables)	728,994	700,797
Appropriation of board-designated endowment assets for general operating expenditures in the following year (estimate based on the fiscal year-end fair values and board approved spending rate for the subsequent year)	9,475	8,560
Total financial assets available within one year to fund general expenses	<u>2,711,613</u>	<u>2,641,774</u>
Liquidity resources (Note 9):		
Revolving line of credit (undrawn) (University)	50,000	50,000
Revolving line of credit (undrawn) (TUHS)	75,000	88,000
Unsecured line of credit (undrawn and unpledged) (University)	7,500	7,500
Total financial assets and liquidity resources available within one year	<u>\$ 2,844,113</u>	<u>\$ 2,787,274</u>

Temple's endowment funds consist of donor-restricted and board-designated endowment funds. Income from donor-restricted endowments is restricted for specific purposes and, therefore, is not available for general expenditure. As described in Note 11, for fiscal year 2025 and 2024 the Board of Trustees approved distribution of 4.00% to 4.25% of the average fair value for the prior 12 fiscal quarters, for a total spending rule appropriation of \$40,194 and \$38,608, respectively.

Temple's cash flows have seasonal variations during the year, primarily attributable to the collection of tuition, the timing of receipts of the Commonwealth appropriation, and the collection of donor contributions, which are typically more concentrated at calendar and fiscal year-end. As part of Temple's liquidity management, Temple structures its financial assets to be available as its general expenses, liabilities, and other obligations come due. In addition, Temple invests cash in excess of daily requirements in cash equivalents and short-term investments. To help manage unanticipated liquidity needs, at June 30, 2025 and 2024, Temple has committed lines of credit in excess of \$150,000 (both years). Additionally, at June 30, 2025 and 2024, Temple's board-designated endowment totaled \$375,766 and \$337,450, respectively, of which \$222,944 and \$201,413, respectively, has been board-designated to support general operations. Although Temple does not intend to spend from its board-designated endowment, other than amounts appropriated for general expenditure as part of its annual budget approval and appropriation process, amounts from its board-designated endowment could be made available if necessary. Both the board-designated endowment and donor-restricted endowments contain investments with lock-up provisions that would reduce the total investments that could be made available. Temple also has unfunded commitments on alternative investments (see Note 9 for line of credit availability, Note 10 for investments, and Note 11 for endowments).

13. Commitments and Contingencies

From time to time, claims are made against Temple based on a variety of theories of liability, including without limitation alleged negligence, acts of discrimination, medical malpractice, breach of contract, or disagreements arising from the interpretation of laws or regulations. In the opinion of management, after consultation with legal counsel, and subject to the disclosure below, the ultimate disposition of these matters is not expected to have a material adverse effect on Temple's future financial position or changes in its net assets.

On May 5, 2020, a putative class action complaint was filed against the University in the United States District Court for the Eastern District of Pennsylvania claiming that the decision to close campus and transition to distance education in response to the COVID-19 pandemic deprived students of the benefits of in-person instruction, access to campus facilities, student activities, and other benefits and services. The complaint alleges that plaintiffs were deprived of certain opportunities and benefits during approximately 40% of the spring 2020 semester for which they paid and seeks disgorgement of a portion of tuition and a pro-rata amount of fees paid for the spring 2020 semester. The complaint was similar to many other lawsuits filed against colleges and universities in the United States since late March 2020. In September 2024, the University and the plaintiffs reached a settlement, with the University paying total monetary damages of \$6,900 in April 2025.

Under its hospital affiliation agreement with Chestnut Hill Hospital, TUHS has committed to making additional capital contributions any time a capital call is approved by the Chestnut Hill Hospital board of directors. See Note 21 for further discussion of the Chestnut Hill Hospital affiliation.

See Note 9 for commitments under finance and operating leases, Note 10 for unfunded investment commitments, and Note 14 for assets pledged as collateral.

14. Pledged Assets

At June 30, 2025 and 2024, TUHIC had restricted cash of \$444 and \$317, respectively, and non-current investments in fixed income securities of \$70,218 and \$65,539, respectively, held in trust in order to secure TUHIC's liabilities under certain reinsurance contracts.

At June 30, 2025 and 2024, the University had \$11,630 and \$6,340, respectively, of non-current investments in fixed income securities pledged as collateral under futures contracts (see Note 3). In addition, at June 30, 2025 and 2024, the University had \$5,919 and \$884, respectively, of postretirement benefits plan assets and \$424 and \$270, respectively, of pension plan assets in fixed income securities pledged as collateral under futures contracts (see Notes 3 and 5).

See Note 9 for amounts pledged as collateral under Temple's bond issuances, lines of credit, and letters and credit and Note 10 for unfunded investment commitments.

15. Net Assets

A summary of Temple's net assets is as follows:

	June 30, 2025	June 30, 2024
Net Assets:		
Without donor restrictions	\$ 3,626,841	\$ 3,327,462
With donor restrictions:		
Term endowments, life income funds, and accumulated endowment gains	221,452	161,522
Contributions for instruction, research, and support	59,978	54,796
Contributions for property, plant, and equipment	184,007	88,880
Corpus of contributions for endowments	482,448	461,957
Corpus of contributions for student loans	217	215
Funds held in trust by others	86,482	81,801
Beneficial interest in Episcopal Foundation	32,489	31,500
Beneficial interest in Fox Chase Cancer Center Foundation	61,304	58,185
Total net assets with donor restrictions	1,128,377	938,856
Total net assets	<u>\$ 4,755,218</u>	<u>\$ 4,266,318</u>

16. Accounts Payable and Other Accrued Expenses

Accounts payable and other accrued expenses at June 30, 2025 and 2024 consist of the following:

	June 30, 2025	June 30, 2024
Accounts payable	\$ 290,272	\$ 235,694
Accrued interest payable	13,545	14,316
Accrued payroll	53,174	60,176
Accrued vacation	51,073	47,845
Claim based liabilities, professional (Note 13), worker's compensation, general liability, and health and welfare benefits	315,549	349,649
Conditional asset retirement obligation (Note 8)	29,577	27,898
Student and other deposits	6,068	6,117
Employee retention credits (Note 24)	—	43,600
Operating lease liabilities (current portion)	13,843	13,125
Estimated settlements with third-party payers (Note 24)	44,887	29,301
Other	150,611	180,381
Total accounts payable and other accrued expenses	968,599	1,008,102
Less: Current portion	(647,334)	(617,830)
Non-current, accounts payable and other accrued expenses	<u>\$ 321,265</u>	<u>\$ 390,272</u>

17. Commonwealth of Pennsylvania Grants and Other Support

Temple receives support from the Commonwealth primarily in the form of appropriations (operations and capital), grants and contracts, and medical assistance supplemental funding. Medical assistance supplemental funding is to provide access to health care services, including care for the uninsured and indigent population of Pennsylvania (see Note 18). Patient care supplemental funding provided by the Commonwealth is included in *Patient care activities* revenue in the consolidated statements of activities. There is no guarantee that funding from the Commonwealth will continue consistent with historical levels or at levels requested by Temple. Under certain circumstances, Temple could be required to repay certain of the support received from the Commonwealth.

Support received from the Commonwealth during 2025 and 2024 is as follows:

	Year Ended June 30,	
	2025	2024
Commonwealth of Pennsylvania support:		
Patient care related:		
Access to care and state and local hospital assessment programs, net	\$ 467,496	\$ 407,090
Academic Health Center funding	6,662	6,521
Total patient care support	<u>474,158</u>	<u>413,611</u>
Non-patient care related:		
Appropriation	158,206	158,206
Share of appropriation used to support matching funds under the Commonwealth of PA Medical Assistance Program*	(111,322)	(92,287)
Appropriation, net	<u>46,884</u>	<u>65,919</u>
Grants and contracts	20,182	24,997
Grants for property, plant, and equipment	93,612	66,159
Total non-patient care support	<u>160,678</u>	<u>157,075</u>
Total Commonwealth of Pennsylvania support	<u><u>\$ 634,836</u></u>	<u><u>\$ 570,686</u></u>

* Amount recorded in *Patient care activities* revenue by TUHS.

Academic Health Center funding from the Commonwealth is transferred from TUHS to the University to support allowable academic health center costs. Such funding is included in *Transfer from TUHS* in the consolidated statements of activities (and eliminated in consolidation).

18. Revenue

Tuition revenue is recognized in the fiscal year in which the academic programs are delivered. Undergraduate and graduate students who adjust their course load or withdraw completely within the “drop/add period”, typically the first two weeks of the academic term, are entitled to receive a full credit for all charges and a refund for any payments made in accordance with the University’s “drop/add” policy. Professional students do not have a formal “drop/add” period and all course load adjustments for professional students are at the discretion of the University. Payments for tuition are due approximately two weeks subsequent to the start of the academic term.

When students enroll or register for classes, a contract exists between the University and the student. For professional students, this typically occurs prior to fiscal year-end for the subsequent academic year. As professional students do not have discretion over the “drop/add” process, the University considers such

contract an indication of the professional student’s financial responsibility for the tuition and fees associated with those courses and a contractual agreement to the related payment terms. For non-professional students, the contract is considered cancellable until the “drop/add” period has ended, therefore, revenue and any deferred revenue contract obligation is recorded subsequent to the “drop/add” period (or if cash is received in advance of performance obligation).

The University offers two summer sessions. Summer I is provided in fiscal quarter four and Summer II spans fiscal years. Because the academic term for Summer II spans two reporting periods, a portion of the payments for Summer II (approximately 90%) are included in deferred revenue at June 30.

Temple’s revenues primarily consist of tuition and fees, auxiliary enterprises, Commonwealth appropriations, grants and contracts, contributions, and patient care activities. Revenue recognition by revenue source is as follows (see Note 2 for additional revenue disclosures):

Revenue Source	Revenue Recognition
Tuition and fees	Ratably over the academic term
Commonwealth operating appropriation	Ratably over the fiscal year
Commonwealth capital appropriation	Expense reimbursement
Grants and contracts (exchange transaction)	As performance obligations are satisfied
Grants and contracts (conditional contributions)	When the barrier (condition) is satisfied
Contributions (non-exchange transaction)	When the barrier (condition) is satisfied. If no barrier and no right of return/release exist, then recognized when received.
Patient care activities	As services are provided
Auxiliary enterprises:	
Housing	Ratably over the academic term
Meal plans	Ratably over the academic term
Ticket sales	After event occurs
Parking passes	Ratably over the parking permit period
Other (e.g., event parking, programs, merchandise, concessions)	Point-of-sale

Deferred Revenue — Deferred revenue primarily includes payments received prior to the start of the academic term. The following table depicts activities for deferred revenue during the years ended June 30, 2025 and 2024.

	Tuition and Fees			Sponsored Contracts (Exchange)	Auxiliary Contract Liabilities	Deferred Rent	Other Deferred Revenues	Total
	Summer II (Undergrad/ Grad/ Professional)	Fall Semester (Undergrad/ Grad)	Fall Semester Professional Students					
Balance at June 30, 2023	\$ 17,288	\$ 272	\$ 18,888	\$ 55,921	\$ 17,612	\$ 2,079	\$ 9,871	\$121,931
Revenue Recognized in 2024	(17,288)	(272)	(18,888)	(55,921)	(7,294)	(932)	(9,871)	(110,466)
Cash received and contracts entered into in advance of performance	16,678	118	17,633	43,799	4,272	550	9,390	92,440
Balance at June 30, 2024	16,678	118	17,633	43,799	14,590	1,697	9,390	103,905
Revenue Recognized in 2025	(16,678)	(118)	(17,633)	(43,799)	(3,529)	(816)	(9,390)	(91,963)
Cash received and contracts entered into in advance of performance	18,231	131	17,918	29,553	3,375	3,447	7,547	80,202
Balance at June 30, 2025	<u>\$ 18,231</u>	<u>\$ 131</u>	<u>\$ 17,918</u>	<u>\$ 29,553</u>	<u>\$ 14,436</u>	<u>\$ 4,328</u>	<u>\$ 7,547</u>	<u>\$ 92,144</u>

The current portion of *Deferred revenue* of \$75,729 at June 30, 2025 will be recognized as revenue in fiscal 2026 in accordance with the revenue recognition policies described above and in Note 2.

Temple has elected the optional exemption to not disclose amounts where the performance obligation is part of a contract that has an original expected duration of one year or less. Temple expects to recognize substantially all revenue on these remaining performance obligations over the next twelve months.

Disaggregation of Revenue — In the fall semester of academic years 2025 and 2024, approximately 62% and 64%, respectively, of the University's students are residents of the Commonwealth, and approximately 38% and 36%, respectively, are from outside of Pennsylvania. The following tables provide the disaggregation of revenues at June 30, 2025 and 2024 for *Tuition and fees*, *Grants and contracts*, *Auxiliary enterprises*, and *Patient care activities*.

Revenues from *Tuition and fees*, during the years ended June 30, 2025 and 2024 were as follows:

	2025	2024
Tuition and fees revenues:		
Undergraduate students	\$ 562,572	\$ 538,526
Graduate students	114,366	110,201
Professional	152,851	150,934
Continuing education	6,117	6,606
Temple's Japan campus	38,860	31,496
Fees	45,503	43,086
Total tuition and fee revenues	<u>920,269</u>	<u>880,849</u>
Less: Discounts	(185,337)	(157,533)
Total tuition and fees revenues, net of discounts	<u>\$ 734,932</u>	<u>\$ 723,316</u>

Revenues from *Grants and contracts*, during the years ended June 30, 2025 and 2024 were as follows:

	2025	2024
Grants and contracts revenues:		
Federal [^]	\$ 220,423	\$ 142,744
Commonwealth of Pennsylvania	20,182	24,997
Local	4,596	4,214
Private	74,053	75,821
Total grants and contracts revenues	<u>\$ 319,254</u>	<u>\$ 247,776</u>

[^] Federal grants and contracts in 2025 includes employee retention credits (see Note 24).

Revenues from *Auxiliary enterprises*, during the years ended June 30, 2025 and 2024 were as follows:

	2025	2024
Auxiliary enterprises revenues:		
Housing	\$ 59,620	\$ 51,474
Meal plans	26,537	22,872
General activity fee	2,510	2,548
Athletics	13,874	12,614
Parking service	6,560	6,378
Liacouras Center	3,970	3,662
Other (primarily includes food services, bookstore, and TU Press)	8,162	8,979
Total auxiliary enterprises revenues	<u>\$ 121,233</u>	<u>\$ 108,527</u>

Revenues from *Patient care activities* recognized by major payor sources based on primary insurance designation during the years ended June 30, 2025 and 2024 were as follows:

	2025			2024		
	Inpatient	Outpatient	Total	Inpatient	Outpatient	Total
Patient care activities:						
Medicare	\$ 460,859	\$ 468,700	\$ 929,559	\$ 428,329	\$ 417,191	\$ 845,520
Medicaid	273,938	181,141	455,079	295,271	190,054	485,325
Commercial	238,444	500,798	739,242	208,675	423,073	631,748
Self-pay	637	6,967	7,604	278	6,202	6,480
Other	499,159	558,309	1,057,468	413,657	395,241	808,898
Total patient care activities*	\$ 1,473,037	\$ 1,715,915	\$ 3,188,952	\$ 1,346,210	\$ 1,431,761	\$ 2,777,971

* *Physician revenue is included in outpatient revenue in the above table.*

19. Expenses by Functional and Natural Classification

Expenses are presented by functional classification in alignment with the overall service mission of Temple. Temple's primary service missions are academic instruction, research, and patient care. Each functional classification displays all expenses related to the underlying operations by natural classification. Natural expenses attributable to more than one functional expense category are allocated using reasonable cost allocation techniques. Operation and maintenance of plant expenses ("O&M") and depreciation expense (excluding depreciation related to auxiliary and library books) are allocated to the functional expense classifications based upon the proportionate share of expenses (excluding O&M and depreciation) reported in each functional classification. Depreciation related to auxiliary fixed assets (e.g., dormitories, parking garages, and athletics) is fully allocated to *Auxiliary enterprises expense* and depreciation related to library books is fully allocated to *Academic support expense*. Interest expense on external debt is allocated to the functional categories which have benefited from the proceeds of the external debt.

Functional expense categories are as follows:

Academic and Student Services:

Instruction: Expenses for all activities that are part of the University's instruction program and include expenses for credit and noncredit courses; academic, vocational, and technical instruction; remedial and tutorial instruction; and regular, special, and extension sessions.

Academic Support: Expenses incurred to provide support services for the University's primary missions of instruction, research, and public service and includes expenses related to providing services that directly assist the academic functions of the University.

Student Services: Expenses incurred for activities with the primary purpose of contributing to students' emotional and physical well-being and intellectual, cultural, and social development outside the context of the formal instruction program. It includes expenses for student services administration; social and cultural development; counseling and career guidance; financial aid administration; student admissions; maintenance of student records; and student health services.

Student aid: Grants-in-aid, trainee stipends, tuition and fee waivers, and prizes to students.

Research and Public Service:

Research: Expenses for activities specifically organized to produce research, whether commissioned by an agency external to Temple or separately budgeted by an organizational unit within Temple.

Public Service: Expenses for activities established primarily to provide non-instructional services beneficial to individuals and groups external to the University. These activities include community service programs (excluding instructional activities) and cooperative extension services.

Institutional Support: Expenses for central, executive-level activities concerned with management and long-range planning for the entire University. Institutional support includes executive management, fiscal operations, general administration, and public relations/development.

Auxiliary Enterprises: Expenses relating to the operation of auxiliary enterprises. Auxiliary enterprises exist to furnish goods or services to students, faculty, staff, other institutional departments, or incidentally to the general public, and charges a fee directly related to, although not necessarily equal to, the cost of the goods or services. The distinguishing characteristic of an auxiliary enterprise is that it is managed as an essentially self-supporting activity. Auxiliary enterprises include residence halls, food services, intercollegiate athletics, University stores, faculty clubs, and parking.

Patient Care Activities: Primarily includes expenses associated with TUHS, as well as expenses from the University's medicine, podiatry and dental programs.

Expenses by functional and natural classification for the year ended June 30, 2025 and 2024 are as follows:

2025	Academic and Student Services	Research and Public Service	Institutional Support	Operations and Maintenance	Auxiliary Enterprises	Patient Care Activities	Total Expenses
Salaries and wages	\$ 458,032	\$ 134,165	\$ 77,392	\$ 37,369	\$ 27,779	\$ 1,292,243	\$ 2,026,980
Employee benefits	132,365	35,293	24,133	9,995	7,955	316,381	526,122
Operating expenses	125,337	88,846	64,079	58,245	70,968	1,318,012	1,725,487
Allocations and cost recoveries:							
Depreciation	61,280	18,606	12,028	140	24,378	60,547	176,979
Interest on indebtedness	6,978	761	709	(207)	10,253	16,866	35,360
Operations and maintenance	55,779	18,764	12,272	(84,399)	—	49,901	52,317
TUHS cost recovery	(535)	5	(10,447)	(21,143)	—	32,120	—
Total operating expenses	<u>\$ 839,236</u>	<u>\$ 296,440</u>	<u>\$ 180,166</u>	<u>\$ —</u>	<u>\$ 141,333</u>	<u>\$ 3,086,070</u>	<u>4,543,245</u>
Other components of net periodic postretirement benefit cost							(12,209)
Total							<u>\$ 4,531,036</u>

2024	Academic and Student Services	Research and Public Service	Institutional Support	Operations and Maintenance	Auxiliary Enterprises	Patient Care Activities	Total Expenses
Salaries and wages	\$ 439,472	\$ 127,561	\$ 81,989	\$ 34,851	\$ 25,786	\$ 1,208,291	\$ 1,917,950
Employee benefits	113,285	30,397	21,826	8,870	6,749	292,053	473,180
Operating expenses	117,466	87,674	58,981	63,461	65,641	1,048,703	1,441,926
Allocations and cost recoveries:							
Depreciation	60,251	18,483	12,395	197	24,463	55,696	171,485
Interest on indebtedness	7,344	1,125	738	(212)	10,911	17,656	37,562
Operations and maintenance	56,485	19,477	13,035	(86,436)	—	48,474	51,035
TUHS cost recovery	(602)	—	(10,114)	(20,731)	—	31,447	—
Total operating expenses	<u>\$ 793,701</u>	<u>\$ 284,717</u>	<u>\$ 178,850</u>	<u>\$ —</u>	<u>\$ 133,550</u>	<u>\$ 2,702,320</u>	<u>4,093,138</u>
Other components of net periodic postretirement benefit cost							(13,373)
Total							<u>\$ 4,079,765</u>

20. Medical Professional Liability Insurance

Temple purchases primary commercial claims-made insurance coverage for medical professional liability claims from a commercial insurer, which in turn reinsures all of the risk with TUHIC, a wholly-owned captive insurance company domiciled in Bermuda. Temple is self-insured through its captive insurance company. In addition, Temple obtains \$500 (\$1,500 aggregate) coverage for its physicians from the Medical Care Availability and Reduction of Error fund (“Mcare”) and also purchases excess coverage from unaffiliated commercial insurers.

The Mcare Act was enacted by the Pennsylvania legislature in 2002. The Mcare Act created the Mcare Fund, which is the state-mandated funding mechanism for the payment of medical malpractice claims exceeding the primary layer of professional liability insurance carried by Temple’s physicians and other health care providers practicing in the state. The Mcare Fund is funded on a pay-as-you-go basis. The Mcare Fund levies health care provider surcharges, calculated as a percentage of the premiums established by the Joint Underwriting Association (also a Commonwealth of Pennsylvania agency) for basic coverage, to pay claims and administrative expenses on behalf of Mcare Fund participants. The Mcare Act legislation provides for the gradual phase-out of Mcare Fund coverage; however, this has been deferred by the Pennsylvania legislation and will be considered in the future.

Self-insured professional liabilities include amounts for reported claims, which, depending on occurrence and aggregate limits, are retained by Temple’s insurance captive or TUHS, and claims incurred but not reported, which are retained by TUHS. The gross carrying amount of accrued asserted and unasserted actuarially determined professional liability claims, includes self-insured professional liabilities plus amounts retained by Mcare and commercial insurers. Professional liabilities (discounted at 4.00% at June 30, 2025 and 4.75% at June 30, 2024) and related recoveries are as follows:

	June 30, 2025	June 30, 2024
Accrued professional liability claims retained, net	\$ 207,384	\$ 239,031
Plus: Accrued liabilities above retention limits (estimated insurance recoveries)	66,208	70,378
Accrued professional liability claims, gross	273,592	309,409
Less: Current portion of accrued professional liability claims, gross	(47,442)	(83,387)
Non-current, accrued professional liability claims, gross	<u>\$ 226,150</u>	<u>\$ 226,022</u>

Professional liability claims are included in *Accrued expenses* with the corresponding estimated insurance recoveries recorded in *Accounts, loans, and contributions receivable, net* in Temple's consolidated balance sheets.

21. Patient Care Activities

Temple provides health care services primarily to area residents through its inpatient and outpatient care facilities in the Greater Philadelphia Metropolitan Area. Temple serves a disproportionately high number of poor or indigent patients and accordingly, derives a substantial portion of its patient care revenues from the Federal Government (Medicare) and Commonwealth of Pennsylvania (Medical Assistance) programs. At June 30, 2025 and 2024, Temple had net accounts receivable from Medicare of \$77,063 and \$78,100, respectively, and from Medical Assistance of \$39,204 and \$36,276, respectively (see Note 4).

Patient accounts receivables are written off against the allowance for doubtful accounts when management determines that recovery is unlikely and Temple ceases collection efforts. Overall, the total of self-pay write-offs for the year ended June 30, 2025 has not changed significantly from the year ended June 30, 2024. Temple has not experienced significant changes in write-off trends nor has Temple changed its charity care policy (see Note 22).

As discussed in Note 2, *Patient care activities* revenue includes estimates of reimbursement from third-party payers. During the years ended June 30, 2025 and 2024, Patient care activities revenue increased by \$35,311 and \$24,611, respectively, as a result of settlements related to prior years and changes in estimates associated with Medicare cost reports and state Medicaid audits. Audits pertaining to fiscal years through 2016 have been closed.

Chestnut Hill Hospital — On August 8, 2022, TUHS formed an alliance with Redeemer Health ("Redeemer") and Philadelphia College of Osteopathic Medicine ("PCOM"), and collectively signed a definitive agreement to acquire Chestnut Hill Hospital and its associated physician practice plan, Chestnut Hill Clinic Company, LLC ("CHC") from Tower Health. The alliance completed the acquisition on January 1, 2023 for a purchase price of \$28,000. CHH Community Health, Inc. ("CHH") is a newly-formed Pennsylvania nonprofit corporation which owns and operates Chestnut Hill Hospital. CHC is a Pennsylvania limited liability company which employs the physicians and operates the physician practices that support Chestnut Hill Hospital, with CHH as its sole member.

TUHS is the majority equity-holder of CHH, with 80% ownership (60% as of June 30, 2025), and manages the 148-bed hospital, operating under the name Temple Health – Chestnut Hill Hospital. PCOM has the remaining 20% ownership in CHH and has substantive participating rights. Through August 27, 2025, Redeemer owned 20% of CHH, however, effective August 28, 2025, TUHS acquired Redeemer's 20% ownership (see Note 25). TUHS accounts for its investment in CHH under the equity method. TUHS's initial investment in CHH was \$16,800. For the years ended June 30, 2025 and 2024, TUHS's share of CHH's net loss was \$(3,663) and \$(17,005), respectively, and is included within *Other sources revenue* in the consolidated statements of operations. At June 30, 2025 and 2024, the value of TUHS' investment in CHH was \$0 (both years). At June 30, 2025 and 2024, TUHS also had \$32,465 and \$35,512, respectively, of current receivables included in current *Accounts, loans, and contributions receivable, net*, and \$9,200 (both years) of long-term receivables due from CHH included in non-current *Other assets*, and \$4,921 and \$4,680, respectively, of payables owed to CHH, current *Accounts payable and accrued expenses* in the consolidated balance sheets.

See Note 18 for a summary of Patient care activities revenues recognized by major payor sources based on primary insurance designation.

22. Charity Care

Temple maintains detailed records to identify and monitor the level of charity care it provides to its patients. Charity care costs are estimated by applying an overall cost to charge ratio to charity care charges. During the years ended June 30, 2025 and 2024, the estimated costs and expenses incurred to provide charity care, including the estimated unreimbursed cost of services in excess of specific payments for services rendered to Medical Assistance recipients, were \$268,557 and \$262,986, respectively (see Note 17).

23. Intangible Assets

At June 30, 2025 there are no intangible assets recorded on the consolidated balance sheet. At June 30, 2024, amortizing intangible assets totaled \$109 and related primarily to the affiliation with American Oncologic Hospital (“AOH”). There were no intangible assets acquired during 2025 or 2024.

At June 30, 2025 and 2024, Temple does not hold any goodwill or other no non-amortizing intangible assets. Details of amortizing intangible assets as of June 30, 2025 and 2024 are as follows:

	Amortizing			
	Gross Carrying Amount*	Accumulated Amortization	Current Year Impairment	Net Book Value
June 30, 2025				
Intellectual property	\$ 3,545	\$ (3,545)	\$ —	\$ —
Contracts and agreements	1,508	(1,508)	—	—
Physician contracts	2,238	(2,238)	—	—
Other	619	(619)	—	—
Total intangible assets	\$ 7,910	\$ (7,910)	\$ —	\$ —
June 30, 2024				
Intellectual property	\$ 3,545	\$ (3,436)	\$ —	\$ 109
Contracts and agreements	1,860	(1,508)	(352)	—
Physician contracts	2,238	(2,238)	—	—
Other	619	(619)	—	—
Total intangible assets	\$ 8,262	\$ (7,801)	\$ (352)	\$ 109

* Net of impairments recorded in prior years.

Amortization expense for the years ended June 30, 2025 and 2024 was \$109 and \$199, respectively. Amounts were fully amortized at June 30, 2025.

The changes in the carrying amount of intangible assets for the years ended June 30, 2025 and 2024 are as follows:

	Other Intangibles
Balance, June 30, 2023	\$ 660
Amortization	(199)
Impairment, amortizing assets	(352)
Balance, June 30, 2024	109
Amortization	(109)
Balance, June 30, 2025	\$ —

24. Employee Retention Credits

In response to the COVID-19 pandemic, the federal government, through the Internal Revenue Service (“IRS”), established the Employee Retention Credit (“ERC”). This credit was available to businesses that continued paying employees during qualifying periods of closure or significant declines in gross receipts, specifically from March 13, 2020, to December 31, 2021. Eligible employers could claim the ERC by filing original or adjusted employment tax returns.

In calendar year 2022, the University filed for ERCs covering March 13, 2020, to June 30, 2021, totaling \$68,308. The University received \$42,078 in ERCs and \$1,522 in accrued interest in the fourth quarter of 2023, and \$26,230 in ERCs and \$4,338 in accrued interest in the first quarter of 2026.

Upon formal review by the IRS and full payment, ERCs of \$68,308 are recorded as federal *Grant revenues*, and the total interest of \$5,860 is included in *Investment return, net of expenses* in the 2025 statement of activities. ERCs and related interest totaling \$30,567, received subsequent to June 30, 2025, are included in current *Accounts, loans, and contributions receivable, net*. ERCs and related interest totaling \$43,600, received in prior periods, are included in non-current *Accrued expenses and other liabilities* in the 2024 balance sheet.

25. Subsequent Events

Temple has evaluated subsequent events through October 28, 2025, the date the consolidated financial statements were available to be issued. Except as noted below, there were no events requiring adjustments to or disclosure in the consolidated financial statements.

In August 2025, TUHS acquired Redeemer’s 20% ownership interest in CHH through the issuance of a promissory note, and all rights related to this ownership interest were transferred to TUHS. Subsequent to the transaction, TUHS owns 80% of CHH. Per the terms of the promissory note, a principal payment of \$6,211, together with simple interest of 5% per annum are due to Redeemer on September 1, 2027 (see Note 21).

In September 2025, the University received ERCs totaling \$26,230 plus \$4,338 of accrued interest (see Note 24).

* * * * *

Supplemental Schedules

The following schedules reflect the changes in net assets without donor restrictions for the University and its controlled entities. The columnar classification reflects the various budgetary categories and operations of Temple. Most patient care activities are provided by TUHS. Activities in the University's *Clinical Practice Plan* include clinical activities performed by the LKSOM. The remaining *Patient care activities* provided by the University's podiatry and dental programs are included in *Educational and General* services. *Other long-term* net assets include the net book value of property, plant, and equipment, net assets set aside to retire debt, University matching of federal loan programs, and the unfunded liability for pensions and postretirement benefits.

TEMPLE UNIVERSITY — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES

Changes in Net Assets Without Donor Restrictions — For the Year Ended June 30, 2025 (in thousands)

	Net Assets Without Donor Restrictions										
	Temple University Health System	Temple Educational Support Services	University, Excluding Temple Educational Support Services							Consolidating Eliminations	Total
			Clinical Practice Plan	Educational and General	Quasi - Endowment	Externally Sponsored Activities	Unexpended Capital	Other Long-term	Total University		
Revenues:											
Tuition and fees, net of discounts of \$185,337	\$ —	\$ 43,010	\$ —	\$ 694,072	\$ —	\$ —	\$ —	\$ —	\$ 694,072	\$ (2,150)	\$ 734,932
Commonwealth of Pennsylvania appropriation	—	—	—	46,884	—	—	—	—	46,884	—	46,884
Strategic support assessment (Note 19)	—	—	—	127,322	—	—	—	—	127,322	(127,322)	—
Grants and contracts	48,796	—	—	49,269	—	221,189	—	—	270,458	—	319,254
Contributions for operations and endowments	4,639	—	—	1,530	7	21,911	—	—	23,448	—	28,087
Investment return	50,062	853	—	56,894	—	35,093	—	2,310	94,297	—	145,212
Sales of educational activities	—	—	—	15,033	—	—	—	—	15,033	—	15,033
Auxiliary enterprises	—	—	—	119,889	—	—	89	1,255	121,233	—	121,233
Patient care activities	3,185,989	—	—	2,963	—	—	—	—	2,963	—	3,188,952
Other sources	47,128	—	—	9,073	—	3,337	114	47	12,571	—	59,699
Net assets released from restrictions	6,741	—	—	—	—	2,500	—	—	2,500	—	9,241
Total revenues	3,343,355	43,863	—	1,122,929	7	284,030	203	3,612	1,410,781	(129,472)	4,668,527
Expenses:											
Educational and general	64,687	37,263	—	932,763	—	179,297	7,493	96,489	1,216,042	(2,150)	1,315,842
Auxiliary enterprises	—	—	—	105,165	—	1,004	534	34,630	141,333	—	141,333
Patient care activities	3,207,346	—	12	5,983	—	—	—	51	6,046	(127,322)	3,086,070
Total expenses	3,272,033	37,263	12	1,043,911	—	180,301	8,027	131,170	1,363,421	(129,472)	4,543,245
Transfers:											
Property, plant, and equipment (PP&E) acquisitions	—	—	—	(35,593)	—	(2,324)	(153,866)	191,783	—	—	—
Retirement of indebtedness	—	—	—	(43,924)	—	—	(1,619)	45,543	—	—	—
Capital replacement and expansion	—	—	(2)	(31,613)	—	(67)	31,682	—	—	—	—
Other transfers	—	—	1	(12,793)	2,098	(29,924)	41,012	(394)	—	—	—
Total transfers	—	—	(1)	(123,923)	2,098	(32,315)	(82,791)	236,932	—	—	—
Excess (deficit) of revenues over expenses and transfers	71,322	6,600	(13)	(44,905)	2,105	71,414	(90,615)	109,374	47,360	—	125,282
Other changes in net assets:											
Investment return	68,088	—	—	19,450	36,211	—	—	591	56,252	—	124,340
Contributions for PP&E	—	—	—	—	—	—	1	—	1	—	1
Loss on extinguishment of debt	—	—	—	—	—	—	—	20,411	20,411	—	20,411
(Loss) gain on disposal of PP&E, net	(213)	(2)	—	—	—	—	—	(886)	(886)	—	(1,101)
Actuarial change in accrued pensions and postretirement	46,450	—	—	—	—	—	—	(10,848)	(10,848)	—	35,602
Other components of NPBC (Note 5)	651	—	—	11,558	—	—	—	—	11,558	—	12,209
Loss on asset retirement obligation	—	—	—	—	—	—	—	(1,052)	(1,052)	—	(1,052)
Transfer from TUHS, net	19,398	—	—	(22,099)	—	—	2,701	—	(19,398)	—	—
Currency translation adjustment	—	1,285	—	136	—	—	—	—	136	—	1,421
Pension settlement charge	(41,992)	—	—	—	—	—	—	—	—	—	(41,992)
Net assets released from restrictions for PP&E	4,733	—	—	19,433	—	—	92	—	19,525	—	24,258
Total other changes in net assets	97,115	1,283	—	28,478	36,211	—	2,794	8,216	75,699	—	174,097
Change in net assets without donor restrictions	168,437	7,883	(13)	(16,427)	38,316	71,414	(87,821)	117,590	123,059	—	299,379
Net assets without donor restrictions, beginning of year	909,828	19,061	11,833	680,353	337,450	119,992	188,977	1,059,968	2,398,573	—	3,327,462
Net assets without donor restrictions, end of year	\$ 1,078,265	\$ 26,944	\$ 11,820	\$ 663,926	\$ 375,766	\$ 191,406	\$ 101,156	\$ 1,177,558	\$ 2,521,632	\$ —	\$ 3,626,841

TEMPLE UNIVERSITY — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES

Changes in Net Assets Without Donor Restrictions — For the Year Ended June 30, 2024 (in thousands)

	Net Assets Without Donor Restrictions										
	Temple University Health System	Temple Educational Support Services	University, Excluding Temple Educational Support Services							Consolidating Eliminations	Total
			Clinical Practice Plan	Educational and General	Quasi - Endowment	Externally Sponsored Activities	Unexpended Capital	Other Long-term	Total University		
Revenues:											
Tuition and fees, net of discounts of \$157,533	\$ —	\$ 35,432	\$ —	\$ 689,933	\$ —	\$ 1	\$ —	\$ —	\$ 689,934	\$ (2,050)	\$ 723,316
Commonwealth of Pennsylvania appropriation	—	—	—	65,919	—	—	—	—	65,919	—	65,919
Strategic support assessment (Note 19)	—	—	—	101,787	—	—	—	—	101,787	(101,787)	—
Grants and contracts	45,590	—	—	47,809	—	154,377	—	—	202,186	—	247,776
Contributions for operations and endowments	4,835	—	—	1,910	804	18,861	—	—	21,575	—	26,410
Investment return	17,933	523	—	55,012	—	27,989	—	1,550	84,551	—	103,007
Sales of educational activities	—	—	—	14,708	—	—	—	—	14,708	—	14,708
Auxiliary enterprises	—	—	—	106,826	—	—	411	1,290	108,527	—	108,527
Patient care activities	2,775,358	—	12	2,601	—	—	—	—	2,613	—	2,777,971
Other sources	25,364	—	—	9,030	—	2,864	432	12	12,338	—	37,702
Net assets released from restrictions	7,565	—	—	—	—	2,339	—	—	2,339	—	9,904
Total revenues	2,876,645	35,955	12	1,095,535	804	206,431	843	2,852	1,306,477	(103,837)	4,115,240
Expenses:											
Educational and general	59,267	29,586	—	891,624	—	168,740	13,515	96,586	1,170,465	(2,050)	1,257,268
Auxiliary enterprises	—	—	—	96,281	—	788	1,107	35,374	133,550	—	133,550
Patient care activities	2,798,341	—	67	5,643	—	—	—	56	5,766	(101,787)	2,702,320
Total expenses	2,857,608	29,586	67	993,548	—	169,528	14,622	132,016	1,309,781	(103,837)	4,093,138
Transfers:											
Property, plant, and equipment (PP&E) acquisitions	—	—	—	(13,118)	—	(4,414)	(109,622)	127,154	—	—	—
Retirement of indebtedness	—	—	—	(44,745)	—	—	(1,619)	46,364	—	—	—
Capital replacement and expansion	—	—	(2)	(49,990)	—	(130)	50,122	—	—	—	—
Other transfers	—	—	—	16,126	146	(32,182)	16,507	(597)	—	—	—
Total transfers	—	—	(2)	(91,727)	146	(36,726)	(44,612)	172,921	—	—	—
Excess (deficit) of revenues over expenses and transfers	19,037	6,369	(57)	10,260	950	177	(58,391)	43,757	(3,304)	—	22,102
Other changes in net assets:											
Investment return	64,255	—	—	10,178	24,881	—	—	19	35,078	—	99,333
Commonwealth grants for PP&E	—	—	—	—	—	—	2,300	—	2,300	—	2,300
Contributions for PP&E	—	—	—	—	—	—	1	—	1	—	1
(Loss) gain on disposal of PP&E, net	(28)	—	—	(56)	—	—	—	(3,942)	(3,998)	—	(4,026)
Actuarial change in accrued pensions and postretirement	(1,760)	—	—	—	—	—	—	(3,570)	(3,570)	—	(5,330)
Other components of NPBC (Note 5)	2,301	—	—	11,072	—	—	—	—	11,072	—	13,373
Loss on asset retirement obligation	20	—	—	—	—	—	—	(8,161)	(8,161)	—	(8,141)
Transfer from TUHS, net	(14,321)	—	—	11,761	—	—	2,560	—	14,321	—	—
Currency translation adjustment	—	394	—	(78)	—	—	—	—	(78)	—	316
Net assets released from restrictions for PP&E	4,504	—	—	—	—	—	113	—	113	—	4,617
Total other changes in net assets	54,971	394	—	32,877	24,881	—	4,974	(15,654)	47,078	—	102,443
Change in net assets without donor restrictions	74,008	6,763	(57)	43,137	25,831	177	(53,417)	28,103	43,774	—	124,545
Net assets without donor restrictions, beginning of year	835,820	12,298	11,890	637,216	311,619	119,815	242,394	1,031,865	2,354,799	—	3,202,917
Net assets without donor restrictions, end of year	\$ 909,828	\$ 19,061	\$ 11,833	\$ 680,353	\$ 337,450	\$ 119,992	\$ 188,977	\$ 1,059,968	\$ 2,398,573	\$ —	\$ 3,327,462

TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES
Subsidiary Organizations
June 30, 2025

The following is a summary of Temple's subsidiary organizations included in the consolidated financial statements and their tax-exempt status. Unless otherwise indicated, all exempt organizations are such under Internal Revenue Code Section 501(c)(3).

**TEMPLE UNIVERSITY —
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION AND ITS SUBSIDIARIES**

Subsidiary Organizations

June 30, 2025

Temple University — Of The Commonwealth System of Higher Education ("Temple"), exempt

Temple Educational Support Services, Ltd. ("TESS"), non-exempt (Japan Domicile)

Temple University School of Podiatric Medicine, Inc. ("TUSPM"), exempt 501(c)(2)

Good Samaritan Insurance Co. Ltd. ("GSIC"), non-exempt (Bermuda Domicile) (inactive)

TUMP Offices, Inc. ("TUMP"), exempt 501(c)(2) (inactive)

Global Technology Management Corp. ("GTM"), non-exempt (inactive)

Temple University Health System, Inc. ("TUHS"), exempt

Temple University Hospital, Inc. ("TUH"), exempt

Temple University Health System Foundation ("TUHSF"), exempt

TUH - Jeanes Campus Auxiliary ("Jeanes"), exempt

Temple Health Subsidiaries, Inc. ("THS"), non-exempt (inactive)

Temple Physicians, Inc. ("TPI"), exempt

Temple Faculty Practice Plan, Inc. ("TFPP"), exempt

Episcopal Hospital ("EH"), exempt

TUHS Insurance Co., Ltd. ("TUHIC"), non-exempt (Bermuda Domicile)

Temple Health System Transport Team, Inc. ("T3"), exempt

Temple Center for Population Health, LLC ("TCPH"), non-exempt

Temple Care, Inc. ("TC"), non-exempt

The American Oncologic Hospital ("AOH"), doing business as, Hospital of the Fox Chase Cancer Center, exempt

Fox Chase Limited ("FC"), non-exempt

The Institute for Cancer Research ("ICR"), doing business as, The Research Institute of Fox Chase Cancer Center, exempt (Delaware Domicile)

Fox Chase Network, Inc. ("Network"), exempt

Fox Chase Cancer Center Medical Group, Inc. ("MGI"), exempt

Temple Health Physicians, P.C. ("THP"), exempt (New Jersey Domicile)

CHH Community Health, Inc. ("CHH"), doing business as, Temple Health – Chestnut Hill Hospital and/or Chestnut Hill Health, exempt. Effective August 18, 2025, TUHS maintains 80% ownership interest in CHH and the Philadelphia College of Osteopathic Medicine ("PCOM"), exempt, maintains 20% ownership interest in CHH. CHH is the sole member of Chestnut Hill Clinic Company, LLC. (doing business as, Chestnut Hill Physicians). Effective May 3, 2022, and through August 17, 2025, ownership of CHH was follows: TUHS 60%, PCOM, exempt, 20%, and Holy Redeemer Health System, exempt, 20%.

FEDERAL AWARDS SECTION

INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF CONSOLIDATED FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

To the Board of Trustees
Temple University- Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Temple University- Of The Commonwealth System of Higher Education and its subsidiaries ("Temple"), which comprise the consolidated balance sheet as of June 30, 2025, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, which collectively comprise Temple's consolidated financial statements (collectively referred to as the "financial statements") and have issued our report thereon dated October 28, 2025.

The financial statements of Temple include various subsidiaries as outlined in Note 1 to the consolidated financial statements. The consolidated financial statements of Temple University- Of The Commonwealth System of Higher Education, includes subsidiaries of Temple University Health System Inc. ("TUHS"). The subsidiary of TUHS; TUHS Insurance Company, Ltd.; was audited by us; and the subsidiary of Temple; Temple Educational Support Services Ltd.; which was audited by other auditors were audited in accordance with generally accepted auditing standards, but were not audited in accordance with *Government Auditing Standards* and accordingly this report does not include reporting on internal control over financial reporting or instances of reportable noncompliance or other matters associated with these entities.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered Temple's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinions on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control. Accordingly, we do not express an opinion on the effectiveness of Temple's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination

of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of Temple's financial statements will not be prevented or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Temple's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Temple's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Temple's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

October 28, 2025



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103-3984
USA
Tel: +1 215 246 2300
Fax: +1 215 569 2441

**INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM;
REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF
EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE**

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Temple University – Of The Commonwealth System of Higher Education's ("Temple") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of Temple's major federal programs for the year ended June 30, 2025. Temple's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Temple complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2025.

Our audit, described below, did not include the operations of Temple Educational Support Services, Ltd; Temple University School of Podiatric Medicine, Inc.; Good Samaritan Insurance Co. Ltd.; TUMP Offices, Inc.; Global Technology Management Corp.; Temple University Health System Foundation; TUH - Jeanes Campus Auxiliary; Temple Health Subsidiaries Inc.; Episcopal Hospital; TUHS Insurance Company, Ltd.; Temple Health System Transport Team, Inc.; Temple Care Inc.; Fox Chase Limited; Fox Chase Network, Inc.; American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center; Temple Physicians, Inc.; and Fox Chase Cancer Center Medical Group, Inc.; because these subsidiaries did not receive federal awards subject to audit in accordance with the Uniform Guidance. Temple's consolidated financial statements include the consolidated operations of Temple University Health System, Inc. and its subsidiaries; Institute for Cancer research d/b/a, The Research Institute of Fox Chase Cancer Center; Temple University Hospital, Inc.; Temple Center for Population Health LLC; and Temple Faculty Practice Plan, Inc.; (collectively referred to herein as "TUHS"), which expended federal awards which are not included in Temple's accompanying Schedule of Expenditures of Federal Awards for the year ended June 30, 2025. Our audit, described below, does not include federal funding awarded to TUHS, because a separate audit in accordance with the Uniform Guidance was performed for TUHS for the year ended June 30, 2025.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our

responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of Temple's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Temple's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Temple's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit will be conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Temple's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Temple's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Temple's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs as item 2025-001. Our opinion on each major federal program is not modified with respect to this matter.

Government Auditing Standards requires the auditor to perform limited procedures on Temple's response to the noncompliance finding identified in our compliance audit described in the accompanying schedule of findings and questioned costs. The Temple's response was not subject to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control over Compliance

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance and therefore, material weaknesses or significant deficiencies may exist that were not identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, as discussed below, we did identify certain deficiencies in internal control over compliance that we consider to be a significant deficiency.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance. We consider the deficiency in internal control over compliance described in the accompanying schedule of findings and questioned costs as item 2025-001 to be a significant deficiency.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

Government Auditing Standards requires the auditor to perform limited procedures on Temple's response to internal control over compliance findings identified in our compliance audit described in the accompanying schedule of findings and questioned costs. Temple's response was not subjected to the other auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of Temple as of and for the year ended June 30, 2025, and have issued our report thereon dated October 28, 2025, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the

financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 31, 2026

**TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SUMMARY OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Grantor/Pass-Through Grantor Program Title	CFDA Number	2025 Subrecipient Expenditures	2025 Total Expenditures
Research and Development:			
Department of Health and Human Services:			
Department of Health and Human Services: Direct Awards	Various	\$ 11,657,628	\$ 82,203,329
Department of Health and Human Services: Pass-Through Funds	Various	524,146	17,646,027
		12,181,774	99,849,356
National Science Foundation:			
National Science Foundation: Direct Awards	Various	650,241	12,651,947
National Science Foundation: Pass-Through Funds	Various	—	1,337,330
		650,241	13,989,277
Department of Defense			
Department of Defense: Direct Awards	Various	249,284	5,902,328
Department of Defense: Pass-Through Funds	Various	—	2,277,888
		249,284	8,180,216
Department of Energy			
Department of Energy: Direct Awards	Various	244,735	2,819,486
Department of Energy: Pass-Through Funds	Various	—	857,374
		244,735	3,676,860
Other:			
Other: Direct Awards	Various	246,031	2,087,154
Other: Pass-Through Funds	Various	416,840	2,664,928
		662,871	4,752,082
Total Research and Development		\$ 13,988,905	\$ 130,447,791
Other Clusters:			
477 CLUSTER	93.558	—	182,404
Economic Development Cluster	11.307	—	29,182
HOPE VI CLUSTER	14.889	—	8,035
Medicaid Cluster	93.778	—	126,638
WIOA Cluster	84.047	—	412,251
TRIO Cluster	17.259 / 278	—	825,451
		—	1,583,961

**TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SUMMARY OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Grantor/Pass-Through Grantor Program Title	CFDA Number	2025 Subrecipient Expenditures	2025 Total Expenditures
Student Financial Assistance:			
Department of Education:			
Federal Work Study	84.033	\$ —	\$ 2,934,717
Federal Supplemental Educational Opportunity Grant (FSEOG)	84.007	—	2,286,453
Pell Grants	84.063	—	53,412,096
Perkins Loans	84.038	—	6,306,795
Perkins Loans Administrative Expenses	84.038	—	383,883
TEACH Grants	84.379	—	38,196
		—	65,362,140
Department of Health and Human Services:			
Health Professional Student Loans & Loans for Disadvantaged Students	93.342	—	22,505,354
Health Professional Student Loans & Loans for Disadvantaged Students Administrative Expenses	93.342	—	244,145
Nursing Student Loans	93.364	—	440,024
Nursing Student Loans Administrative Expenses	93.364	—	4,021
		—	23,193,544
Federally Guaranteed Student Loans			
Direct Subsidized Loans	84.268	—	39,219,962
Direct Unsubsidized Loans	84.268	—	131,983,252
Direct Parent Plus Loans	84.268	—	64,608,248
Direct Graduate Plus Loans	84.268	—	61,742,282
		—	297,553,744
Total Student Financial Assistance		\$ —	\$ 386,109,428
Other Programs:			
Other - Direct Awards	Various	\$ 764,230	\$ 5,821,912
Other - Pass Through Funds	Various	—	3,217,442
COVID-19: Other - Pass Through Funds	21.027 / 84.425 / 97.036	—	3,078,930
		764,230	12,118,284
Total Other Programs		764,230	12,118,284
Total Federal Awards		\$ 14,753,135	\$ 530,259,464

See notes to schedule of expenditures of federal awards

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
10	309		Specialty Crop Research Initiative	Research and Development	\$ 1,183	\$ 130,447,791	N	Pennsylvania State University	S000331-USDA	N		\$ 1,183
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 951
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00004407 (417938-1)	N		\$ (100)
17	289		Community Project Funding/congressionally Directed Spending	Research and Development	\$ 3,441	\$ 130,447,791	N	Villanova University	05-0205	N		\$ 3,441
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 121,490
84	324A		Research In Special Education	Research and Development	\$ 58,788	\$ 130,447,791	Y			Y	\$ 21,169	\$ 58,788
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Delaware	R01NS102157	N		\$ (505)
10	025		Plant And Animal Disease, Pest Control, And Animal Care	Research and Development	\$ 255,335	\$ 130,447,791	Y			N		\$ 24,092
10	025		Plant And Animal Disease, Pest Control, And Animal Care	Research and Development	\$ 255,335	\$ 130,447,791	Y			N		\$ 28,287
10	025		Plant And Animal Disease, Pest Control, And Animal Care	Research and Development	\$ 255,335	\$ 130,447,791	Y			N		\$ 56,505
10	025		Plant And Animal Disease, Pest Control, And Animal Care	Research and Development	\$ 255,335	\$ 130,447,791	Y			N		\$ 77,995
10	025		Plant And Animal Disease, Pest Control, And Animal Care	Research and Development	\$ 255,335	\$ 130,447,791	Y			N		\$ 68,456
10	215		Sustainable Agriculture Research And Education	Research and Development	\$ 16,684	\$ 130,447,791	N	Clemson University	2440-215-2015298	N		\$ 16,684
10	310		Agriculture And Food Research Initiative (Afri)	Research and Development	\$ 133,867	\$ 130,447,791	Y			N		\$ 36,761
10	310		Agriculture And Food Research Initiative (Afri)	Research and Development	\$ 133,867	\$ 130,447,791	N	Purdue University	F0013585302012	N		\$ 79,386
10	310		Agriculture And Food Research Initiative (Afri)	Research and Development	\$ 133,867	\$ 130,447,791	N	Clemson University	2533-207-2016051	N		\$ 17,720
10	699		Partnership Agreements	Research and Development	\$ 3,915	\$ 130,447,791	Y			N		\$ 3,915
10	707		Research Joint Venture And Cost Reimbursable Agreements	Research and Development	\$ 25,645	\$ 130,447,791	Y			N		\$ 25,645
10	RD1	22-CS-11242308-056	Us Department Of Agriculture Contract	Research and Development	\$ 65,572	\$ 130,447,791	Y			Y	\$ 44,074	\$ 65,572
11	303		Economic Development Technical Assistance	Research and Development	\$ 31,438	\$ 130,447,791	N	Harvard Business School	167936-5095583	Y		\$ 31,438
11	431		Climate And Atmospheric Research	Research and Development	\$ 46,608	\$ 130,447,791	Y			Y	\$ 3,008	\$ 33,126
11	463		Habitat Conservation	Research and Development	\$ 259,333	\$ 130,447,791	Y			N		\$ 125,561
11	463		Habitat Conservation	Research and Development	\$ 259,333	\$ 130,447,791	N	The National Marine Sanctuary Foundation	5300-23-07- 068	N		\$ 133,772
11	482		Coral Reef Conservation Program	Research and Development	\$ 159,879	\$ 130,447,791	N	Consolidated Safety Services Incorporated	GSA7-24-EC	N		\$ 159,879
12	225		Commercial Technologies For Maintenance Activities Program	Research and Development	\$ 966	\$ 130,447,791	N	National Center for Manufacturing Sciences	2019145-141028	N		\$ 966
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ (182)
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ (3)
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ (1,012)
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ 39,136
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ 208,872
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ 380,192
12	300		Basic And Applied Scientific Research	Research and Development	\$ 688,860	\$ 130,447,791	Y			N		\$ 61,857
12	351		Scientific Research - Combating Weapons Of Mass Destruction	Research and Development	\$ 431,365	\$ 130,447,791	Y			Y	\$ 63,462	\$ 334,145
12	351		Scientific Research - Combating Weapons Of Mass Destruction	Research and Development	\$ 431,365	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00004334 (417861-1)	N		\$ 97,220
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599290	N		\$ (358)
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599805	N		\$ (177)
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599763	N		\$ (177)
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599780	N		\$ 2,779
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599688	N		\$ (175)
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300599299	N		\$ 44
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300786497	N		\$ 9,028
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300786265	N		\$ 116,369
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300786278	N		\$ 103,823
12	401		National Guard Military Operations And Maintenance (O&m) Projects	Research and Development	\$ 354,325	\$ 130,447,791	N	Pennsylvania Department of Military and Veterans Affairs	4300786084	N		\$ 123,169
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ (506)
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 16,504
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			Y	\$ 25,794	\$ 180,548
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			Y	\$ 38,677	\$ 140,187
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 63,568
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 252,450

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 334,640
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 172,703
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 130,657
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 143,835
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 117,056
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 112,687
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 30,105
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 36,899
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 14,641
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	Y			N		\$ 3,699
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	State of Maryland	F302348-9	N		\$ 181
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	The Johns Hopkins Bloomberg School of Public Health	W81XWH1920062	N		\$ 4,547
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	State of Maryland	F302348-9	N		\$ 21,115
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	University of Maryland, Baltimore County	20532	N		\$ 6,248
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	Fox Chase Cancer Center	2404800 Yr 1 01	N		\$ 18,666
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	Fox Chase Cancer Center	FCCEC NO. 2406200	N		\$ 69,316
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	University of Illinois	113583-19609	N		\$ 82,738
12	420		Military Medical Research And Development	Research and Development	\$ 1,975,013	\$ 130,447,791	N	Montclair State University	HT9425-23-1-0473_Temple	N		\$ 21,678
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	Y			N		\$ (907,780)
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	Y			N		\$ 68,761
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	Y			N		\$ 111,709
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	Y			Y	\$ 121,351	\$ 3,254,746
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	N	Drexel University	950042	N		\$ 96,500
12	431		Basic Scientific Research	Research and Development	\$ 3,574,209	\$ 130,447,791	N	Northeastern University	555080-78055 & 555092-78052	N		\$ 959,273
12	630		Basic, Applied, And Advanced Research In Science And Engineering	Research and Development	\$ (11,108)	\$ 130,447,791	N	Northeastern University	555089-78051	N		\$ (40,790)
12	632		Legacy Resource Management Program	Research and Development	\$ 43,453	\$ 130,447,791	N	The Ohio State University	60057144	N		\$ 43,453
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	Y			N		\$ 8,508
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	Y			N		\$ 156,501
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	Y			N		\$ 100,086
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	Y			N		\$ 133,661
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	Y			N		\$ 153,348
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	N	University of Illinois	097110-17600	N		\$ 1,754
12	800		Air Force Defense Research Sciences Program	Research and Development	\$ 690,602	\$ 130,447,791	N	University Of Minnesota	A009678502	N		\$ 136,744
12	RD2	N6449820P5158	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	Y			N		\$ (1,184)
12	RD2	W81XWH-21-P-0204	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	Y			N		\$ 171
12	RD2	N6264522C0007	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	Y			N		\$ 50,172
12	RD2	1001689-09	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Baylor University	1001689-09	N		\$ 40,159
12	RD2	5012208	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	APTIM	5012208	N		\$ (49)
12	RD2	SUBAWARD NO: 940006	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Drexel University	SUBAWARD NO: 940006	N		\$ 61,454
12	RD2	N00024-13-D-6400/ PO# 170744	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Johns Hopkins University Applied Physics Laboratory	N00024-13-D-6400/ PO# 170744	N		\$ 7,731
12	RD2	ScrTech 22-22-F-0037-02	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	SciTech Services Inc.	ScrTech 22-22-F-0037-02	N		\$ (4,432)
12	RD2	555074-78050	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Northeastern University	555074-78050	N		\$ (241)
12	RD2	FA9453-22-C-A127	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Intelligent Fusion Technology, Inc	FA9453-22-C-A127	N		\$ 11,630
12	RD2	A39024	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	Booz, Allen, Hamilton, Inc.	A39024	N		\$ (1,917)
12	RD2	SUB00003295	Us Department Of Defense Contract	Research and Development	\$ 453,213	\$ 130,447,791	N	University of Georgia	SUB00003295	N		\$ 289,719
15	441		Safety And Environmental Research And Data Collection For Offshore Energy And Mineral Activities	Research and Development	\$ (19,539)	\$ 130,447,791	N	TDI-Brooks International	M17PC00009	N		\$ (19,539)
15	506		Water Desalination Research And Development	Research and Development	\$ 170,154	\$ 130,447,791	Y			Y	\$ 26,328	\$ 170,154
15	670		Adaptive Science	Research and Development	\$ 33,114	\$ 130,447,791	Y			N		\$ 33,114
15	684		White-nose Syndrome National Response Implementation	Research and Development	\$ 61,990	\$ 130,447,791	Y			Y	\$ 1,528	\$ 21,338
15	684		White-nose Syndrome National Response Implementation	Research and Development	\$ 61,990	\$ 130,447,791	N	National Fish and Wildlife Foundation	0406.23.080376	Y	\$ 4,725	\$ 40,652
15	805		Assistance To State Water Resources Research Institutes	Research and Development	\$ 10,628	\$ 130,447,791	N	The Pennsylvania State University	S004687-USGS	N		\$ 10,628
15	926		American Battlefield Protection	Research and Development	\$ (2,960)	\$ 130,447,791	Y			N		\$ (2,960)
16	026		Ovw Research And Evaluation Program	Research and Development	\$ 275,563	\$ 130,447,791	Y			Y	\$ 41,894	\$ 147,582
16	026		Ovw Research And Evaluation Program	Research and Development	\$ 275,563	\$ 130,447,791	Y			Y	\$ 25,798	\$ 121,949

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
16	026		Ovw Research And Evaluation Program	Research and Development	\$ 275,563	\$ 130,447,791	N	UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	SA0004377	N		\$ 6,032
16	052		Restorative Practices To Address Domestic Violence, Dating Violence, Sexual Assault, And Stalking	Research and Development	\$ 2,636	\$ 130,447,791	N	New York University	F2677-02	N		\$ 2,636
16	560		National Institute Of Justice Research, Evaluation, And Development Project Grants	Research and Development	\$ 319,919	\$ 130,447,791	Y			N		\$ 201,927
16	560		National Institute Of Justice Research, Evaluation, And Development Project Grants	Research and Development	\$ 319,919	\$ 130,447,791	Y			N		\$ 70,811
16	560		National Institute Of Justice Research, Evaluation, And Development Project Grants	Research and Development	\$ 319,919	\$ 130,447,791	N	George Washington University	18-S37	N		\$ (1,329)
16	560		National Institute Of Justice Research, Evaluation, And Development Project Grants	Research and Development	\$ 319,919	\$ 130,447,791	N	University of Chicago	20005	N		\$ 48,510
16	585		Treatment Court Discretionary Grant Program	Research and Development	\$ 343,491	\$ 130,447,791	N	John Jay College	CM00011172-00	N		\$ 343,491
16	601		Corrections Training And Staff Development	Research and Development	\$ 56	\$ 130,447,791	Y			N		\$ 56
16	738		Edward Byrne Memorial Justice Assistance Grant Program	Research and Development	\$ 244,409	\$ 130,447,791	N	Pennsylvania Commission On Crime And Delinquency	2019-JG-LS-28510-2	N		\$ (4,238)
16	738		Edward Byrne Memorial Justice Assistance Grant Program	Research and Development	\$ 244,409	\$ 130,447,791	N	Pennsylvania Commission On Crime And Delinquency	2023-BC-SS-44398	N		\$ 171,540
16	825		Smart Prosecution Initiative	Research and Development	\$ (60)	\$ 130,447,791	N	Pennsylvania Office of the attorney General	Contract Number 2020158	N		\$ (60)
17	RD3	5125-4548-630000	Department Of Labor Contract	Research and Development	\$ 32,553	\$ 130,447,791	N	Delaware County	NO ID PROVIDED	Y	\$ 6,243	\$ 32,553
21	009		Volunteer Income Tax Assistance (Vita) Matching Grant Program	Research and Development	\$ 18,644	\$ 130,447,791	Y			Y	\$ 12,500	\$ 18,644
43	001		Science	Research and Development	\$ 137,343	\$ 130,447,791	Y			Y	\$ (1,957)	\$ (1,941)
43	001		Science	Research and Development	\$ 137,343	\$ 130,447,791	Y			Y	\$ 3,938	\$ 82,650
43	001		Science	Research and Development	\$ 137,343	\$ 130,447,791	N	American Museum Of Natural History	B78-2021-3	N		\$ 15,797
43	001		Science	Research and Development	\$ 137,343	\$ 130,447,791	N	University of Southern California	SCON-00004071	N		\$ 40,837
43	008		Office Of Stem Engagement (Ostem)	Research and Development	\$ 14,263	\$ 130,447,791	N	The Pennsylvania State University	S000977-NASA	N		\$ 14,263
45	169		Promotion Of The Humanities Office Of Digital Humanities	Research and Development	\$ 77,739	\$ 130,447,791	Y			N		\$ 76,315
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 97,722
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ (9,737)
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 92,502
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 132,348
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 69,063
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 2,126
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 68,902
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 54,891
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 98,752
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 71,743
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 1,767
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 62,109
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 2,167
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 30,992
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 27,195
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 3,982
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			Y	\$ 59,080	\$ 111,184
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 81,349
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 4,994
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 12,754
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 100,202
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 14,993
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 32,637
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	Y			N		\$ 43,034
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	N	Texas A&M Research Foundation	M2103385	N		\$ 79,088
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	N	Princeton University	SUB0000553	N		\$ 218,175
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	N	University Of South Florida	2121-1017-00-A	N		\$ 17,959
47	041		Engineering	Research and Development	\$ 1,600,987	\$ 130,447,791	N	Various Industries	IIP-0855881	N		\$ 78,094
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (9,190)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (35,812)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (438)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (6,687)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 10,318
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (579)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 6,798
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 3,145
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (1,331)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 58,249
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 60,567
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 141,009
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (1,600)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 8,559
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (638)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ (550)
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 195,886
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 43,339
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 87,280
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 2,741
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 2,323
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 111,287
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 156,724
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 80,093
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 158,503
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 243,882
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 118,267
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 141,065
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 126,837
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 149,740
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 116,967
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 49,107
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 147,674
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 83,015
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 147,311
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 77,760
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 84,051
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 121,235
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 27,498
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 48,439
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 5,887
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 87,748
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 34,959
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 66,127
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 103,281
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 107,832
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 25,779
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 16,169
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	Y			N		\$ 126,675
47	049		Mathematical And Physical Sciences	Research and Development	\$ 3,402,021	\$ 130,447,791	N	Indiana University	2221062	N		\$ 74,720
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			N		\$ (15)
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			N		\$ 24,718
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			N		\$ 19,636
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			Y	\$ 5,315	\$ 34,894
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			N		\$ 2,992
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	Y			N		\$ 10,702
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	N	The Pennsylvania State University	5858-TU-NSF-8934	N		\$ 24,321
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	N	University of Alaska Fairbanks	UAF 18-0129	N		\$ 15
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	N	Oregon State University	S2089B-C	N		\$ 35,362
47	050		Geosciences	Research and Development	\$ 152,624	\$ 130,447,791	N	Woods Hole Oceanographic Institution	A101623/81236000	N		\$ (1)
47	067		Materials Development, Research, And Informal Science Education	Research and Development	\$ 147,610	\$ 130,447,791	N	University Of California Irvine	2020-1371	N		\$ 147,610
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ (8,190)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 15,624
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ (1,181)
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			Y	\$ 19,151	\$ 19,151
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ (3,842)
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 56,770
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 27,286
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 49,762
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 100,147
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 141,917
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 59,348
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 114,443
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			Y	\$ 135,302	\$ 481,219
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			Y	\$ 60,443	\$ 155,267
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 55,143
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 35,177
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 137,998
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 77,562
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 73,462
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 154,563
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			Y	\$ 15,134	\$ (96,842)
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 121,613
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 35,090
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 137,275
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			Y	\$ 10,000	\$ 15,850
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 9,044
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 216,651
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 52,859
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 21,960
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 26,367
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	Y			N		\$ 27,186
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	N	Mississippi State University	060700.363656.01	N		\$ 115,354
47	070		Computer And Information Science And Engineering	Research and Development	\$ 2,523,928	\$ 130,447,791	N	University Of South Florida	2121-1013-00-A	N		\$ 99,895
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ (144)
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 376
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ (262)
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ (5)
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 75,531
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 126,370
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 8,337
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 256,135
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 290,371
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	Y			N		\$ 90,353
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	N	Georgia State University	SP00015791-01	N		\$ 39,693
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	N	The Pennsylvania State University	S006078-NSF	N		\$ 26,634
47	074		Biological Sciences	Research and Development	\$ 913,384	\$ 130,447,791	N	Oxford Circle Christian Community Development Association	SP00015791-01	N		\$ (5)
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 76,423
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 3,498
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 63,890
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			Y	\$ 41,987	\$ 368,856
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 24,903
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 25,255
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 100,451
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			Y	\$ 4,530	\$ 114,804
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 36,851
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 183,303
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	Y			N		\$ 25,521
47	075		Social, Behavioral, And Economic Sciences	Research and Development	\$ 1,034,134	\$ 130,447,791	N	University Of Oregon	2517701	N		\$ 10,379

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ (133,685)
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 924
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 57,506
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 70,965
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 19,401
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 74,839
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			Y	\$ 34,188	\$ 213,443
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 79,870
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 14,102
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			Y	\$ 184,871	\$ 551,627
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 107,356
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 310,457
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 116,677
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			Y	\$ 35,535	\$ 433,530
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 161,223
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 16,893
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 83,046
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 574,010
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 24,454
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	Y			N		\$ 5,532
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	N	Drexel University	920085	N		\$ 113,069
47	076		Stem Education (Formerly Education And Human Resources)	Research and Development	\$ 3,082,128	\$ 130,447,791	N	University of Illinois	113288-19540	N		\$ 65,399
47	078		Polar Programs	Research and Development	\$ 182,067	\$ 130,447,791	Y			N		\$ 65,071
47	078		Polar Programs	Research and Development	\$ 182,067	\$ 130,447,791	Y			N		\$ 41,994
47	078		Polar Programs	Research and Development	\$ 182,067	\$ 130,447,791	Y			N		\$ 75,002
47	079		Office Of International Science And Engineering	Research and Development	\$ 38,242	\$ 130,447,791	N	Texas A&M University	M2301290	N		\$ 38,242
47	083		Integrative Activities	Research and Development	\$ 292,920	\$ 130,447,791	Y			N		\$ 11,171
47	083		Integrative Activities	Research and Development	\$ 292,920	\$ 130,447,791	Y			Y	\$ 10,000	\$ 24,386
47	083		Integrative Activities	Research and Development	\$ 292,920	\$ 130,447,791	Y			N		\$ 260,342
47	083		Integrative Activities	Research and Development	\$ 292,920	\$ 130,447,791	Y			N		\$ (2,979)
47	084		Nsf Technology, Innovation, And Partnerships	Research and Development	\$ 619,232	\$ 130,447,791	Y			Y	\$ 34,705	\$ 56,884
47	084		Nsf Technology, Innovation, And Partnerships	Research and Development	\$ 619,232	\$ 130,447,791	Y			N		\$ 409,021
47	084		Nsf Technology, Innovation, And Partnerships	Research and Development	\$ 619,232	\$ 130,447,791	N	University of Wisconsin-Madison	2617	N		\$ 33,063
47	084		Nsf Technology, Innovation, And Partnerships	Research and Development	\$ 619,232	\$ 130,447,791	N	University of Arkansas	UA2023-368	N		\$ 110,157
47	084		Nsf Technology, Innovation, And Partnerships	Research and Development	\$ 619,232	\$ 130,447,791	N	SusMaX Inc	2321815	N		\$ 10,107
59	037		Small Business Development Centers	Research and Development	\$ 222,575	\$ 130,447,791	N	Kutztown University	SBA20240110	N		\$ 224,534
66	509		Science To Achieve Results (Star) Research Program	Research and Development	\$ 149,113	\$ 130,447,791	Y			N		\$ 68,529
66	509		Science To Achieve Results (Star) Research Program	Research and Development	\$ 149,113	\$ 130,447,791	Y			Y	\$ 5,001	\$ 80,584
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ (574)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ (71,720)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 254,070
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 34,119
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	Alliance For Sustainable Energy, LLC	DE-AC36-08GO28308	N		\$ (2,286)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ (851)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 445,698
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 234,913
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			Y	\$ 13,924	\$ 703,381
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ (11,334)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			Y	\$ 230,811	\$ 350,079
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 111,481
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 82,318
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 580,426
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	Y			N		\$ 107,629
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	Princeton University	SUB0000284	N		\$ 446,692
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	ThirdLaw, LLC	Subaward No. 265006	N		\$ (7,931)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	Brookhaven National Laboratory	368727	N		\$ (10,981)
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	ExesaLibero Pharma, Inc.	RAR074812B	N		\$ (462)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	Fermi National Accelerator Laboratory	DE-AC02-07CH11359	N		\$ 81,995
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	Board of the Leland Stanford Junior University	63288359-267901	N		\$ 112,410
81	049		Office Of Science Financial Assistance Program	Research and Development	\$ 3,444,008	\$ 130,447,791	N	University of North Carolina at Wilmington	587840-23-0367	N		\$ 4,936
81	086		Conservation Research And Development	Research and Development	\$ 28,886	\$ 130,447,791	Y			N		\$ (149)
81	086		Conservation Research And Development	Research and Development	\$ 28,886	\$ 130,447,791	N	University of California - Berkeley	10314	N		\$ 7,499
81	086		Conservation Research And Development	Research and Development	\$ 28,886	\$ 130,447,791	N	University Of Delaware	UDR0000276	N		\$ (16,189)
81	086		Conservation Research And Development	Research and Development	\$ 28,886	\$ 130,447,791	N	PARC A XEROX COMPANY	PO94264	N		\$ 37,725
81	087		Renewable Energy Research And Development	Research and Development	\$ 18,905	\$ 130,447,791	N	Clemson University	2336-219-2024419	N		\$ 15
81	087		Renewable Energy Research And Development	Research and Development	\$ 18,905	\$ 130,447,791	N	National Renewable Energy Laboratory	SUB-2022-10334	N		\$ 18,890
81	135		Advanced Research Projects Agency - Energy	Research and Development	\$ 50,862	\$ 130,447,791	N	Drexel University	950002	N		\$ (38,317)
81	135		Advanced Research Projects Agency - Energy	Research and Development	\$ 50,862	\$ 130,447,791	N	University Of Delaware	UDR0000252	N		\$ 89,179
81	RD4	4F-60240	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Argonne National Laboratory	4F-60240	N		\$ 45,133
81	RD4	486.1A	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Brookhaven National Laboratory	486.1A	N		\$ 50,801
81	RD4	COVID-19 - 8F-30190	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Argonne National Laboratory	8F-30190	N		\$ (66,408)
81	RD4	PO-2407526	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Sandia National Laboratories	PO-2407526	N		\$ 102,956
81	RD4	267860	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Idaho National Laboratory	267860	N		\$ (16,700)
81	RD4	2554385	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Sandia National Laboratories	2554385	N		\$ 16,056
81	RD4	461179	Us Department OfEnergy Contract	Research and Development	\$ 134,199	\$ 130,447,791	N	Brookhaven National Laboratory	461179	N		\$ 2,361
84	126		Rehabilitation Services Vocational Rehabilitation Grants To States	Research and Development	\$ 26,074	\$ 130,447,791	N	Pennsylvania Department of Labor And Industry	4300770052	N		\$ 26,074
84	407		Transition Programs For Students With Intellectual Disabilities Into Higher Education	Research and Development	\$ 15,855	\$ 130,447,791	N	Millersville University	4500635820	N		\$ 15,855
84	002A		Adult Education - Basic Grants To States	Research and Development	\$ 25,525	\$ 130,447,791	N	Pennsylvania Department Of Education	FA-064-24-0030 A	N		\$ 25,469
84	220A		Centers For International Business Education	Research and Development	\$ 266,054	\$ 130,447,791	Y			N		\$ 724
84	220A		Centers For International Business Education	Research and Development	\$ 266,054	\$ 130,447,791	Y			N		\$ 265,564
84	287C		Twenty-first Century Community Learning Centers	Research and Development	\$ 402	\$ 130,447,791	N	Pennsylvania Department Of Education	SAP FUND: 7051600000	N		\$ 402
84	305A		Education Research, Development And Dissemination	Research and Development	\$ 401,064	\$ 130,447,791	Y			Y	\$ 62,750	\$ 62,890
84	336S		Teacher Quality Partnership Grants	Research and Development	\$ 65,152	\$ 130,447,791	Y			N		\$ 65,152
84	365Z		English Language Acquisition State Grants	Research and Development	\$ 705,795	\$ 130,447,791	Y			N		\$ (631)
84	380W		Special Education - Special Olympics Education Programs	Research and Development	\$ 4,430	\$ 130,447,791	N	University Of Minnesota	SUBA00000831-A012603801	N		\$ 4,430
93	011		National Organizations For State And Local Officials	Research and Development	\$ (62,155)	\$ 130,447,791	Y			N		\$ (62,155)
93	043		Special Programs For The Aging, Title Iii, Part D, Disease Prevention And Health Promotion Services	Research and Development	\$ 36,712	\$ 130,447,791	N	New York City Department for the Aging	CT112520201409590	N		\$ 36,712
93	070		Environmental Public Health And Emergency Response	Research and Development	\$ 320,470	\$ 130,447,791	N	RTI International	888-16-08-12 / PO 65748L	N		\$ 320,470
93	072		Lifespan Respite Care Program	Research and Development	\$ (8,776)	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	RSG-19-113-01-CCG	N		\$ (8,776)
93	103		Food And Drug Administration Research	Research and Development	\$ 1,451	\$ 130,447,791	N	University Of Minnesota	N009958008	N		\$ 1,451
93	109		Linking Community-based Primary Care, Substance Abuse, Hiv/aids, And Mental Health Treatment Services	Research and Development	\$ (530)	\$ 130,447,791	N	Education Northwest	REL 2021-TEM191	N		\$ (530)
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	Y			N		\$ (212)
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	Y			N		\$ 382,531
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	Y			N		\$ 146,231
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	Y			N		\$ 204,049
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	CNVA00059250	N		\$ (4,318)
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	N	PHILADELPHIA REGIONAL CENTER FOR CHILDREN'S ENVIRONMENTAL HE	P2CES033428	Y	\$ 25,000	\$ 45,250
93	113		Environmental Health	Research and Development	\$ 810,479	\$ 130,447,791	N	University of Texas at San Antonio	174588/174352	N		\$ 36,948
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ (10,043)
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 395,232
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ (2,183)
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 177,142
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			Y	\$ 22,100	\$ 87,956
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 173,682
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 807,490

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 159,522
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			Y	\$ 11,155	\$ 197,671
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			N		\$ 114,308
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			Y	\$ 15,510	\$ 359,387
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	Y			Y	\$ 5,815	\$ 118,447
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	N	University of Pennsylvania	SUBAWARD 575712	N		\$ (148)
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	N	Boston University	4500003205	N		\$ (8)
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	N	University of Pennsylvania	575712	N		\$ (31,785)
93	121		Oral Diseases And Disorders Research	Research and Development	\$ 2,544,873	\$ 130,447,791	N	University of Iowa	S03569-01	N		\$ (1,797)
93	136		Injury Prevention And Control Research And State And Community Based Programs	Research and Development	\$ 84,330	\$ 130,447,791	Y			Y	\$ 23,958	\$ 68,529
93	136		Injury Prevention And Control Research And State And Community Based Programs	Research and Development	\$ 84,330	\$ 130,447,791	N	Pennsylvania Department of Health	4300830996	N		\$ 15,801
93	145		Hiv-related Training And Technical Assistance	Research and Development	\$ 10,621	\$ 130,447,791	N	University of Illinois at Chicago	19507	N		\$ 10,621
93	172		Human Genome Research	Research and Development	\$ 332,585	\$ 130,447,791	Y			N		\$ 183,174
93	172		Human Genome Research	Research and Development	\$ 332,585	\$ 130,447,791	N	University of Pittsburgh	AWD00008308 (139555-1)	N		\$ 69,848
93	172		Human Genome Research	Research and Development	\$ 332,585	\$ 130,447,791	N	The Jackson Laboratory	213014-0325-10	N		\$ 79,563
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 6,174
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			Y	\$ (5,491)	\$ (5,491)
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			Y	\$ (77,106)	\$ (77,106)
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ (10,108)
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 210,417
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 45,026
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 589,345
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 179,456
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			Y	\$ 117,144	\$ 466,514
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	Y			N		\$ 25,606
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Regents Univ Of California LA	2020-1248	N		\$ 65,720
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Boston University	4500003960	N		\$ 289,097
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Northeastern University	500800-78050	N		\$ 53,078
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Purdue University	11001185-006	N		\$ 56,418
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	The Regents of the University of Michigan	SUBK00019761	N		\$ (3,937)
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Vanderbilt University Medical Center	VUMC124817	N		\$ 49,997
93	173		Research Related To Deafness And Communication Disorders	Research and Development	\$ 1,970,199	\$ 130,447,791	N	Trustees of the Univ of PA	1-R21-DC-021833-01A1	N		\$ 29,993
93	185		Immunization Research, Demonstration, Public Information And Education Training And Clinical Skills Improvement Projects	Research and Development	\$ 1,572,156	\$ 130,447,791	Y			Y	\$ 47,832	\$ 1,572,156
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ 103
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ (42,500)
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ 275,384
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ 1,582
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ 206,127
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	Y			N		\$ 217,621
93	213		Research And Training In Complementary And Integrative Health	Research and Development	\$ 681,191	\$ 130,447,791	N	The Regents of the University of California, Berkeley	11025	N		\$ 22,874
93	226		Research On Healthcare Costs, Quality And Outcomes	Research and Development	\$ 14,562	\$ 130,447,791	Y			N		\$ 14,562
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (92)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (12,196)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (156,490)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 1,480	\$ 1,480
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (72,622)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (856)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (9,537)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 215,249	\$ 251,695
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 76,688	\$ 78,277
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 274,570
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 720,412
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 6,737	\$ 681,874
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 24,672

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 52,693	\$ 52,648
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (665)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 1
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 243,448	\$ 340,903
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 119,247
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 5,364
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 5,509
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 33,141
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 38,638	\$ 209,540
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ (14,548)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 45,494
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 664,404
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 280,802
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 31,073	\$ 85,712
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 43,564	\$ 112,512
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 98,519
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 52
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			N		\$ 636
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 453,161	\$ 400,320
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	Y			Y	\$ 436,644	\$ 1,375,439
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Drexel University	800002 / PO#U0213485	N		\$ 18,321
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Administrators of the Tulane Edu Fund	TUL-HSC-555326-17/18	N		\$ (3,445)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	University of North Carolina Chapel Hill	5111514	N		\$ (17,942)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Washington University	WU-19-34/ WU-21-168-ST00000643	N		\$ (4,999)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	University of North Carolina Chapel Hill	5115573	N		\$ (52,258)
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Yale University	CON-80005186 GR120601	N		\$ 495,240
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	University of Pennsylvania	1R01-MH-128155-02/ 5104780	N		\$ 4,488
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	The Children's Hospital of Philadelphia	GRT-00001455	N		\$ 17
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Drexel University	2R01MH110360-06/ PO# U0262456	N		\$ 356,239
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Research Foundation for Mental Hygiene, Inc.	P.O. 158236	N		\$ 6,367
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Drexel University	900252	N		\$ 15,915
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Administrators of the Tulane Edu Fund	TUL-HSC-560962-2223	N		\$ 7,952
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	The Ohio State University	SPC-1000012032	N		\$ 461,143
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	University of Pennsylvania	585776	N		\$ 124,928
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	234271	N		\$ 40,657
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	227898	N		\$ 2,239
93	242		Mental Health Research Grants	Research and Development	\$ 7,274,796	\$ 130,447,791	N	Yale University	CON-80005239 (GR124958)	N		\$ 223,717
93	262		Occupational Safety And Health Program	Research and Development	\$ 255,363	\$ 130,447,791	Y			N		\$ 205,068
93	262		Occupational Safety And Health Program	Research and Development	\$ 255,363	\$ 130,447,791	N	Drexel University	1 R21OH011740-01-00	N		\$ (1,744)
93	262		Occupational Safety And Health Program	Research and Development	\$ 255,363	\$ 130,447,791	N	University of Pittsburgh	AWD00004787 (136999-4)	N		\$ 52,039
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			N		\$ (18,326)
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			N		\$ (2,196)
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			Y	\$ 33,661	\$ 887,669
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			N		\$ 60,416
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			Y	\$ 36,863	\$ 728,627
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	Y			N		\$ 15,598
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	N	Yale University	GR101519 (CON-80001025	N		\$ (15,816)
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	N	New York University	5P01AA027057-02/ PO # M2003623	N		\$ (15,143)
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	N	Sanford Research North	CY21-022-TU	N		\$ 26,558
93	273		Alcohol Research Programs	Research and Development	\$ 1,896,070	\$ 130,447,791	N	University Of Toledo	F-2023-16	N		\$ 228,683
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (18,456)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (8,891)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 6,455
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (305,143)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 125
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (50,587)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 12,085
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (1,474)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (54)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 21,588
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 95,434
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (20,165)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 341,963
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 343,327	\$ 635,747
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 487,210
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Rand Corporation	SCON-00000312	N		\$ (936)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 7,878
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 1,014
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 131,817	\$ 379,401
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 324,238
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 25,999	\$ 373,035
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (4,111)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 397,882
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 7,918	\$ 313,818
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 18,797	\$ 106,663
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 363,481	\$ 576,088
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 117,258	\$ 596,328
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (1,710)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 93,549	\$ 334,045
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 191,678	\$ 213,720
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 191,413
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 80,299	\$ 885,421
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 127,862
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 267,352
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 60,062	\$ 560,162
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			Y	\$ 48,941	\$ 522,613
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 3,553
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 1,011
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 42,667
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ (94,460)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	Y			N		\$ 1,701,045
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	University of South Carolina	Subaward No. 17-3378	N		\$ (21,105)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00008373 PO# 3005195830	N		\$ (2,837)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Mebias Discovery LLC	1UG3DA047700-01	N		\$ (4,965)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Brown University	1461	N		\$ 747,705
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	University of Tennessee	Subaward A20-0184-S002	N		\$ 119
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Creative Bio-Peptides	1R43DA050349	N		\$ 10,030
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	George Mason University	E2051111	N		\$ (13,898)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Fannin Partners	FPTU001	N		\$ (16,792)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	San Diego State University Research Foundation	D8253-04 SA00 5A441A 7804	N		\$ 11,286
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Creative Bio-Peptides	2R44DA050349-02	N		\$ 1,950
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Washington University	WU-22-0215	N		\$ (5,982)
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Praeventix, L.L.C.	A2020-221-002	N		\$ 215,908
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	215225-1	N		\$ 9
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Brown University	2168	N		\$ 53,780
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Regents of the University Of Michigan	3007581222	N		\$ 9,197
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00019572	N		\$ 21,886
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Yale University	CON-80004854	N		\$ 21,655

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Georgia State University	SP00015818-01	N		\$ 285,640
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	George Washington University	R01DA054751	N		\$ 40,890
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Georgia State University	SP00016236-02	N		\$ 81,566
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Fannin Partners	FPTU002	N		\$ 52,888
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Rutgers University	3403	N		\$ 132,943
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	University Of Florida	SUB00004532	N		\$ 672,538
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Virginia Commonwealth University	FP00020730_SA001	N		\$ 66,521
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	New York University	23-A0-00-1009368	N		\$ 18,468
93	279		Drug Use And Addiction Research Programs	Research and Development	\$ 11,401,200	\$ 130,447,791	N	Praeventix, L.L.C.	1R44DA055443-01A1	N		\$ (29)
93	286		Discovery And Applied Research For Technological Innovations To Improve Human Health	Research and Development	\$ 272,674	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00010811/ PO# 3006521301	N		\$ 11,833
93	286		Discovery And Applied Research For Technological Innovations To Improve Human Health	Research and Development	\$ 272,674	\$ 130,447,791	N	DxDiscovery, Inc	DX_3408	N		\$ 59,054
93	286		Discovery And Applied Research For Technological Innovations To Improve Human Health	Research and Development	\$ 272,674	\$ 130,447,791	N	Regents of the University of Minnesota	A009800501	N		\$ 201,787
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			N		\$ (135)
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			Y	\$ 234,826	\$ 1,118,152
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			N		\$ 245,900
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			N		\$ 93,272
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			N		\$ 153,576
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			Y	\$ 53,973	\$ 215,343
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	Y			Y	\$ 22,810	\$ 72,084
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	N	Benten Technologies, Inc	NIMHD-TUH-09-2021	N		\$ (8,709)
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	N	Trustees of the Univ of PA	584949	N		\$ 24,392
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	N	Fox Chase Cancer Center	1522000 YEAR_01	N		\$ 77,212
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	N	Fox Chase Cancer Center	1519500	N		\$ 52,669
93	307		Minority Health And Health Disparities Research	Research and Development	\$ 2,066,364	\$ 130,447,791	N	Benten Technologies, Inc	NIMHD-TUH-09-2023	N		\$ 22,608
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	Y			Y	\$ 42,752	\$ 504,021
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	N	University of Pennsylvania	PO 4884998	N		\$ (763)
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	N	University of Arkansas for Medical Sciences	56493-TEMPLE	N		\$ (75)
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	N	University Of Massachusetts	SUB00000457	N		\$ 136,472
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	N	Asian Community Health Coalition	Asian CHESI- Temple	N		\$ 43,215
93	310		Trans-nih Research Support	Research and Development	\$ 796,143	\$ 130,447,791	N	HEALTHY AMERICAS FOUNDATION	OT2OD025277	N		\$ 9,994
93	323		Epidemiology And Laboratory Capacity For Infectious Diseases (Elc)	Research and Development	\$ 93,318	\$ 130,447,791	N	Philadelphia Department of Public Health	2220502	N		\$ 93,318
93	350		National Center For Advancing Translational Sciences	Research and Development	\$ (704)	\$ 130,447,791	N	Duke University	WBSE	N		\$ (4,516)
93	350		National Center For Advancing Translational Sciences	Research and Development	\$ (704)	\$ 130,447,791	N	University of Alabama at Birmingham	000518169-001	N		\$ 3,812
93	361		Nursing Research	Research and Development	\$ 117,776	\$ 130,447,791	Y			N		\$ 117,776
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	Y			N		\$ (1,311)
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	Y			N		\$ 962
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	Public Health Institute	AGREEMENT NO.01040	N		\$ (541)
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	Fox Chase Cancer Center	1515200	N		\$ 237,948
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	Fox Chase Cancer Center	1R01CA2380610115137-01	N		\$ 1,100
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	The Regents of the University of California	12051SC	N		\$ 11,982
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of Highe	AWD00003953	N		\$ 197,429
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	Fox Chase Cancer Center	1R01CA262551-01A1	N		\$ 28,007
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	The Ohio State University	SPC-1000006684 GR127426	N		\$ 25,599
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	Virginia Commonwealth University	FP00018919_SA001	N		\$ 106,947
93	393		Cancer Cause And Prevention Research	Research and Development	\$ 986,256	\$ 130,447,791	N	University of California San Francisco	15384sc	N		\$ 378,134
93	394		Cancer Detection And Diagnosis Research	Research and Development	\$ 538,014	\$ 130,447,791	Y			N		\$ 511,146
93	394		Cancer Detection And Diagnosis Research	Research and Development	\$ 538,014	\$ 130,447,791	N	University Of Minnesota	P009745403	N		\$ 18,807
93	394		Cancer Detection And Diagnosis Research	Research and Development	\$ 538,014	\$ 130,447,791	N	University of Pennsylvania	588782	N		\$ 8,061
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			Y	\$ 163,108	\$ 495,492
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			N		\$ 295,750
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			N		\$ 201,933

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			N		\$ (1,054)
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			N		\$ (604)
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	Y			N		\$ 182,507
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	N	University Of California Irvine	2020-JX-FX-0001	N		\$ (20,827)
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	N	Fox Chase Cancer Center	1518800 Yr 01	N		\$ 35,947
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	N	Fox Chase Cancer Center	1520100 YR 01	N		\$ 49,404
93	395		Cancer Treatment Research	Research and Development	\$ 1,386,557	\$ 130,447,791	N	University of Pittsburgh	AWD00010434 (200860-2)	N		\$ 148,009
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	Y			N		\$ 209,853
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	Y			Y	\$ 85,326	\$ 391,294
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	Y			N		\$ 391,260
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	Y			N		\$ 124,733
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	University of Pennsylvania	574290	N		\$ (4,583)
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	University of Pennsylvania	579383	N		\$ 116,592
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	AWD00003405 (135524-1)	N		\$ 50,119
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	University of Pennsylvania	584574	N		\$ (17,235)
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	Fox Chase Cancer Center	1519800 Yr 01	N		\$ 161,498
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	Coriell Institute For Medical Research	A24-0006-S001	N		\$ 3,529
93	396		Cancer Biology Research	Research and Development	\$ 1,523,905	\$ 130,447,791	N	University of Texas at San Antonio	174296174295	N		\$ 96,845
93	397		Cancer Centers Support Grants	Research and Development	\$ 2,032,754	\$ 130,447,791	Y			N		\$ (11)
93	397		Cancer Centers Support Grants	Research and Development	\$ 2,032,754	\$ 130,447,791	Y			N		\$ (75,317)
93	397		Cancer Centers Support Grants	Research and Development	\$ 2,032,754	\$ 130,447,791	Y			Y	\$ 552,826	\$ 2,073,031
93	397		Cancer Centers Support Grants	Research and Development	\$ 2,032,754	\$ 130,447,791	N	Fox Chase Cancer Center	PROJECT # 7918100, Yr. 1	N		\$ 16,079
93	398		Cancer Research Manpower	Research and Development	\$ 246,162	\$ 130,447,791	Y			N		\$ 214,593
93	398		Cancer Research Manpower	Research and Development	\$ 246,162	\$ 130,447,791	Y			N		\$ 31,569
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	Research and Development	\$ 393,339	\$ 130,447,791	Y			N		\$ 403,175
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	Research and Development	\$ 393,339	\$ 130,447,791	N	The Task Force For Global Health	NU380T000316	N		\$ 20,664
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	Research and Development	\$ 393,339	\$ 130,447,791	N	National Association of County and City Health Officials	2022-121504	N		\$ 116
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	Research and Development	\$ 393,339	\$ 130,447,791	N	National Association of County and City Health Officials	2023-101707	N		\$ 16,669
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	Research and Development	\$ 393,339	\$ 130,447,791	N	Association of State and Territorial Health Officials	Project 83-FE-2047-04-00	N		\$ (30,688)
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 23,000	\$ 436,398
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 115,467
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 93,602
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 425,776
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ (2,320)
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 4,250	\$ 203,309
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 244,767
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 4,937
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 30,168	\$ 54,572
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 36,342
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 24,514
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 8,801	\$ 76,841
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 35,909	\$ 135,934
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 132,223
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			N		\$ 152,536

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	Y			Y	\$ 58,594	\$ 344,304
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	N	University Of Minnesota	A005198601	N		\$ (906)
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	N	University Of South Florida	P000039214	N		\$ 7,281
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	N	University Of Massachusetts	SUB00000434	N		\$ 99,344
93	433		Acl National Institute On Disability, Independent Living, And Rehabilitation Research	Research and Development	\$ 2,639,310	\$ 130,447,791	N	Drexel University	900358- TEMPLE; PO# U0305508	N		\$ 54,389
93	464		Acl Assistive Technology	Research and Development	\$ 785,055	\$ 130,447,791	Y			N		\$ 19,064
93	464		Acl Assistive Technology	Research and Development	\$ 785,055	\$ 130,447,791	Y			N		\$ (3,307)
93	464		Acl Assistive Technology	Research and Development	\$ 785,055	\$ 130,447,791	Y			Y	\$ 92,867	\$ 55,620
93	595		Welfare Reform Research, Evaluations And National Studies	Research and Development	\$ 10,874	\$ 130,447,791	N	Wayne State University	WSU25028	N		\$ 10,874
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	Pennsylvania Developmental Disabilities Council	4100095486	N		\$ 84,555
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	Pennsylvania Developmental Disabilities Council	4100095815	N		\$ 75,441
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	Pennsylvania Developmental Disabilities Council	19-22	N		\$ 11,012
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	Pennsylvania Developmental Disabilities Council	4100095818	N		\$ 65,598
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	PA Dept of Human Services	4100096085	N		\$ 37,189
93	630		Developmental Disabilities Basic Support And Advocacy Grants	Research and Development	\$ 341,703	\$ 130,447,791	N	Pennsylvania Developmental Disabilities Council	4100095995	N		\$ 67,908
93	632		University Centers For Excellence In Developmental Disabilities Education, Research, And Service	Research and Development	\$ 636,010	\$ 130,447,791	Y			N		\$ 14,538
93	632		University Centers For Excellence In Developmental Disabilities Education, Research, And Service	Research and Development	\$ 636,010	\$ 130,447,791	Y			N		\$ (208)
93	632		University Centers For Excellence In Developmental Disabilities Education, Research, And Service	Research and Development	\$ 636,010	\$ 130,447,791	Y			N		\$ 621,664
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	COPD Foundation, Inc.	2R01HL089897-06A1	N		\$ 11,558
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Brigham & Women's Hospital	5U01HL130163-02	N		\$ (4,669)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK000012342	Y	\$ 172,500	\$ 290,870
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Fred Hutchinson Cancer Research Center	1204261	N		\$ 21,124
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 23
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 2,708
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (190)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 2,143	\$ 12,082
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (4,438)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (54)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (6,781)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 16,000
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 90,993
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 247,697
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 317,694
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 43,667	\$ 303,023
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 23,822
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 439,802
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (12,408)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (4,902)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 205,748
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 4,235
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 57,717
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 43,891
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 370,937
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 732,820
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 12,431
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 172,143
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 151,867
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 563,255
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 65,870
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 67,719	\$ 765,334

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 17,751	\$ 53,936
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 25,846
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 23,213
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 14,825	\$ 351,723
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ 15,648
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (1,225)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			N		\$ (15,212)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	Y			Y	\$ 333,285	\$ 2,060,808
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Massachusetts General Hospital	230744	N		\$ 8
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Thomas Jefferson University	080-04000-S29201	N		\$ 1
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	The Johns Hopkins University	2003918282	N		\$ (3,335)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University Of Colorado	SUBAWARD # FY19.753.003	N		\$ 57,251
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of Pennsylvania	PO 5098672, 579313	N		\$ 165,953
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Thomas Jefferson University	SUBAWARD 080-31050-R98703	N		\$ 6,216
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of Pennsylvania	581905	N		\$ 2,617
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of Pittsburgh	AWD00004507 (136765-1)	N		\$ (450)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of South Carolina	23-5104 PO 2000066923	N		\$ 7,386
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of Pennsylvania	10081092	N		\$ 181,651
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	AWD00004314 (137168-48A)	N		\$ 1,132
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Duke University	303003216	N		\$ 577,530
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Duke University	303003210	N		\$ 308,825
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Duke University	303003214	N		\$ 280,835
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Duke University	303003212	N		\$ 211,961
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Fox Chase Cancer Center	1521000 YR 01 NEW	N		\$ 325,737
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Massachusetts General Hospital	243119	N		\$ (1,786)
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Beth Israel Deaconess Medical Center	GRT65498 CRISP-AS Temple	N		\$ 12,662
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Massachusetts General Hospital	235136	N		\$ 2,082
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	University Of Massachusetts	SUB00000502	N		\$ 168,413
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	State University of New York	100-1153112-31-100080	N		\$ 79,961
93	837		Cardiovascular Diseases Research	Research and Development	\$ 9,893,627	\$ 130,447,791	N	Northeastern University	500976-78050	N		\$ 104,038
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	National Jewish Health	20072309	N		\$ 4,448
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	9012549 (128373-11)	N		\$ 10,279
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00013404	N		\$ 9,924
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	192243-6	N		\$ (3,600)
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	National Jewish Medical and Research Center	20128191	N		\$ 28
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Alabama at Birmingham	2P01HL114470-06	N		\$ 105
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Pennsylvania	581435	N		\$ (1,069)
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Board of the Leland Stanford Junior University	62346547-131009	N		\$ 46,363
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	220367-8	N		\$ (3,400)
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Alabama at Birmingham	000530409-SC003	N		\$ 1,203
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	210581-15	N		\$ 56
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	226628-15	N		\$ 2,473
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	915501833	N		\$ 7,544
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University Of Massachusetts	SUB00000624	N		\$ 1,719
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	Y			N		\$ 141,404
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	Y			N		\$ 520,623
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	Y			N		\$ 673,966
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	Y			N		\$ 29,606
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University Of Minnesota	P001344010	N		\$ 4,538

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of California	10502sc	N		\$ 6,130
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Pittsburgh of the Comlth Sys of High	AWD00005589 (418897-2)	N		\$ (6,726)
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of North Carolina Chapel Hill	5125336	N		\$ 1,080
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Regents of the University Of Michigan	PO# 3007022630	N		\$ 69,429
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	192243-6	N		\$ 7,953
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00014059	N		\$ 171,525
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Alabama at Birmingham	000530409-SC003	N		\$ 69,159
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	225005-8	N		\$ 49,081
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	226628-15	N		\$ 1,346
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Michigan	SUBK00015660	N		\$ 16,004
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	214655-5	N		\$ 1,346
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Pittsburgh	AWD00007150 (420051-1)	N		\$ (10,338)
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University of Pennsylvania	585830	N		\$ 7,139
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	The Trustees of Columbia University in the City of New York	15(GG015997-03)	N		\$ 17,366
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Verra Therapeutics, LLC	2R44HL149580-02	N		\$ 51,035
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	231781-5	N		\$ 27,326
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	Johns Hopkins University	2006275401	N		\$ 32,817
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University Of Massachusetts	SUB00000624	N		\$ 28,725
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	University Of Massachusetts	SUB00000599	N		\$ 16,071
93	838		Lung Diseases Research	Research and Development	\$ 2,003,746	\$ 130,447,791	N	COPD Foundation, Inc.	NO ID PROVIDED	N		\$ 1,068
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	Y			N		\$ (30,900)
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	Y			Y	\$ 7,229	\$ 73,176
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	Y			N		\$ 1,092,363
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	Y			N		\$ 227,993
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	Y			Y	\$ 64,857	\$ 744,804
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	N	Coriell Institute For Medical Research	A22-0003-S001	N		\$ 19,292
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	N	Case Western Reserve University	RES516976	N		\$ 13,546
93	839		Blood Diseases And Resources Research	Research and Development	\$ 2,149,127	\$ 130,447,791	N	Molecular Targeting Technologies	MTT1167303-01	N		\$ 8,853
93	840		Translaton And Implementation Science Research For Heart, Lung, Blood Diseases, And Sleep Disorders	Research and Development	\$ 51,953	\$ 130,447,791	N	University of Pennsylvania	1-R01-HL-153735-01	N		\$ 31,536
93	840		Translaton And Implementation Science Research For Heart, Lung, Blood Diseases, And Sleep Disorders	Research and Development	\$ 51,953	\$ 130,447,791	N	New York university, Grossman school of Medicine	270095	N		\$ 20,417
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			N		\$ (78)
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			N		\$ (84)
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			Y	\$ 6,140	\$ 845,604
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			N		\$ 83,489
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			N		\$ 15,827
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	Y			N		\$ 236,535
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	N	University of California, San Diego	S9002366 120233868	N		\$ 10,377
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	N	Praeventix, L.L.C.	1R43AR081768-01	N		\$ 2,035
93	846		Arthritis, Musculoskeletal And Skin Diseases Research	Research and Development	\$ 1,235,923	\$ 130,447,791	N	University of Queensland	RM2021002676	N		\$ 42,218
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ (2,829)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ (29,200)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ (1,162)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ (579)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ (1,669)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 2,422
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 10,152	\$ 76,827
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 229,334	\$ 526,948
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 94,818	\$ 688,721

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 535,793
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 638,741
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 281,730
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 210,861	\$ 460,397
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 493,668
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 143,448	\$ 663,048
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 191,054	\$ 569,270
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 19,460	\$ 287,889
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 10,579	\$ 212,840
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			N		\$ 28,655
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	Y			Y	\$ 52,588	\$ 484,810
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Regents of the University Of Michigan	3003289634	N		\$ 2,183
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Regents of the University Of Michigan	3003773941	N		\$ (41,051)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Regents of the University Of Michigan	3004195236	N		\$ (16,826)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	McGill University	OB-16-09-21	N		\$ (54)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Translational Genomics Research Institute (TGEN)	DISTEFANO-18-01	N		\$ (3,430)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Pennsylvania	SUBAWARD 576328	N		\$ (17,398)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Translational Genomics Research Institute (TGEN)	DISTEFANO-19-01	Y	\$ 37,796	\$ 246,509
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	The Trustees of Columbia University in the City of New York	GG011642-04	N		\$ (23,181)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Pennsylvania	582552	N		\$ (348)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	The Children's Hospital of Philadelphia	GRT-0000222/PO# 20265644	N		\$ 7,179
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Pennsylvania	576045	N		\$ 1
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Louisville	ULRF_21-0699-02	N		\$ (16,040)
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	The Pennsylvania State University	1R01DK132953-01	N		\$ 19,115
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Pennsylvania	PO 5297690	N		\$ 24,918
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Washington University School of Medicine in St. Louis	P30DK092950	N		\$ 931
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University Of Massachusetts	SUB00000356	N		\$ 38,968
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Augusta University	36350-22	N		\$ 52,296
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Hartford Hospital	126403-Temple	N		\$ 62,814
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University Of Massachusetts	SUB00000407	N		\$ 424
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Trustees of Columbia University In The City of New York	8(GG016550-01)	N		\$ 3,577
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Thomas Jefferson University	080-04000-S54301	N		\$ 226,706
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University Of North Carolina at Chapel Hill	5132381	N		\$ 22,813
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Augusta University	40346-2	N		\$ 4,404
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	The Children's Hospital of Philadelphia	GRT-0000457720650485	N		\$ 127,336
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	University of Louisville	ULRF_23-0543-02	N		\$ 9,739
93	847		Diabetes, Digestive, And Kidney Diseases Extramural Research	Research and Development	\$ 6,654,766	\$ 130,447,791	N	Trustees of the Univ of PA	502027	N		\$ 6,861
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	1U01NS095869-01	N		\$ (4,511)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK9083CSPR #001	Y	\$ 33,000	\$ 33,000
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00008528	Y	\$ 209,250	\$ 218,614
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University of Cincinnati	Subaward No. 011266-135714	N		\$ (7,732)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	Subaward No. 011337-135714	N		\$ 28,209
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	012044-135714	N		\$ 11,269
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	012043-135714	N		\$ 23,364
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	014059-135714	N		\$ (16)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00014507	Y	\$ 14,400	\$ 14,400
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University of Michigan	SUBK00017295	Y	\$ 25,000	\$ 39,801
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	012765-135714	N		\$ 10,918
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	013934-135714	N		\$ (1,353)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	013888-135714	N		\$ 23,522
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	University Of Cincinnati	015151-135714	N		\$ 19,552
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00022275	Y	\$ 7,200	\$ 13,220
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Massachusetts General Hospital	1U01NS136021-01	N		\$ 51,828
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (2,152)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (195)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 24,421
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			Y	\$ 12,932	\$ 161,818
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 183,833
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 226,623
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 430,328
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (160)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 4,731
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 429,642
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			Y	\$ 14,195	\$ 770,322
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 519,868
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 341,983
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 490,606
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (136)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (4,565)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (3,160)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 335,727
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 306,581
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 667,578
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			Y	\$ 26,255	\$ 276,856
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ (223)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 140,607
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 200,066
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 1,038
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 267,147
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			Y	\$ 84,974	\$ 207,308
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 32,461
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 31,307
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	Y			N		\$ 24,082
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	State of Maryland	SR00004947	N		\$ 3
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Regents of the University Of Michigan	3004677567-ESSETT-PK	N		\$ 103
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Dignity Health St. Joseph's Hospital and Medical Center	Temple33144	N		\$ (72,987)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	ThirdLaw, LLC	W15QKN209C004	N		\$ 156,079
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	KannaLife Sciences, Inc.	KLS2-01	N		\$ (8,815)
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Northwestern University	60061958 TU	N		\$ 125,834
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	The Children's Hospital of Philadelphia	GRT-00002928 PO# 20463501	N		\$ 149,795
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Thomas Jefferson University	080-19250-509104	N		\$ 51,198
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	The University of Texas at Arlington	2022GC0864	N		\$ 68,207
93	853		Extramural Research Programs In The Neurosciences And Neurological Disorders	Research and Development	\$ 7,051,474	\$ 130,447,791	N	Joan&Sanford I. Weill Medical College of Cornell University	235775-2	N		\$ 44,135
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Benaroya Research Institute At Virginia Mason	FY22ITN547	N		\$ 18,303
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 96,406
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ (1,260)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ (1,372)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 15,956	\$ 99,828
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 628,900
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 120,381	\$ 756,339
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 5,402
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 19,547	\$ 473,956
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 8,245

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 123,313
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 362,195
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 89,653	\$ (50,917)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 495,344	\$ 694,155
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 130,005
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 347,936
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 111,934
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			Y	\$ 3,365,585	\$ 4,894,019
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	Y			N		\$ 49,110
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Pennsylvania State University	5674-TU-DHHS-4384	N		\$ (2,374)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	University of North Carolina Chapel Hill	5110850	N		\$ 6,177
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Board of Trustees of Michigan State Univ	RC110226TU	N		\$ (4,411)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	The Johns Hopkins University	204455738	N		\$ (70)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Drexel University	940009	N		\$ (3,996)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	The University of Texas Medical Branch at Galveston	22-85692-04	N		\$ (12,151)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Seattle Children's Hospital	13097SUB	N		\$ 139,957
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	The Salk Institute for Biological Studies	A17-0059-S003	N		\$ 12,474
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Vironika LLC	ZT2-R43A1167400-TU	N		\$ (41,328)
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Fox Chase Cancer Center	1519200 Yr 01 New	N		\$ 237,390
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Albany Medical College	6745-Temp	N		\$ 40,922
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Virginia Commonwealth University	FP00021850_SA002	N		\$ 18,776
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Pennsylvania State University	S005828-DHHS	N		\$ 470,943
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	University Of Massachusetts	SUB00000446 PO# :WA01541413	N		\$ 73,896
93	855		Allergy And Infectious Diseases Research	Research and Development	\$ 9,685,040	\$ 130,447,791	N	Institute For Cancer Research	1109900 YR 11 NEW	N		\$ 2,338
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ (15,073)
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ (14,617)
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ (3,596)
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ (12,805)
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 185
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 38,802
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 37,595
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 60
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 149,934
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 738,856
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 392,560
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 1,023
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 473,413
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 264,339
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 329,381
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 203,446
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 465,287
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			Y	\$ 129,132	\$ 563,244
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 341,284
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			Y	\$ 19,112	\$ 444,335
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 464,537
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 257,449
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 490,623
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 420,479
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	Y			N		\$ 109,172
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	The Pennsylvania State University	S001457-DHHS	N		\$ 3,344
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	Seattle Children's Hospital	12767SUB	N		\$ (1,139)
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	Fox Chase Cancer Center	15168-01	N		\$ 53,585
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	CFD Research Corporation	2979	N		\$ 33,568
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	Rutgers University	SUB000002457	N		\$ 152,179
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	Texas A&M University	M2203808	N		\$ 85,454

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	859		Biomedical Research And Research Training	Research and Development	\$ 6,504,741	\$ 130,447,791	N	AIMLOXY LLC	1R41GM142406-01A1	N		\$ 37,837
93	860		Emerging Infections Sentinel Networks	Research and Development	\$ 101,491	\$ 130,447,791	N	Olive View UCLA Edu & Res Inst	16-26	N		\$ 3,138
93	860		Emerging Infections Sentinel Networks	Research and Development	\$ 101,491	\$ 130,447,791	N	UCLA Olive View	#22-41	N		\$ 25,778
93	860		Emerging Infections Sentinel Networks	Research and Development	\$ 101,491	\$ 130,447,791	N	University of California at Los Angeles	157168870	N		\$ 72,575
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 129,033
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 358,856
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 12,787
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ (766)
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 94,917
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 246,360	\$ 506,073
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 741,307
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 347,448
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 116,247
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 72,810	\$ 205,556
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 26,140
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 215,712	\$ 330,914
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 15,010
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 31,639
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 1,786	\$ 99,378
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 23,617	\$ 79,272
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			Y	\$ 80,306	\$ 351,519
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 104,482
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	Y			N		\$ 53,337
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	University of Pennsylvania	574940	N		\$ 1
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Colorado State University	G-92849-02	N		\$ 48,562
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	RTI International	2-312-0216911-65664L	N		\$ (4,134)
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Recombination Therapeutics, LLC	A2020-470	N		\$ (990)
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Indiana University	9272	N		\$ 10,736
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Widener University	33376-1D	N		\$ (14,631)
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	The Regents of the University of California	14152sc	N		\$ 181,465
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	The Trustees of Columbia University in the City of New York	2(GG018819-01)	N		\$ 23,543
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	University Of Minnesota	N010478701	N		\$ 49,752
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	University of Michigan	SUBK00018736	N		\$ 20,996
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Drexel University	910005-TEMPLE	N		\$ 12,328
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	ABLELINK SMART LIVING TECHNOLOGIES	1R44HD113503-01A1	N		\$ 65,662
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	Regents of the University Of Michigan	SUBK00020589	N		\$ 275,356
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	University Of Massachusetts	SUB00000460	N		\$ 13,341
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	University of Pennsylvania	501265	N		\$ 45,325
93	865		Child Health And Human Development Extramural Research	Research and Development	\$ 4,360,999	\$ 130,447,791	N	The Trustees of Columbia University in the City of New York	1(GG019178-01)	N		\$ 9,723
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ (16,444)
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 221,049
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 245,819
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ (13,438)
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 2,979
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			Y	\$ 73,439	\$ 338,417
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ (191,795)
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 576,242
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 558,880
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 210,411
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 30,695
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			Y	\$ 307,470	\$ 939,377
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 144,084
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 140,971

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 140,673
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 909,436
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 28,919
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 27,674
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	Y			N		\$ 30,000
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	The Johns Hopkins University	A2020-221-001	N		\$ 1
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	The Regents of the University of California, Santa Cruz	A18-0719-S001-P0687641	N		\$ 97,369
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Montclair State University	GR00506	N		\$ 62,035
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Ohio University	UT21864	N		\$ 29,214
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Yale University	CON-80002777	N		\$ (96,349)
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	XYKEN, LLC	1R44AG069564-3024V	N		\$ 21,368
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	The University of Texas at Dallas	2109649	N		\$ 1
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Dignity Health St. Joseph's Hospital and Medical Center	Temple 1033988	N		\$ 231,750
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	University of Pittsburgh	AWD00008289 (139540-2)	N		\$ 16,800
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Yale University	CON-80004756(GR122418)	N		\$ 6,083
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	Johns Hopkins University	2006415094	N		\$ 64,719
93	866		Aging Research	Research and Development	\$ 4,808,775	\$ 130,447,791	N	University of Pennsylvania	1-U01-AG-089107-01	N		\$ 51,835
93	867		Vision Research	Research and Development	\$ 263,345	\$ 130,447,791	Y			N		\$ 9,175
93	867		Vision Research	Research and Development	\$ 263,345	\$ 130,447,791	Y			N		\$ 222,510
93	867		Vision Research	Research and Development	\$ 263,345	\$ 130,447,791	N	University of Pennsylvania	581583	N		\$ 31,655
93	867		Vision Research	Research and Development	\$ 263,345	\$ 130,447,791	N	New York university, Grossman school of Medicine	22-A1-00-1007131	N		\$ 5
93	879		Medical Library Assistance	Research and Development	\$ 498,033	\$ 130,447,791	Y			N		\$ 232,592
93	879		Medical Library Assistance	Research and Development	\$ 498,033	\$ 130,447,791	Y			N		\$ 265,441
93	924		Ryan White Hiv/aids Dental Reimbursement And Community Based Dental Partnership Grants	Research and Development	\$ 110,895	\$ 130,447,791	Y			N		\$ (2,478)
93	958		Block Grants For Community Mental Health Services	Research and Development	\$ 85,970	\$ 130,447,791	N	TRILLIUM HEALTH RESOURCES	0097C-000-FY25	N		\$ 85,970
93	RD5	3002545932	Department Of Health And Human Services Contract	Research and Development	\$ 364,606	\$ 130,447,791	N	Regents of the University Of Michigan	3002545932	N		\$ 4,647
93	RD5	OTA-20-011A	Department Of Health And Human Services Contract	Research and Development	\$ 364,606	\$ 130,447,791	N	National Jewish Health	OTA-20-011A	N		\$ 21,635
93	RD5	201387011 TEM	Department Of Health And Human Services Contract	Research and Development	\$ 364,606	\$ 130,447,791	N	National Jewish Health	201387011 TEM	N		\$ 338,324
93	RD6	26-312-0217597-67803L	Food And Drug Administration Contract	Research and Development	\$ 39,467	\$ 130,447,791	N	Food and Drug Administration	26-312-0217597-67803L	N		\$ 39,467
93	RD7	75D30123C17147	Center For Disease Control Contract	Research and Development	\$ 107,808	\$ 130,447,791	Y			N		\$ 107,808
93	RD8	75N95D24P00122	National Institutes Of Health Contract	Research and Development	\$ 25,003	\$ 130,447,791	Y			N		\$ 25,003
93	RD9	AWD00003449-2	Department Of Health And Human Services Contract	Research and Development	\$ 804,996	\$ 130,447,791	N	University of Pittsburgh	AWD00003449-2	N		\$ 254
93	RD9	500884-TEMPLE/PO GRT2300002	Department Of Health And Human Services Contract	Research and Development	\$ 804,996	\$ 130,447,791	N	Feinstein Institute for Medical Research	500884-TEMPLE/PO GRT2300002	N		\$ 294,841
93	RD9	TU-01-4198	Department Of Health And Human Services Contract	Research and Development	\$ 804,996	\$ 130,447,791	N	McKing Consulting Corporation	TU-01-4198	N		\$ 420,293
93	RD9	75D30123C16626	Department Of Health And Human Services Contract	Research and Development	\$ 804,996	\$ 130,447,791	N	Cerner Corporation	75D30123C16626	N		\$ 5,773
93	RD9	75N92024D00012	Department Of Health And Human Services Contract	Research and Development	\$ 804,996	\$ 130,447,791	N	University of California San Francisco	75N92024D00012	N		\$ 83,835
97	061		Centers For Homeland Security	Research and Development	\$ (6,927)	\$ 130,447,791	N	Florida Board of Trustees	GR107453	N		\$ (6,927)
98	001		Usaid Foreign Assistance For Programs Overseas	Research and Development	\$ 1,229,815	\$ 130,447,791	N	The American University in Cairo	72026319CA00001	N		\$ 352,187
98	001		Usaid Foreign Assistance For Programs Overseas	Research and Development	\$ 1,229,815	\$ 130,447,791	N	PACT	72012122CA00001	Y	\$ 405,872	\$ 877,628
93	558		Temporary Assistance For Needy Families	477 CLUSTER	\$ 182,404	\$ 182,404	N	Philadelphia Works	090-20-336-1	N		\$ 113
93	558		Temporary Assistance For Needy Families	477 CLUSTER	\$ 182,404	\$ 182,404	N	Philadelphia Works	YT24-012	N		\$ 182,042
93	558		Temporary Assistance For Needy Families	477 CLUSTER	\$ 182,404	\$ 182,404	N	Public Health Management Corporation	NO ID PROVIDED	N		\$ 249
11	307		Economic Adjustment Assistance	Economic Development Cluster	\$ 29,182	\$ 29,182	N	Philadelphia Works	GJ25-120	N		\$ 29,182
14	889		Choice Neighborhoods Implementation Grants	HOPE VI CLUSTER	\$ 8,035	\$ 8,035	N	Philadelphia Housing Authority	5166	N		\$ 8,035
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	Pennsylvania Department Of Public Welfare	4400011166	N		\$ (13,701)
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	Pennsylvania Department Of Public Welfare	4300591464	N		\$ (14,015)
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	Pennsylvania Department Of Public Welfare	4300621036	N		\$ (5,187)
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	PA Dept of Human Services	PO# 4300731672	N		\$ (2,260)

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	PA Dept of Human Services	4300784612	N		\$ 33,827
93	778		Medical Assistance Program	Medicaid Cluster	\$ 126,638	\$ 126,638	N	PA Dept of Human Services	4300793585	N		\$ 127,974
93	342		Heath Professions Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 22,749,499	\$ 386,109,428	Y			N		\$22,505,354
93	342		Heath Professions Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 22,749,499	\$ 386,109,428	Y			N		\$ 244,145
93	364		Nursing Student Loan	STUDENT FINANCIAL ASSISTANCE	\$ 444,045	\$ 386,109,428	Y			N		\$ 440,024
93	364		Nursing Student Loan	STUDENT FINANCIAL ASSISTANCE	\$ 444,045	\$ 386,109,428	Y			N		\$ 4,021
84	007		Federal Supplemental Educational Opportunity Grants	STUDENT FINANCIAL ASSISTANCE	\$ 2,286,453	\$ 386,109,428	Y			N		\$ 2,286,453
84	033		Federal Work Study Program	STUDENT FINANCIAL ASSISTANCE	\$ 2,972,913	\$ 386,109,428	Y			N		\$ 2,934,717
84	038		Federal Perkins Loan Program	STUDENT FINANCIAL ASSISTANCE	\$ 6,690,678	\$ 386,109,428	Y			N		\$ 6,306,795
84	038		Federal Perkins Loan Program	STUDENT FINANCIAL ASSISTANCE	\$ 6,690,678	\$ 386,109,428	Y			N		\$ 383,883
84	063		Federal Pell Grant Program	STUDENT FINANCIAL ASSISTANCE	\$ 53,412,096	\$ 386,109,428	Y			N		\$53,412,096
84	268		Federal Direct Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 297,553,744	\$ 386,109,428	Y			N		\$39,219,962
84	268		Federal Direct Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 297,553,744	\$ 386,109,428	Y			N		\$131,983,252
84	268		Federal Direct Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 297,553,744	\$ 386,109,428	Y			N		\$64,608,248
84	268		Federal Direct Student Loans	STUDENT FINANCIAL ASSISTANCE	\$ 297,553,744	\$ 386,109,428	Y			N		\$61,742,282
84	379		Teacher Education Assistance For College And Higher Education Grants (Teach Grants)	STUDENT FINANCIAL ASSISTANCE	\$ 38,196	\$ 386,109,428	Y			N		\$ 38,196
84	047A		Trio Upward Bound	TRIO Cluster	\$ 535,353	\$ 825,451	Y			N		\$ 535,353
84	047M		Trio Upward Bound	TRIO Cluster	\$ 290,098	\$ 825,451	Y			N		\$ 290,098
17	259		Wioa Youth Activities	WIOA Cluster	\$ 358,101	\$ 412,251	N	Philadelphia Works	090-22-330-1	N		\$ 358,101
17	278		Wioa Dislocated Worker Formula Grants	WIOA Cluster	\$ 54,150	\$ 412,251	N	Pennsylvania Department of Labor And Industry	292234132	N		\$ 54,150
93	397		Cancer Centers Support Grants	N/A	\$ 2,032,754	\$ —	N	The Board of Trustees of the Leland Stanford Junior Univ	63352682	N		\$ 18,972
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation's Health	N/A	\$ 393,339	\$ —	N	Association of State and Territorial Health Officials	24209411129	N		\$ 9,349
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation's Health	N/A	\$ 393,339	\$ —	N	Association of State and Territorial Health Officials	24209411177	N		\$ 6,730
93	865		Child Health And Human Development Extramural Research	N/A	\$ 4,360,999	\$ —	N	Administrators of the Tulane Edu Fund	TUL-HSC-562947-24/25	N		\$ 20,815
97	036	COVID-19	Disaster Grants - Public Assistance (Presidentially Declared Disasters)	N/A	\$ 434,573	\$ —	N	Pennsylvania Emergency Management Agency	COVID-19 - PEMA-DAP-9	N		\$ 405,483
11	431		Climate And Atmospheric Research	N/A	\$ 46,608	\$ —	N	University Corporation for Atmospheric Research	SUBAWD004205	N		\$ 13,482
12	431		Basic Scientific Research	N/A	\$ 3,574,209	\$ —	Y			N		\$ (9,000)
12	630		Basic, Applied, And Advanced Research In Science And Engineering	N/A	\$ (11,108)	\$ —	N	National Science Teachers Association	23-871-025	N		\$ (507)
12	630		Basic, Applied, And Advanced Research In Science And Engineering	N/A	\$ (11,108)	\$ —	N	National Science Teachers Association	24-871-031	N		\$ 16,189
12	630		Basic, Applied, And Advanced Research In Science And Engineering	N/A	\$ (11,108)	\$ —	N	National Science Teachers Association	25-871-034	N		\$ 14,000
12	740		Past Conflict Accounting	N/A	\$ 113,359	\$ —	N	The Ohio State University	SPC-1000004995 GRT00057086	N		\$ 113,359
12	U01	N6449820P5353	Us Department Of Defense Contract	N/A	\$ 237,027	\$ —	Y			N		\$ 17,390
12	U01	N6449822P5100	Us Department Of Defense Contract	N/A	\$ 237,027	\$ —	Y			N		\$ 13,892
12	U01	N6449823P5156	Us Department Of Defense Contract	N/A	\$ 237,027	\$ —	Y			N		\$ 90,196
12	U01	N6449824P5194	Us Department Of Defense Contract	N/A	\$ 237,027	\$ —	Y			N		\$ 115,549
16	045		Community-based Violence Intervention And Prevention Initiative	N/A	\$ 125,183	\$ —	N	New Kensington Community Development Corporation	TU - 1001	N		\$ 125,183
16	575		Crime Victim Assistance	N/A	\$ 201,895	\$ —	N	Pennsylvania Commission On Crime And Delinquency	201820192020-VF-05-33217	N		\$ (3,090)
16	575		Crime Victim Assistance	N/A	\$ 201,895	\$ —	N	Pennsylvania Commission On Crime And Delinquency	2021-VF-05-40278	N		\$ 67,968
16	575		Crime Victim Assistance	N/A	\$ 201,895	\$ —	N	Pennsylvania Commission On Crime And Delinquency	2022-VF-05-40278-2	N		\$ 137,017
16	603		Corrections Technical Assistance/clearinghouse	N/A	\$ (118)	\$ —	Y			N		\$ (118)
16	710		Public Safety Partnership And Community Policing Grants	N/A	\$ 250,000	\$ —	Y			N		\$ 250,000
16	738		Edward Byrne Memorial Justice Assistance Grant Program	N/A	\$ 244,409	\$ —	N	Pennsylvania Commission On Crime And Delinquency	2022-JG-SS-39823	N		\$ 77,107

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
16	753		Congressionally Recommended Awards	N/A	\$ 199,719	\$ —	Y			N		\$ 199,719
16	839		Stop School Violence	N/A	\$ 549,966	\$ —	Y			N		\$ 549,966
16	U02	15PBJA-21-GG-04111-BCJI	Us Department Of Justice Contract	N/A	\$ 11,698	\$ —	N	Mt. Vernon Manor, Inc.	15PBJA-21-GG-04111-BCJI	N		\$ 11,698
19	040		Public Diplomacy Programs	N/A	\$ 151,399	\$ —	Y			N		\$ 151,399
21	008		Low Income Taxpayer Clinics	N/A	\$ 175,734	\$ —	Y			N		\$ 78,636
21	008		Low Income Taxpayer Clinics	N/A	\$ 175,734	\$ —	Y			N		\$ 97,098
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Pennsylvania Department Of Education	FA-SRS-22-0003	N		\$ 148,842
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Pennsylvania Commission On Crime And Delinquency	2022-CV-VI-39769	N		\$ 487,484
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Pennsylvania Department Of Education	4100095634	N		\$ 186,554
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Pennsylvania Commission On Crime And Delinquency	2022-CL-01-39097	N		\$ 1,111,786
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Pennsylvania Department Of Education	4100096364	N		\$ 535,293
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	National Opinion Reseach Center	G324.Temple.01	N		\$ 223,897
21	027	COVID-19	Coronavirus State And Local Fiscal Recovery Funds	N/A	\$ 2,717,808	\$ —	N	Commonwealth of PA Department of Human Services	4100096805	N		\$ 23,952
32	U03	DA-19-557	Federal Communications Commission Contract	N/A	\$ 301,726	\$ —	Y			N		\$ 195
32	U03	DA 21-653	Federal Communications Commission Contract	N/A	\$ 301,726	\$ —	Y			N		\$ (193)
32	U03	CG Docket No. 10-210	Federal Communications Commission Contract	N/A	\$ 301,726	\$ —	Y			N		\$ (242)
32	U03	CG Docket No. 10-210	Federal Communications Commission Contract	N/A	\$ 301,726	\$ —	Y			N		\$ 2,767
32	U03	10-210	Federal Communications Commission Contract	N/A	\$ 301,726	\$ —	Y			N		\$ 299,199
42	011		Library Of Congress Grants	N/A	\$ 49,981	\$ —	Y			N		\$ 49,981
43	U04	2901-TU-NASAF84H	National Air & Space Administration Contract	N/A	\$ (242)	\$ —	N	Pennsylvania State University	2901-TU-NASAF84H	N		\$ (242)
45	169		Promotion Of The Humanities Office Of Digital Humanities	N/A	\$ 77,739	\$ —	Y			N		\$ 724
45	169		Promotion Of The Humanities Office Of Digital Humanities	N/A	\$ 77,739	\$ —	Y			N		\$ 700
45	312		National Leadership Grants	N/A	\$ 98,226	\$ —	Y			N		\$ 98,226
59	037		Small Business Development Centers	N/A	\$ 222,575	\$ —	N	Kutztown University	SBA20210411	N		\$ (1,959)
84	324		Research In Special Education	N/A	\$ (37)	\$ —	N	Lehigh University	543385-78001	N		\$ (37)
84	367		Supporting Effective Instruction State Grants (Formerly Improving Teacher Quality State Grants)	N/A	\$ 10,153	\$ —	N	Pennsylvania Department Of Education	524-23-0008	N		\$ 10,153
84	002A		Adult Education - Basic Grants To States	N/A	\$ 25,525	\$ —	N	The Pennsylvania State University	S002317-COP	N		\$ (1)
84	002A		Adult Education - Basic Grants To States	N/A	\$ 25,525	\$ —	N	Pennsylvania Department Of Education	FA-064-23-0030	N		\$ 57
84	048A		Career And Technical Education -- Basic Grants To States	N/A	\$ 5,716	\$ —	N	Commonwealth of Pennsylvania	PROJECT# FA-119-18-0001	N		\$ 115
84	048A		Career And Technical Education -- Basic Grants To States	N/A	\$ 5,716	\$ —	N	Pennsylvania Department Of Education	FA-119-24-1002	N		\$ 5,601
84	220A		Centers For International Business Education	N/A	\$ 266,054	\$ —	Y			N		\$ (234)
84	305A		Education Research, Development And Dissemination	N/A	\$ 401,064	\$ —	Y			N		\$ 260,245
84	305A		Education Research, Development And Dissemination	N/A	\$ 401,064	\$ —	N	WestEd	S-00018320	N		\$ 77,929
84	325D		Special Education - Personnel Development To Improve Services And Results For Children With Disabilities	N/A	\$ 482,083	\$ —	Y			Y	\$ 230,650	\$ 482,083
84	365Z		English Language Acquisition State Grants	N/A	\$ 705,795	\$ —	Y			Y	\$ 75,819	\$ 706,426
84	425D	COVID-19	Education Stabilization Fund	N/A	\$ (73,433)	\$ —	N	Philadelphia School District	2240	N		\$ 2,314
84	425D	COVID-19	Education Stabilization Fund	N/A	\$ (73,433)	\$ —	N	Philadelphia School District	PUR115370	N		\$ (75,747)
93	048		Special Programs For The Aging, Title Iv, And Title Ii, Discretionary Projects	N/A	\$ (44,175)	\$ —	N	Pennsylvania Department of Aging	SAP VENDOR NUM 117671	N		\$ (39,496)
93	048		Special Programs For The Aging, Title Iv, And Title Ii, Discretionary Projects	N/A	\$ (44,175)	\$ —	N	Pennsylvania Department of Aging	4100092915	N		\$ (4,679)
93	059		Training In General, Pediatric, And Public Health Dentistry	N/A	\$ 82,040	\$ —	Y			N		\$ (19,135)
93	059		Training In General, Pediatric, And Public Health Dentistry	N/A	\$ 82,040	\$ —	Y			N		\$ 101,175
93	084		Prevention Of Disease, Disability, And Death By Infectious Diseases	N/A	\$ 914,517	\$ —	Y			Y	\$ 302,572	\$ 914,517
93	092		Affordable Care Act (Aca) Personal Responsibility Education Program	N/A	\$ 113,374	\$ —	N	Pennsylvania Department of Health	SAP# :4100095359	N		\$ 113,374
93	110		Maternal And Child Health Federal Consolidated Programs	N/A	\$ 37,514	\$ —	N	The Children's Hospital of Philadelphia	3204510622 PO# 20562654	N		\$ 37,514
93	137		Community Programs To Improve Minority Health	N/A	\$ 170,481	\$ —	N	National Network of Public Health Institutes	G2447_AG-1077	N		\$ 34,098
93	137		Community Programs To Improve Minority Health	N/A	\$ 170,481	\$ —	N	National Network of Public Health Institutes	G3063_AG-1634	N		\$ 78,763
93	137		Community Programs To Improve Minority Health	N/A	\$ 170,481	\$ —	N	National Network of Public Health Institutes	G3067_AG-1635	N		\$ 57,620

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025

Federal Agency Prefix	ALN Three Digit Extension	Additional Award Identification	Federal Program Name	Cluster Name	Federal Program Total	Cluster Total	Direct Award	Name of Passthrough Entity	Identifying Number Assigned by the Pass-through Entity, if assigned	Federal Award Passed Through to Subrecipients	Amount Passed Through to Subrecipients	Amount Expended
93	153		Coordinated Services And Access To Research For Women, Infants, Children, And Youth	N/A	\$ (1,490)	\$ —	N	Access Matters	186306	N		\$ (1,885)
93	153		Coordinated Services And Access To Research For Women, Infants, Children, And Youth	N/A	\$ (1,490)	\$ —	N	Access Matters	216306	N		\$ 395
93	235		Title V State Sexual Risk Avoidance Education (Title V State Srae) Program	N/A	\$ (3,730)	\$ —	N	Pennsylvania Department of Health	4100082233	N		\$ (3,730)
93	243		Substance Abuse And Mental Health Services Projects Of Regional And National Significance	N/A	\$ 344,327	\$ —	N	Philadelphia Department of Behavioral Health	2220321-02	N		\$ 191,438
93	243		Substance Abuse And Mental Health Services Projects Of Regional And National Significance	N/A	\$ 344,327	\$ —	N	CITY OF PHILADELPHIA: DEPARTMENT OF BEHAVIORAL HEALTH AND IN	2220321	N		\$ 152,889
93	310		Trans-nih Research Support	N/A	\$ 796,143	\$ —	N	George Mason University	E2060461	N		\$ 103,279
93	391		Activities To Support State, Tribal, Local And Territorial (Slt) Health Department Response To Public Health Or Healthcare Crises	N/A	\$ 1,188,830	\$ —	N	Pennsylvania Department of Health	4100090589	N		\$ 1,188,830
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	N/A	\$ 393,339	\$ —	N	Association of State and Territorial Health Officials	0242 OO-FE-2052-05-00	N		\$ (18,584)
93	421		Strengthening Public Health Systems And Services Through National Partnerships To Improve And Protect The Nation s Health	N/A	\$ 393,339	\$ —	N	National Association of County and City Health Officials	2022- 031102	N		\$ (14,092)
93	464		Acl Assistive Technology	N/A	\$ 785,055	\$ —	Y			N		\$ 330
93	464		Acl Assistive Technology	N/A	\$ 785,055	\$ —	Y			Y	\$ 155,189	\$ 713,348
93	493		Congressional Directives	N/A	\$ 254,915	\$ —	Y			N		\$ 254,915
93	632		University Centers For Excellence In Developmental Disabilities Education, Research, And Service	N/A	\$ 636,010	\$ —	Y			N		\$ 16
93	639		Section 9813: State Planning Grants For Qualifying Community-based Mobile Crisis Intervention Services	N/A	\$ (1)	\$ —	N	PA Dept of Human Services	4100096245	N		\$ (1)
93	747		Elder Abuse Prevention Interventions Program	N/A	\$ 288,769	\$ —	Y			N		\$ 288,769
93	898		Cancer Prevention And Control Programs For State, Territorial And Tribal Organizations	N/A	\$ 959	\$ —	N	Se Ahec-Pa Department Of Health	4400017651	N		\$ 959
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW9700	N		\$ (1,163)
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW0700	N		\$ (2,415)
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW0419	N		\$ (1,670)
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW1419	N		\$ (165)
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RM1222	N		\$ 338
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW1701	N		\$ (142)
93	914		Hiv Emergency Relief Project Grants	N/A	\$ (5,819)	\$ —	N	AIDS Activities Coordinating Office	RW1700	N		\$ (602)
93	918		Grants To Provide Outpatient Early Intervention Services With Respect To Hiv Disease	N/A	\$ 33,466	\$ —	N	Philadelphia Department of Public Health	2220191	N		\$ 33,466
93	924		Ryan White Hiv/aids Dental Reimbursement And Community Based Dental Partnership Grants	N/A	\$ 110,895	\$ —	Y			N		\$ 113,373
93	940		Hiv Prevention Activities Health Department Based	N/A	\$ 1,337	\$ —	N	AIDS Activities Coordinating Office	1820421-02	N		\$ (794)
93	940		Hiv Prevention Activities Health Department Based	N/A	\$ 1,337	\$ —	N	AIDS Activities Coordinating Office	EC1002	N		\$ (209)
93	940		Hiv Prevention Activities Health Department Based	N/A	\$ 1,337	\$ —	N	AIDS Activities Coordinating Office	EC2002	N		\$ 2,495
93	940		Hiv Prevention Activities Health Department Based	N/A	\$ 1,337	\$ —	N	AIDS Activities Coordinating Office	2220529	N		\$ (155)
93	994		Maternal And Child Health Services Block Grant To The States	N/A	\$ 520,568	\$ —	N	Pennsylvania Department of Health	4100095921	N		\$ 520,568
93	U05	CDC7110	Center For Disease Control Contract	N/A	\$ 4,503	\$ —	N	ChangeLab Solutions	CDC7110	N		\$ 4,503
94	006		Americorps State And National 94.006	N/A	\$ 66,789	\$ —	N	Jumpstart National	2920230	N		\$ (2,433)
94	006		Americorps State And National 94.006	N/A	\$ 66,789	\$ —	N	Jumpstart National	2920250	N		\$ 69,222
97	036	COVID-19	Disaster Grants - Public Assistance (Presidentially Declared Disasters)	N/A	\$ 434,573	\$ —	N	Pennsylvania Emergency Management Agency	COVID Relief Funds	N		\$ 29,072
97	036		Disaster Grants - Public Assistance (Presidentially Declared Disasters)	N/A	\$ 434,573	\$ —	N	Philadelphia Mental Health Care Corporation	NH23IP922583	N		\$ 18

**TEMPLE UNIVERSITY –
OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION**

**NOTES TO SCHEDULE OF EXPENDITURES – FEDERAL AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

(1) BASIS OF PRESENTATION

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) summarizes the expenditures of Temple University – Of The Commonwealth System of Higher Education (“Temple”) under programs of the federal government for the year ended June 30, 2025. The information in the Schedule is presented in accordance with the requirements of *Title 2 U.S. Code of Federal Regulations (“2 CFR”) Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (“Uniform Guidance”). The Schedule does not include the federal funding awarded to Temple University Health System, Inc. and its subsidiaries (“TUHS”). A separate audit in accordance with the U.S. Office of Management and Budget (“OMB”) *Compliance Supplement* was performed for TUHS for the year ended June 30, 2025.

Because the Schedule presents only a selected portion of the operations of Temple University, it is not intended to, and does not, present the financial position, revenues, expenses, and changes in net assets of Temple. For the purposes of the Schedule, federal awards include all grants, contracts, and similar agreements entered into directly between Temple and agencies or departments of the federal government and all subawards to Temple by nonfederal organizations pursuant to federal grants, contracts, and similar agreements.

Temple’s consolidated financial statements include the consolidated operations of Temple University Health System, Inc. and its subsidiaries, which received federal awards, which are not included in Temple’s Schedule of Expenditures of Federal Awards for the year ended June 30, 2025.

Federally guaranteed loans issued to students of Temple directly by Temple are also included in the Schedule.

Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented where available.

Certain costs reflected in the Schedule may represent costs incurred in prior years that have been approved for reimbursement by the granting agency and recorded in the current year financials.

Assistance Listing Numbers (“ALN”) numbers are from those published by the Office of Management and Budget and the General Services Administration. As provided for in 2 CFR section 200.42(b); Programs without an ALN number are presented with only the federal agency’s two-digit prefix followed by the abbreviation “RD” for those programs in the research and development cluster or “U” (i.e. unknown) and sequentially numbered by federal agency in place of a ALN number. The federal agency two-digit prefixes are as follows:

Prefix Federal Agency

10	Department of Agriculture
11	Department of Commerce
12	Department of Defense
14	Department of Housing and Urban Development
15	Department of the Interior
16	Department of Justice
17	Department of Labor
19	Department of State
20	Department of Transportation
21	Department of the Treasury
32	Federal Communication Commission
43	National Aeronautics & Space Administration
45	National Foundation on the Arts and the Humanities
47	National Science Foundation
59	Small Business Administration
64	Department of Veterans Affairs
81	Department of Energy
84	Department of Education
93	Department of Health and Human Services
94	Corporation for National and Community Service
95	Executive Office of the President
97	Department of Homeland Security
98	Agency for International Development

The Schedule is presented using the accrual basis of accounting. Expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Pass-through entity identifying numbers are presented where available.

The consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America for not-for-profit organization.

(2) INDIRECT COSTS

Temple does not elect to use the de minimis indirect cost rate allowed under the Uniform Guidance.

(3) FEDERAL STUDENT LOAN PROGRAMS

Federally guaranteed loans (including subsidized and unsubsidized loans) issued to students of Temple directly by Temple during the year ended June 30, 2025, are summarized below:

	ALN Number	Amount Authorized
Direct Parent Plus Loans	84.268	\$ 64,608,248
Direct Graduate Plus Loans	84.268	61,742,282
Direct Subsidized Loans	84.268	39,219,962
Direct Unsubsidized Loans	84.268	131,983,252
		<u>\$ 297,553,744</u>

Temple is responsible only for the performance of certain administrative duties with respect to the federally guaranteed student loan programs; therefore, the net assets and transactions for those programs are not included in the Temple’s consolidated financial statements.

Temple also participated in and administers the following student loan programs:

	ALN Number	Loans Outstanding as of June 30, 2025	Loans Made During Year Ended June 30, 2025
Perkins Loans	84.038	\$ 6,306,795	\$ -
Health Professionals Student Loans and Loans for Disadvantaged Students	93.342	22,505,354	3,226,035
Nursing Student Loans	93.364	440,024	49,637
		<u>\$ 29,252,173</u>	<u>\$ 3,275,672</u>

Temple accounts for such loan programs in separate revolving loan funds. As such, the balances and transactions of these loan programs are recorded in Temple’s consolidated financial statements. The amounts on the Schedule for these loan programs also include expenditures for the administrative costs of the respective programs.

(4) SUBRECIPIENTS

Uniform Guidance defines a subrecipient as a nonfederal entity that receives a subaward from a pass-through entity to carry out part of a federal program but does not include an individual who is a beneficiary of such program or payments to a contractor. A contractor is an entity that receives a contract by which a nonfederal entity purchases property or services needed to carry out the project or program under a federal award. A nonfederal entity may concurrently receive federal funds as a recipient, subrecipient, and contractor, depending on the substance of its agreements with federal awarding agencies and pass-through entities. Therefore, Temple must make case-by-case determinations whether each agreement it makes for the disbursement of federal program funds casts the party receiving the funds as a subrecipient or a contractor based on the Uniform Guidance definitions and management’s judgment. The total amount identified as provided to subrecipients during the year ended June 30, 2025, was \$14,753,135.

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

SCHEDULE OF FINDINGS AND QUESTIONED COSTS – FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2025

SECTION I—SUMMARY OF AUDITOR’S RESULTS		
<i>Financial Statements</i>		
Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: UNMODIFIED		
Internal control over financial reporting:		
• Material weakness (es) identified?	_____ yes	<u> X </u> no
• Significant deficiency (ies) identified?	_____ yes	<u> X </u> no
Noncompliance material to financial statements noted?	_____ yes	<u> X </u> no
<i>Federal Awards</i>		
Internal control over major federal programs:		
• Material weakness (es) identified?	_____ yes	<u> X </u> no
• Significant deficiency (ies) identified?	<u> X </u> yes	_____ no
Type of auditor’s report issued on compliance for major federal programs: UNMODIFIED		
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	<u> X </u> yes	_____ no
Identification of major federal programs: Research and Development Cluster (See Schedule of Federal Expenditures for various ALN) Activities to Support State, Tribal, Local and Territorial (STLT) Health Department Response to Public Health or Healthcare Crises (ALN 93.391)		
Dollar threshold used to distinguish between type A and type B programs:	\$ 3,000,000	
Auditee qualified as low-risk auditee?	<u> X </u> yes	_____ no

SECTION II—FINANCIAL STATEMENT FINDINGS

The audit disclosed no items required to be disclosed in this section.

SECTION III—FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

See page 100

**TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF
HIGHER EDUCATION
SCHEDULE OF PRIOR YEAR FINDINGS – FEDERAL AWARDS FOR
THE YEAR ENDED JUNE 30, 2024**

Prior year audit Schedule of Findings and Questioned Costs of Federal Awards contained the following finding:

Reference Number: 2024-001

Federal Agency: National Institutes of Health

Federal Program: Research and Development Cluster

Pass-through: University of Pennsylvania; University of Alabama at Birmingham

ALN Number: 93.242; 93.279; and 93.847

Contract numbers: # 5R01-MH-128155-03; 1DP2DA056172-01; K01DA046308; 5R01DK108438-05

Compliance Requirement: Equipment and Real Property Management

Status:

Corrected. The University implemented corrective actions to address equipment transfers associated with sponsored awards, including updating its equipment management policy to address transfers between institutions, adding equipment transfers to the PI transfer checklist, and enhancing training for equipment managers. No similar findings were identified in the current year audit.

Corrective Action Plan

FINDING 2025-001

Planned Corrective Action: The award period ended on June 30, 2025. Management performed a comprehensive re-review of invoices associated with FY25 billings to confirm that amounts submitted for reimbursement were accurately presented and that cumulative expenditures remained within approved budget limits. In connection with this review, the University identified invoiced amounts associated with incorrectly classified budget categories and has refunded \$243,852.41 to the Pennsylvania Department of Health (PADOH) in full.

To address the identified control deficiencies and prevent recurrence, the University has implemented and continues to formalize enhanced controls over the grant invoicing process. These actions establish appropriate segregation of duties, strengthen pre-submission review procedures, and enhance monitoring of budget-to-actual expenditures.

Effective immediately, the University has centralized invoice preparation and submission within the post-award office. Departments are no longer permitted to submit invoices directly to sponsors. All invoices must be prepared, reviewed, and submitted by a post-award grant analyst. This control establishes clear ownership and appropriate segregation of duties between transaction processing and independent review.

As part of the enhanced review process, all invoices are subject to a documented pre-submission review to:

- (1) reconcile invoice line items to the underlying general ledger detail, and
- (2) compare year-to-date expenditures to the approved award budget by category to ensure allowability, accuracy, and compliance with budget constraints.

Additionally, all invoices are digitally signed by the reviewing post-award grant analyst prior to submission, providing evidence of review and creating an auditable record of approval.

The University is further strengthening preventive and detective controls by developing a formal grant invoicing policy and enhancing monitoring processes. The formal policy will codify roles and responsibilities for invoice preparation, review, approval, and submission; require documented budget-to-actual monitoring; and require that any reallocation of costs between approved budget categories be supported by sponsor approval, preferably through a formal budget amendment, prior to invoice submission.

In addition, the University is implementing an enhanced invoice-tracking and monitoring process within the post-award office to ensure that all expected invoices are prepared, reviewed, and submitted through the appropriate control structure. This process will include identifying and investigating exceptions, such as instances where invoicing activity does not align with expected billing patterns, to support the timely detection and resolution of discrepancies.

Collectively, these actions strengthen internal controls over compliance with federal award requirements, improve accuracy and transparency in financial reporting to sponsors, and address the root causes identified in the finding.

Anticipated Completion Date: June 30, 2026

Responsible Contact Person: Josh Gladden, Vice President for Research

CITY OF PHILADELPHIA AWARDS SECTION



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103-3984
USA
Tel: +1 215 246 2300
Fax: +1 215 569 2441

INDEPENDENT AUDITOR’S REPORT ON COMPLIANCE FOR EACH MAJOR CITY OF PHILADELPHIA AWARD; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS AND SCHEDULES REQUIRED BY *THE CITY OF PHILADELPHIA SUBRECIPIENT AUDIT GUIDE*

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

Report on Compliance for Each Major City of Philadelphia Award

Opinion on Each Major City of Philadelphia Award

We have audited Temple University – Of The Commonwealth System of Higher Education’s (“Temple”) compliance with the types of compliance requirements identified as subject to audit in the *City of Philadelphia Subrecipient Audit Guide* that could have a direct and material effect on each of Temple’s major City of Philadelphia Awards for the year ended June 30, 2025. Temple’s major City of Philadelphia Awards are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

In our opinion, Temple complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major City of Philadelphia Awards for the year ended June 30, 2025.

Our audit, described below, did not include the operations of Temple Educational Support Services, Ltd; Temple University School of Podiatric Medicine, Inc.; Good Samaritan Insurance Co. Ltd.; TUMP Offices, Inc.; Global Technology Management Corp.; Temple University Health System Foundation; TUH - Jeanes Campus Auxiliary; Temple Health Subsidiaries, Inc.; Temple Physicians, Inc.; Temple Faculty Practice Plan, Inc.; Episcopal Hospital; TUHS Insurance Company, Ltd.; Temple Health Transport Team, Inc.; Temple Center for Population Health, LLC; American Oncologic Hospital d/b/a The Hospital of Fox Chase Cancer Center; Fox Chase Limited; Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center; Fox Chase Cancer Center Medical Group, Inc.; Fox Chase Network, Inc.; because these subsidiaries did not receive City of Philadelphia awards subject to audit in accordance with the City of Philadelphia Subrecipient Audit Guide. As discussed in Note 1, Temple’s consolidated financial statements include the consolidated operations of Temple University Temple, Inc. and its subsidiary, Temple University Hospital Inc.; (collectively referred to herein as “TUHS”), which expended City of Philadelphia awards which are not included in Temple’s accompanying Schedule of Expenditures of City of Philadelphia Awards for the year ended June 30, 2025. Our audit, described below, does not include City of Philadelphia awards to TUHS, because a separate audit in accordance with the *City of Philadelphia Subrecipient Audit Guide* was performed for TUHS for the year ended June 30, 2025.

Basis for Opinion on Each City of Philadelphia Awards

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of *The City of Philadelphia Subrecipient Audit Guide*, issued by the City of Philadelphia- Office of the Director of Finance, Grants Accounting and Administration Unit (collectively “Standards and Guidance”).

Our responsibilities under those Standards and Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of Temple and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major City of Philadelphia Awards. Our audit does not provide a legal determination of Temple's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to Temple's City of Philadelphia Awards.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on Temple's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Standards and Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about Temple's compliance with the requirements of each major City of Philadelphia Awards as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Standards and Guidance, we

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding Temple's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of Temple's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Standards and Guidance, but not for the purpose of expressing an opinion on the effectiveness of Temple's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a City of Philadelphia

Awards on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a City of Philadelphia Awards will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a City of Philadelphia Awards that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Standards and Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of City of Philadelphia Awards required by the City of Philadelphia Subrecipient Audit Guide

We have audited the financial statements of Temple as of and for the year ended June 30, 2025, and have issued our report thereon dated October 28, 2025, which contained an unmodified opinion on those financial statements. Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of City of Philadelphia awards is presented for purposes of additional analysis as required by the *City of Philadelphia Subrecipient Audit Guide* and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of City of Philadelphia awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 31, 2026

**TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Grantor/Pass-Through Grantor Program Title	Agency Number	ALN	2025 Subrecipient Federal	2025 Subrecipient State	2025 Subrecipient City	2025 Total Federal	2025 Total State	2025 Total City	2025 Subrecipient Expenditures	2025 Total Expenditures
City of Philadelphia Awards (City funds noted below may have been passed through federal agencies and may be included in the federal schedule):										
Direct Awards:										
Philadelphia Department of Human Services										
2023-2024 Achieving Independence Center	NO ID PROVIDED		\$ —	\$ —	\$ —	\$ —	\$ —	\$ 4,590	\$ —	\$ 4,590
2024-2025 Achieving Independence Center - Educational Services	NO ID PROVIDED		—	—	—	—	—	184,239	—	184,239
College Enrichment Program at Temple University	NO ID PROVIDED		—	—	—	—	—	7,073	—	7,073
Grandma's Kids - Family Friends Program FY21	2120137		—	—	—	—	774	—	—	774
Grandma's Kids - Family Friends Program FY23	2120137-02		—	—	—	—	—	(1,322)	—	(1,322)
Grandma's Kids - Family Friends Program FY24	2120137-03		—	—	—	—	—	55	—	55
Grandma's Kids - Family Friends Program FY25	2120137		—	—	—	—	56,485	14,121	—	70,607
Grandma's Kids - Family Friends Program FY25	2120137		—	—	—	—	—	86,136	—	86,136
OST program	NO ID PROVIDED	93.558	—	—	—	249	45	48	—	341
Out Of School Time Programming	20647		—	—	—	—	—	(2,253)	—	(2,253)
Temple Center City Space Rental FY24	2120192-04		—	—	—	—	—	35,877	—	35,877
Temple Center City Space Rental FY25	2120192-05		—	—	—	—	—	138,558	—	138,558
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 249</u>	<u>\$ 57,305</u>	<u>\$ 467,121</u>	<u>\$ —</u>	<u>\$ 524,674</u>
Philadelphia Department of Behavioral Health and Disability Services										
2024-2025 ReCAST	2220321	93.243	\$ —	\$ —	\$ —	\$ 152,889	\$ 271,803	\$ —	\$ —	\$ 424,692
Cure Violence Program - FY24	2220224-02		—	—	—	—	—	7,266	—	7,266
Intellectual Disability Service	2120007-05		—	—	—	—	—	352,445	—	352,445
Philadelphia Ceasefire Cure Violence Program - FY25	2220224		—	—	—	—	—	199,991	—	199,991
Philadelphia Recast Program	2220321-02	93.243	—	—	—	191,438	340,334	—	—	531,772
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 344,327</u>	<u>\$ 612,137</u>	<u>\$ 559,702</u>	<u>\$ —</u>	<u>\$ 1,516,165</u>
Philadelphia Department of Public Health										
Ambulatory Outpatient HIV Medical Care	RW9700	93.914	\$ —	\$ —	\$ —	\$ (13,809)	\$ —	\$ —	\$ —	\$ (13,809)
Ambulatory Outpatient HIV Medical Care	RW0700	93.914	—	—	—	(28,669)	—	—	—	(28,669)
Care Services Case Management - Rm1222	RM1222	93.914	—	—	—	4,012	—	2,788	—	6,801
Care Services Case Management Rw1701	RW1701	93.914	—	—	—	(1,689)	—	(1,174)	—	(2,863)
CVI Workforce Development Program - FY25	2520368		—	—	—	—	—	30,652	—	30,652
Detection Of Sars-Cov-2 In Wastewater For Public Health Surveillance	2220502	93.323	—	—	—	93,318	—	—	—	93,318
Ending The Epidemic In Philadelphia	EC1002	93.940	—	—	—	(2,478)	—	—	—	(2,478)
Ending the Epidemic in Philadelphia	EC2002	93.940	—	—	—	29,612	—	—	—	29,612
Health Centers 3 & 4n	2220191	93.918	—	—	—	33,466	—	—	—	33,466
HIV Testing In Health Care Settings	1820421-02	93.940	—	—	—	(9,421)	—	—	—	(9,421)
HIV Testing in Health Care Settings	2220529	93.940	—	—	—	(1,842)	—	—	—	(1,842)
Neighborhood-Based Community Health Workers for COVID Response and Resilient Communities in Philadelphia	2220598		—	—	—	—	—	12,600	—	12,600
Outpatient Ambulatory Medical Care Rw1700	RW1700	93.914	—	—	—	(7,148)	—	—	—	(7,148)
Part A Supplemental RW HIV AIDS Treatment Modernization Act	2120606-03		—	—	—	—	—	79,444	—	79,444

**TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Grantor/Pass-Through Grantor Program Title	Agency Number	ALN	2025 Subrecipient Federal	2025 Subrecipient State	2025 Subrecipient City	2025 Total Federal	2025 Total State	2025 Total City	2025 Subrecipient Expenditures	2025 Total Expenditures
Part A Supplemental RW HIV AIDS Treatment Modernization Act	H89HA00013		—	—	—	—	—	32,767	—	32,767
PHL Airport Passenger Surveys	2220081-01		—	—	—	—	—	67,828	—	67,828
Ryan White HIV AIDS Treatment Extension Act Of 2009 Services FY 2019 - Continuation For Fy21	RS1648	93.914	\$ —	\$ —	\$ —	(2) \$	— \$	— \$	— \$	(2)
Ryan White HIV AIDS Treatment Extension Act of 2009 Services FY 2020 - Continuation for FY23	2120606-02		—	—	—	—	—	—	—	—
Substance Abuse Services	RW0419	93.914	—	—	—	(19,823)	—	—	—	(19,823)
Substance Abuse Services - Rw1419	RW1419	93.914	—	—	—	(1,959)	—	—	—	(1,959)
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 73,569</u>	<u>\$ —</u>	<u>\$ 224,905</u>	<u>\$ —</u>	<u>\$ 298,474</u>
Mayor's Fund For Philadelphia, Inc.										
PHL Connected Caregiver Digital Literacy Initiative	2022-CAREGIVERS-06		\$ —	\$ —	\$ —	\$ —	\$ —	120	\$ —	120
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 120</u>	<u>\$ —</u>	<u>\$ 120</u>
City of Philadelphia Department of Prisons										
2024 GED Testing Services at the Philadelphia Department of Prisons	2420546		\$ —	\$ —	\$ —	\$ —	\$ —	2,499	\$ —	2,499
Branching Up	2420546		—	—	—	—	—	(285)	—	(285)
GED Testing at Philadelphia Department of Prisons	2520398		—	—	—	—	—	3,029	—	3,029
GED Testing Center At Philadelphia Department Of Prisons	22 20554		—	—	—	—	—	1,651	—	1,651
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 6,894</u>	<u>\$ —</u>	<u>\$ 6,894</u>
Philadelphia Housing Authority										
PHA CARES (Community Action, Resources and Educational Services)	005271		\$ —	\$ —	267,006	\$ —	\$ —	466,898	\$ 267,006	\$ 466,898
PHA Cares (Covid-19 Action Response And Educational Services)	004970		—	—	—	—	—	(13)	—	(13)
PHA Cares (Covid-19 Action Response And Educational Services)	004970		—	—	—	—	—	(65,528)	—	(65,528)
Sharswood Choice Community Health Worker	005166	14.889	—	—	—	8,035	—	3,781	—	11,816
Sharswood Choice Neighborhoods Implementation Grant	005166/323		—	—	—	—	—	49,226	—	49,226
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ 267,006</u>	<u>\$ 8,035</u>	<u>\$ —</u>	<u>\$ 454,365</u>	<u>\$ 267,006</u>	<u>\$ 462,400</u>
Office of Children and Families										
Out Of School Time Programming	NO ID PROVIDED		\$ —	\$ —	\$ —	\$ —	\$ —	80	\$ —	80
Out of School Time Programming	NO ID PROVIDED		—	—	—	—	—	212,315	—	212,315
Summer Academy	SL033		—	—	—	—	—	(740)	—	(740)
Summer Academy	NO ID PROVIDED		—	—	—	—	—	(1,521)	—	(1,521)
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 210,134</u>	<u>\$ —</u>	<u>\$ 210,134</u>
Office of the District Attorney of the City										
2nd Annual Reentry Job and Resource Fair	NO ID PROVIDED		\$ —	\$ —	\$ —	\$ —	\$ —	1,739	\$ —	1,739
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 1,739</u>	<u>\$ —</u>	<u>\$ 1,739</u>
City of Philadelphia										
Career Connected Learning - Philadelphia (C2L-PHL)	CCLS24-0422		\$ —	\$ —	\$ —	\$ —	\$ —	31,826	\$ —	31,826
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 31,826</u>	<u>\$ —</u>	<u>\$ 31,826</u>

TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
 SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS
 FOR THE YEAR ENDED JUNE 30, 2025

Grantor/Pass-Through Grantor Program Title	Agency Number	ALN	2025 Subrecipient Federal	2025 Subrecipient State	2025 Subrecipient City	2025 Total Federal	2025 Total State	2025 Total City	2025 Subrecipient Expenditures	2025 Total Expenditures
City of Philadelphia Managing Director's Office										
Philadelphia Resident Survey	1920449		\$ —	\$ —	\$ —	\$ —	\$ —	\$ (5,963)	\$ —	\$ (5,963)
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ (5,963)</u>	<u>\$ —</u>	<u>\$ (5,963)</u>
Philadelphia Water Department										
Development Of Polymerase Chain Reaction (Pcr) Capabilities At The Philadelphia Water Department's Central Laboratory	1920233		\$ —	\$ —	\$ —	\$ —	\$ —	\$ 139	\$ —	\$ 139
			<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ —</u>	<u>\$ 139</u>	<u>\$ —</u>	<u>\$ 139</u>
Total City of Philadelphia Direct Awards			<u>\$ —</u>	<u>\$ —</u>	<u>\$ 267,006</u>	<u>\$ 426,179</u>	<u>\$ 669,442</u>	<u>\$ 1,950,982</u>	<u>\$ 267,006</u>	<u>\$ 3,046,603</u>

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

NOTES TO SCHEDULE OF EXPENDITURES – CITY OF PHILADELPHIA AWARDS FOR THE YEAR ENDED JUNE 30, 2025

(1) DESCRIPTION OF BUSINESS AND OPERATIONS

Founded in 1884, Temple University – Of The Commonwealth System of Higher Education (“Temple”) is a comprehensive state-related research university with its headquarters and largest campus located in Philadelphia, Pennsylvania. With 17 schools and colleges, eight campuses, and approximately 32,800 undergraduate, graduate, and professional students.

(2) BASIS OF PRESENTATION – SCHEDULE OF EXPENDITURES OF CITY OF PHILADELPHIA AWARDS

The accompanying Schedule of Expenditures of City of Philadelphia (the “Schedule”) summarizes the expenditures of Temple under programs of the City of Philadelphia for the year ended June 30, 2025. The information in the Schedules is presented in accordance with the requirements of *City of Philadelphia Subrecipient Audit Guide*. The Schedule does not include the City of Philadelphia funding awarded to Temple University Health System, Inc. and its subsidiaries.

Negative amounts shown on the Schedule represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years. Pass-through entity identifying numbers are presented where available.

(3) BASIS OF ACCOUNTING

The Schedule is presented using the accrual basis of accounting. For the purposes of the Schedule, City of Philadelphia awards include all grants, contracts, and similar agreements entered into directly between Temple and agencies or departments of the City of Philadelphia local government and all subawards to Temple by nonfederal organizations pursuant to City of Philadelphia grants, contracts, and similar agreements, except for Temple University Health System, Inc. and its subsidiaries as noted above.

**SCHEDULE OF FINDINGS AND QUESTIONED COSTS - CITY OF PHILADELPHIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Section I—Summary of Auditors’ Results

City of Philadelphia Awards:

Internal control over compliance with requirements applicable to City of Philadelphia Awards—*No material weakness identified, no significant deficiency identified.*

1. Type of independent auditors’ report issued on compliance for City of Philadelphia Awards—*Unmodified.*
2. Audit findings disclosed that are required to be reported in accordance with *The City of Philadelphia Subrecipient Audit Guide*—*None identified.*
3. The University’s City of Philadelphia Major Award:

Name of City of Philadelphia Award	Contract Number
Department of Public Health Detection Of Sars-Cov-2 In Wastewater For Public Health Surveillance	2220502

Section II—City of Philadelphia Award Findings and Questioned Costs

None noted.

* * * * *

PENNSYLVANIA DEPARTMENT OF HEALTH SECTION



Deloitte & Touche LLP
1700 Market Street
Philadelphia, PA 19103-3984
USA
Tel: +1 215 246 2300
Fax: +1 215 569 2441

INDEPENDENT AUDITOR'S REPORT ON SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH REQUIRED BY THE *PENNSYLVANIA DEPARTMENT OF HEALTH AUDIT GUIDANCE*

To the Board of Trustees
Temple University – Of The Commonwealth System of Higher Education
Philadelphia, Pennsylvania

We have audited the financial statements of Temple University – Of The Commonwealth System of Higher Education's ("Temple") as of and for the year ended June 30, 2025, and have issued our report thereon dated October 28, 2025, which contained unmodified opinions on those financial statements. Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health is presented for purposes of additional analysis as required by the Pennsylvania Department of Health Audit Guide and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

March 31, 2026

**TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
SCHEDULE OF EXPENDITURES OF STATE OF PENNSYLVANIA AWARDS
FOR THE YEAR ENDED JUNE 30, 2025**

Grantor/Pass-Through Grantor Program Title	Agency Number	ALN	2025 Beginning Balance Deferred Revenue (Accounts Receivable)	Recognized Revenue FY25	Cash Receipts FY25	Ending Balance Deferred Revenue (Accounts Receivable)
Pennsylvania Department of Health						
Certified Investigator's Training Program	4300784599		\$ 494,288	\$ 713,540	\$(581,728)	\$ 626,100
Enhancing Healthy Reintegration And Recovery For High-Risk Opioid Users (Non-Formula)	4100083339		(489,405)	7,831	(2,229)	(483,803)
FY2015 PA Commonwealth Universal Research Enhancement (CURE) Non-Formula Funding	4100077079		(494,241)	(42,060)	536,302	—
FY2016 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	4100077087		153	(153)	—	—
FY2018 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	4100083099		(5,920)	4,987	932	—
FY2019 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	4100085728		(30,234)	30,234	—	—
FY2019 PA Commonwealth Universal Research Enhancement (CURE) Non-Formula Funding	4100087336		(1,018,141)	1,007,524	(37,711)	(48,328)
FY2020 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	4100088561		(500,944)	522,169	(21,773)	(548)
FY2021 PA Commonwealth Universal Research Enhancement (CURE) Formula Funding	4100095616		(1,658,141)	491,625	(76,036)	(1,242,552)
FY2021 PA Commonwealth Universal Research Enhancement (CURE) Non-Formula Funding	4100094296		(49,593)	51,007	(1,414)	—
Overdose Data to Action in States Funding - Biosurveillance	4300830996	93.136	—	15,801	—	15,801
Pa-Cccp Implementation Services And Workplan Development	4400017651	93.898	(5,753)	5,753	—	—
Pennsylvania Inclusive Health Equity Collaborative	4100090589	93.391	472,920	1,709,087	(1,832,618)	349,389
Personal Responsibility Education Program (PREP)	4100095359	93.092	25,537	113,374	(109,321)	29,589
Teen Outreach Program (TOP)	4100082233	93.235	10,125	(3,730)	—	6,395
Teen Outreach Program Replication Partner	4100095921	93.994	136,620	520,568	(480,556)	176,633
Tele-exercise for individual with SCI	4100094295		32,213	13,820	(43,683)	2,350
Training And Investigative Services	4100083406	93.778	190,376	(4,306)	(78,352)	107,718
Transplantation of synaptogenic astrocytes for reconnecting respiratory circuitry	4100094298		3,224	6,772	(8,847)	1,149
			\$ (2,886,916)	\$ 5,163,843	\$(2,737,036)	\$ (460,107)

TEMPLE UNIVERSITY – OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

NOTES TO SCHEDULE OF REVENUE FOR THE COMMONWEALTH OF PENNSYLVANIA DEPARTMENT OF HEALTH FOR THE YEAR ENDED JUNE 30, 2025

(1) STATE OF PENNSYLVANIA DEPARTMENT OF HEALTH

State of Pennsylvania Department of Health provides Federal and state financial assistance to Temple University – Of the Commonwealth System of Higher Education (“Temple”). Temple is required to comply with all applicable Federal and state Grant requirements including *Pennsylvania Department of Health Audit Guidance*.

(2) BASIS OF PRESENTATION

The accompanying Schedule of Revenue for the Commonwealth of Pennsylvania Department of Health (the “Schedule”) summarizes the deferred revenue, revenue recognized and cash receipts by Pennsylvania Department of Health on an accrual basis of accounting.

The Schedule does not include the federal/State funding awarded to Temple University Health System, Inc. and its subsidiaries (“TUHS”). Separate audits in accordance with the U.S. Office of Management and Budget Compliance Supplement were performed for TUHS for the year ended June 30, 2025.
